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ABSTRACT 
 
Walter Jose Wever: Studies Towards The Chemoenzymatic Syntheses Of Thiopeptides And 
Thiomarinol And Visible Light Catalyzed O-Glycosylation Of Thioglycosides 
(Under the direction of Albert A. Bowers) 
 
 
 
 Over 2 million people in the United States, and millions more worldwide, are affected 
by antibiotic resistant bacterial infections. The discovery of new antibiotics has been stalled 
by the lack of incentives from pharmaceutical companies and academia from both an 
economic and regulatory standpoint. The advent of next-generation DNA sequencing and 
gene annotation through homology models has provided a vast pool of biosynthetic clusters 
from which new and old bioactive molecules can be predicted. This research focuses on the 
characterization of the enzymes TclM, TmlU, and HolE and the visible light activated O-
glycosylation of thioglycosides. 
We have characterized the enzyme TclM in the thiocillin biosynthetic pathway from 
Bacillus cereus ATCC 14579 as a pyridine synthase by ligating a leader peptide recognition 
sequence to a semi-synthetic core substrate through native chemical ligation and subsequent 
conversion of cysteine side chains to dehydroalanines by elimination of a trialkylated 
tetrahydrothiophene.  
We have additionally characterized the enzymes TmlU and HolE from the thiomarinol 
biosynthetic pathway from Pseduoalteromonas spp. SANK7339 and found them to be 
responsible for ligating the components pseudomonic acid C-coenzyme A thioester and 
holothin, respectively, to create the hybrid antibiotic. Structure-activity-relationship studies 
 iv 
were done on the dithiolopyrrolone holothin and found group promiscuity at the endocyclic 
and exocyclic amides but bioactivity was lost when the disulfide was oxidized to the 
thiosulfinate moiety. Further reactivity studies showed the ability of dioxoholomycin to 
oxidize small molecule thiols and redox-sensitive cysteines in the proteins YwlE and 
AtAPSK. 
We have also designed a visible light mediated O-glycosylation of thioglycosides by 
utilizing blue LEDs as a light source in the presence of an Ir (III) catalyst. It was found that 1o, 
2o, and 3o alcohols react and serve as acceptors. Mechanistic studies showed the need for a 
bromine-trihalogenated carbon bond for the initiation step, but that subsequent propagation 
relies on the p-methoxythiophenol disulfide, formed through dimerization from the activated 
starting material. 
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CHAPTER I  
INTRODUCTION 
 
1.1 Antibiotic Resistance 
 With over 3.2 billion people worldwide at risk for common infectious diseases like 
malaria and pneumonia, the need for new antibiotics is imperative.1,2 Each year in the United 
States, at least 2 million people become infected with antibiotic resistance bacteria, and at 
least 23,000 of those infected die from the disease.3 The rapid emergence of resilient strains 
threatens the efficacies of current therapeutics that have saved millions of lives thus far.4 
Since the discovery of penicillin by Sir Alex Fleming, Howard Florey, and Ernst Chain5,6, 
resistant strains have been identified not too far from the time they are introduced (Figure 
1.1). 
  
       
Figure 1.1. Timeline depicting bacterial resistance. 
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Natural products are at the forefront of drug discovery. Their privileged scaffolds 
have been extensively utilized as antibiotics or as antibiotic leads7,8 for the treatment of 
common pathogens such as Staphylococcus epidermidis, Streptococcus pyogenes, and 
Mycobacterium tuberculosis.9,10 The isolation of natural products is highly dependent on the 
ability of scientists to grow the specific bacterium in conditions in which it can produce the 
molecule of interest in sufficient quantities to be able to detect it and isolate in enough 
quantity for characterization. Furthermore, the constant fight for resources within microbial 
communities have selected for production of these natural products under the right 
environments and ecosystems.11 Thus, a method that would allow for the prediction of these 
compounds would greatly enhance the rate of discovery.  
The overuse and inappropriate prescription of antibiotics has increased bacterial 
resistance.12 This trend has led many pharmaceutical companies to abandon exploring new 
antibacterials due to the increasing financial and regulatory obstacles, which compromise a 
good return on investment. Moreover, of the 18 largest pharmaceutical companies, 15 have 
abandoned the antibiotic field in order to focus on more chronic diseases such as diabetes and 
asthma.13 In parallel, the high incidence of rediscovery of old scaffolds has limited the 
potential of harnessing bacteria for more bioactive molecules.14 Yet, recent advances in next-
generation DNA sequencing and bioinformatics have provided scientists with a broad pool of 
untapped resources for annotating gene clusters. These clusters can produce bioactive 
molecules based on sequence similarity of previously established ones.15 Scientists can now 
harbor these biosynthetic machineries and utilize them to characterize new active 
biomolecules.16 Moreover, it has provided a foundation from which chemists can take 
advantage of years of evolution and design compounds that are analogous to those found in 
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nature in order to replicate and/or enhance bioactivity. Among the most well characterized 
biosynthetic clusters are the polyketide synthases, the non-ribosomal peptide synthesis, and 
the ribosomally-encoded and post-translationally modified peptides. These biosynthetic 
machineries produce secondary metabolites with various degrees of complexity and 
bioactivities. 
Polyketide synthases (PKS) have an architecture in which successive modules 
catalyze carbon-carbon linear extensions through Claisen condensations of malonyl, 
methylmalonyl, or keto-functionalities processing reactions on intermediates covalently 
tethered to carrier domains. 17  They constitute about a third of currently available 
pharmaceuticals,18 and key members in this family are the pseudomonic acids, erythromycin, 
and amphotericin b (Figure 1.2).19 Erythromycin is a commonly utilized antibiotic for the 
treatment of Gram-positive and Gram-negative infections and is involved in disrupting 
protein synthesis by blocking the 50S polypeptide export tunnel.20 Like PKS, non-ribosomal 
peptide synthesis (NRPS) molecules are produced by a modular architecture in which small 
peptides are covalently linked to core domains that serve as carriers by which a set of 
tailoring domains modify the core structure. NRPS have the advantage of being able to 
access a wide chemical space due to modification of amino acid side chains or of the 
termini.21 An important NRPS is gramicidin (Figure 1.2), an antibiotic used in the treatment 
of eye infections. In contrast to a modular-like assembly, the ribosomally-encoded and post-
translationally modified peptides (RiPPs) biosynthetic pathways take advantage of gene-
encoded polypeptides that are extensively post-translationally modified.22 RiPPs present the 
advantage of being able to modify the expected mature product by genomic mutagenesis. 
Patellamide A (Figure 1.2) is an example of a RiPP that has been characterized as active 
 4 
towards the inhibition of tumor cell growth. 23  With this great arsenal of chemical 
modifications at their disposal, it is no surprise that bacteria are constantly evolving new 
means of defense against foreign molecules, and hence why antibiotic resistance presents a 
great challenge. 
 
 
Figure 1.2. Bioactive molecules from three biosynthetic machineries. 
 
New venues in drug discovery have focused on utilizing the nucleotide sequence of 
enzymes from the PKS, NRPS, and RiPPs pathways to predict new biosynthetic pathways 
from metagenomic sequencing of bacteria. This has facilitated the annotation of the clusters 
responsible for producing known antibiotics and reducing the rediscovery rate. In addition, 
scientists now have the ability to clone these new sets of genes and heterologously express 
them in more manageable bacterial systems or yeast,24 opening a new era of innovative drug 
discovery of these orphan clusters. 
Moreover, the advent of new enzymology and drug delivery systems have the 
advantage of coupling moieties that can enhance targeted drug delivery. For instance, the 
attachment of a rhamnose cap in the delivery of doxorubicin greatly enhanced its efficacy in 
murine liver tumor cells by taking advantage of the high density of lectins (carbohydrate 
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 5 
binding proteins) in eukaryotic cell surfaces.25 The use of liposomes and other nanoparticles, 
often coated with sugars at the surface, have also been very successful,26 suggesting a strong 
role for carbohydrates in drug delivery. 
A recent study by the PEW charitable trust reported the need for the discovery of 
antibiotics from natural products.27 There have been no new classes of antibiotics registered 
for therapeutic use since 1984; hence, the antimicrobial agents that have become 
commercially available tend to be just slight variants of previously established antibiotics. A 
main problem with this approach stems from the potential resistance to a family of antibiotics 
by individual resistance to one of the introduced variants. Moreover, natural product 
antibiotics have evolved for an extensive number of years to be enticing to the targeted 
microorganism. Thus, the discovery of new natural products classes is essential for antibiotic 
development.    
In the present work, the design of new antibiotics will be explored by characterizing 
key transformation in enzymes involved in recently annotated gene clusters. More 
specifically, we will explore the enzymes involved in the formal [4+2] pyridine construction 
in the biosynthetic pathways of thiocillin and thiomuracin. A solid-phase peptide synthesis 
method for exploring substrate promiscuity and core sequence requirements will be 
developed. Additionally, we will utilize organic syntheses to produce analogues of the 
dithiolopyrrolone family of natural products for probing the mechanism of action and 
understanding their involvement in redox cycling in bacterial cells. We will further explore 
an O-glycosylation method for coupling carbohydrates into alcohol acceptors through visible 
light catalysis to establish a method for coupling into natural products.  
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CHAPTER II 
CHEMOENZYMATIC SYNTHESES OF THIAZOLYL PEPTIDES 
2.1 Introduction 
 Natural products have provided scientists a vast library of compounds for drug 
discovery. Their isolation has not only led to their use as therapeutics, but also to 
advancements in our understanding of the chemistry found in natural sources. 1 , 2 
Unfortunately, since the “golden era” of natural product discovery in the 1950s, high 
frequencies of bacterial resistance and molecule rediscovery3 have dissuaded advancement in 
this area. Moreover, the usually complex structures of these compounds make them difficult 
to synthesize in quantities amenable for high-throughput screenings and biological testing.4,5 
 Historically, bacteria have been a rich source to discover bioactive compounds.6  
Their competition for resources have caused them to evolve secondary metabolites in order 
to gain a fitness advantage over their competitors, which has allowed scientists to grow 
bacteria, extract these metabolites, and utilize them as lead compounds for drug discovery.7  
This strategy has an important limitation: growing the bacteria under the right conditions to 
produce the desired natural products. Advancements in genome sequencing during the 21st 
century has allowed the identification of gene clusters that produce new compounds not been 
previously seen in the laboratory setting,8,9 
 RiPPs are a class of natural products derived from a linear precursor peptide that is 
heavily post-translationally modified to create the mature compound (Figure 2.1).10,11 The 
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precursor peptide consists of a primary sequence of amino acids subdivided into two 
components: the leader peptide and the core peptide. It is the leader peptide that provides the 
recognition sequence by which the modifying enzymes can act upon the core peptide;12 the 
leader peptide is subsequently cleaved during a late stage modification, or by a protease 
encoded in the gene cluster, and the mature compound is released. Common modifications 
found in RiPPs include the dehydration of serine and/or threonine side chains to their 
corresponding dehydroalanine (Dha) and dehydrobutyrine (Dhb) analogs,13 thioether cross-
linkages,14 oxazoles and/or thiazoles from serine, threonine and cysteine residues,15 and 
sactionine thioether linkages16 among many others.10 
 
 
Figure 2.1. Overview of ribosomally encoded and post-translationally modified peptides.  
 
 The pathways involved in RiPP biosynthesis have opened the door for bioengineering 
from these clusters due to the direct correlation of gene to product.17 The modifying enzymes 
in RiPPs tend to be promiscuous towards different cores if the leader peptide sequence 
remains intact.18,19 This allows for modifications at the DNA level by simple molecular 
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cloning techniques such as site-directed mutagenesis. In theory, one can envision mutating 
the individual amino acid components of the core peptide with other proteinogenic ones to 
create compound libraries from a single encoded gene. This elegant utilization of amino acids 
has the evolutionary advantage of providing the producing species a reliable source of 
building blocks with great structural variety. The complexity of RiPP products are diverse 
and can vary from simple dehydrations and thioether linkages,20 to very complex thiazoles, 
pyridine rings, and methyl-indole groups, such as the ones found in nosiheptide.21 Amongst 
the most complex RiPP products are the ones belonging to the family of thiazolyl peptides. 
Thiazolyl peptides feature a unique combination of functionalities that include 
thiazoles, thiazolines, dehydroalanines, dehydrobutyrines, and a ring-closure, 6-membered N-
containing heterocycle, often dehydropiperidine or pyridine (Figure 2.2). They have potent 
activity against both Gram-positive and Gram-negative bacteria, 22  and even against 
methicillin resistant Staphylococcus aureus and vancomycin-resistant Enterococci. 23,24 There 
are over 100 known members in the family of these structurally complex, and high molecular 
weight compounds (typically >1000 Da). Their associated bacterial target is based on their 
architecture. Thiocillin (2-1), a 26-member macrocycle when counted by the shortest atom 
travel inside the ring, targets a crevice in the 50S ribosomal subunit between the 23 sRNA 
and protein L11, halting translation by inhibiting binding of elongation-factor G (EF-G) and 
subsequent translocation of tRNA.25 Another member is thiostrepton (2-2); it has two 
macrocycles in its core structure and, while it also targets EF-G, it has been shown to be 
involved in inhibition of the proteasome and the oncogenic transcription factor FoxM1.26 
Additionally, GE2270A, a 29-atom macrocycle, has been extensively studied and found to 
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target the ribosomal co-chaperone EF-Tu by inhibiting its ability to deliver amino-acyl 
tRNA.27 
 
Figure 2.2. Members of the thiazolyl peptide family. 
 
The thiazolyl peptides have great chemical characteristics that make them highly 
desirable as potential leads. They are rigid and thus conformationally stable to degradation by 
proteases; they are derived from canonical amino acids, which allows for the examination of 
substitutions at various positions inside the ring to probe activity. However, members of the 
thiazolyl peptides have traditionally shown poor pharmacological profiles due to poor 
solubility and low bioavailability. Overcoming these limitations would require a modular 
synthetic approach that allows for functional group interchange. While total syntheses of 
thiazolyl peptides have been reported,28,29 the most successful semi-synthetic derivative has 
come from a natural source. Functional group modifications in GE2270A (2-3) through 
removal of C-terminal groups, and subsequent introduction of the solubilizing urethane 
moiety, yielded the compound LFF571. This compounds was until recently in phase II 
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clinical trials for the treatment of Clostridium difficile infections in the upper gastrointestinal 
tract.30 
The thiocillin biosynthetic gene cluster from Bacillus cereus ATCC 14579 has been 
shown to produce the mature compound from a cascade of fourteen post-translational 
modifications from the precursor peptide (Figure 2.3),31 which is found in four copies on the 
gene cluster (tclE-H). The precursor peptide consists of a 38 amino acid leader peptide linked 
to a 14 amino acid core. Genetic manipulation experiments have demonstrated that the 
pathway can be promiscuous to site-directed mutagenesis about the core peptide, allowing 
for a biosynthetic library of thiocillin analogues with various degrees of antibiotic activity.32 
Interestingly, all the gene products can be functionally annotated based on sequence 
homology to other known enzyme functions, except for tclM. A tlcM knockout (M-KO) of 
the producer strain Bacillus cereus ATCC 14579 was accomplished by homologous 
recombination of a plasmid containing sequence homology to the areas adjacent to, but not 
containing, tclM.33  After standard expression conditions of thiocillin, cell extractions, and 
characterization by HPLC and LC/MS showed a post-translationally modified linear form of 
the core peptide, where only a few amino acids from the leader peptide remained. This 
suggests that the enzyme TclM is involved in the putative [4+2] cyclization of the central 
pyridine core and that most other modifications precede the ring closure step. Moreover, 
when tclM was reintroduced into the M-KO on a plasmid, reconstitution of the central 
pyridine was accomplished. This function would categorize TclM as a new class of enzyme 
catalyzing a formal heteroannulation between two dehydroalanines. Because initial attempts 
to obtain a linear substrate for TclM in vivo proved to be unsuccessful due to leader peptide 
cleavage,33 we hypothesized that if we built a linear analogue of thiocillin with its leader 
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peptide and subjected it to TclM in vitro, we could effect the cyclization to the mature 
thiazolyl peptide analogue. 
 
 
Figure 2.3. Thiocillin biosynthetic pathway. 
 
 While enzymes such as SpnF34 and VstJ35 are known as natural occurring Diels-
Alderases, they only enhance the rates of already spontaneous reactions. These Diels-
Alderases utilize the required 4π diene and a 2π dienophile in order to make two new carbon-
carbon bonds with the formation of a cyclohexene ring. TclM, however, would be the first 
example of an enzyme catalyzing a formal [4+2] cycloaddition when the reaction is non-
spontaneous (Figure 2.4), as the starting Dha residue would have to tautomerize to its imidic 
acid form to yield the 4π partner and make the tetrahydropyridine core. A previous report by 
Moody and co-workers demonstrated that they needed to trap the imidic acid as the imidate 
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ethyl ester and irradiate with microwave at 120 oC to effect the cyclization with a small 
molecule Dha, and ensuing aromatization, in only 33% yield at an early stage during the total 
synthesis of the thiazolyl peptide amythiamycin.36 This report emphasizes the harshness 
needed for the pyridine formation, and the need for a mild, late stage catalytic system to 
overcome this limitation. 
 
   
Figure 2.4. Suggested mechanism for pyridine ring formation in thiocillins. 
 
2.2 Isolation of TclM 
 Our initial efforts focused on obtaining pure TclM. Thus, the gene tclM was amplified 
from genomic DNA of Bacillus cereus ATCC 14579 and cloned into the ligation 
independent cloning (LIC)-vector pMCSG9, which encodes for an N-terminal 6xHis-maltose 
binding protein (MBP) linked through a tobacco etch virus (TEV) cutting sequence to TclM 
to improve solubility during the isolation process.37 The construct was transformed into E. 
coli RIPL cells for heterologous expression. 6xHis-MBP-TEV-TclM was obtained after 
nickel-affinity purification and size exclusion chromatography. Removal of the N-terminal 
tag was accomplished by treating the construct with 1% (w/w) TEV for 12 h at 4 oC. 
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Subtractive purification of our cleavage reaction yielded 300 µL of TclM as an 8.09 mg/mL 
stock in over 90% purity. 
 
2.3 Synthesis of Thiazolyl Peptide Analogue of Thiocillin 
With our enzyme purified, we next focused on the rational design of a TclE-H 
analogue that would allow us to test the in vitro function of TclM. Building the 52 amino 
acid linear substrate by solid phase peptide synthesis (SPPS) would challenge the limits of 
the method. Thus, our initial efforts took us to explore different avenues. We surveyed the 
idea of linking the unmodified leader peptide sequence with the highly modified core peptide 
through a ligation strategy such as native chemical ligation (NCL, Figure 2.5). NCL provides 
for a convergent synthesis of multiple cores that we can subsequently ligate to the leader 
peptide. 
 
Figure 2.5. Strategy for substrate preparation for TclM. 
 
2.3.1 Isolation of TclE-H’s Leader Peptide 
 TclE’s leader peptide (LP) was amplified from genomic DNA of Bacillus cereus 
ATCC 14579 and cloned into the sequence and ligase independent cloning (SLIC)-vector 
pETXSH; this construct allowed expressing the short leader peptide with a C-terminal intein 
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from Mycobacterium xenopi that contains a 6xHis-tag at the C-terminus. In the presence of 
excess thiol, this intein protein self-excises to yield C-terminal thioesters.38 The construct 
was transformed into E. coli RIPL cells for heterologous expression. Upon isolation of the 
LP-Intein-6xHis construct by nickel-affinity purification, our initial attempt at the formation 
of the LP-thioester by addition of 2-mercaptoethanesulfonate sodium salt (MESNa) to a final 
concentration of 0.5 M yielded a truncated version of the thioester, with removal of the 
terminal two amino acids (Gly and Ala). Quickchange mutagenesis of the C-terminus 
allowed us to add an extra Gly-Ala sequence, and now the desired thioester was obtained 
upon MESNa treatment (Figure 2.6). Isolation of the LP-MESNa thioester was performed by 
removal of the excised intein through nickel-affinity purification. 
 
 
Figure 2.6. Isolation of TclE-H’s leader peptide as a C-terminal thioester. 
 
2.3.2 Synthesis of Thiazolyl Peptide Analogue Core 
 Having one of the coupling partners for native chemical ligation, we then focused on 
the synthesis of an analogue of the highly modified core. Over 65 mutations through site-
directed mutagenesis of in vivo processing of TclE-H had shown that mutations inside the 
macrocycle are well tolerated, but mutations of the residues around the pyridine ring are 
not.39 Previous mutagenesis results are summarized in Figure 2.7. 
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Figure 2.7. Effects of substitutions in thiocillin. 
 
We envisioned a modular synthetic approach to a simplified core through peptide 
couplings of thiazole-containing amino acids (Scheme 2.1). Our simplified analogue would 
substitute Thr4, Val6, and Thr8 with alanine side chains and truncate the C-terminus after 
Cys12 to the ethyl ester; furthermore, it was crucial to keep the Dha moieties at positions 1 
and 10 and the thiazoles at positions 2, 9, and 11 in order to keep a core that TclM would be 
active towards. We also decided to keep Thr3 since it is an unmodified residue and it is 
commercially available. Our analysis led us to synthesize the building blocks containing 
thiazoles by utilizing a known method28c-d from tert-butyloxycarbonyl (Boc)-protected amino 
acids. More specifically, from N-Boc- and N,S-dimethylthiazolidine protected cysteine 
thiazole (2-5), N-Boc-alanine thiazole (2-7), and N-Boc- and N,S-dimethylthiazolidine 
protected cysteine bis-thiazole (2-8). 
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Scheme 2.1.  Retrosynthetic analysis of thiocillin core analogue. 
 
We began our synthesis by building from L-cysteine (2-9) the N,S-
dimethylthiazolidine, N-Boc thioamide (2-10) in 4 steps (Scheme 2.2). Cyclization of 2-10 
with ethylbromopyruvate (EBP) and subsequent elimination with trifluoroacetic anhydride 
(TFAA) in the presence of 2,6-lutidine yielded the building block 2-11. 2-11 was split and 
hydrolyzed to 2-5 with 0.4 M NaOH and utilized to build a second thiazole by amidation 
with ammonium hydroxide and thiolation with Lawesson’s reagent to afford 2-12 in 73% 
yield. Cyclization with EBP and TFAA afforded the bis-thiazole 2-13. In parallel, amidation 
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and thiolation of L-Boc-alanine succinimide ester (2-14) afforded the Boc-alanine thioamide 
2-15, which was cyclized with EBP and TFAA to yield the Boc-alanine thiazole ethyl ester 
2-16 in 47% yield. Having all the three main building blocks, 2-5 was coupled to L-threonine 
methyl ester hydrochloride (2-17) with (Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) to make the dipeptide 2-18 in 65% yield; separately, 2-16 was 
hydrolyzed to the corresponding acid and coupled to the trifluoroacetate salt of Boc-alanine 
ethyl ester 2-19 to yield the dipeptide 2-20. We next hydrolyzed the ester 2-18 and coupled it 
to the fully deprotected 2-21 with N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC*HCl) to afford the trithiazole, tetrapeptide 2-22, which was hydrolyzed 
to its corresponding acid 2-23. The last coupling block was made by hydrolyzing 2-16 to 2-7 
with 0.4 M NaOH and coupling it to the trifluoroacetate salt of L-cysteine-(S-trityl)-thiazole 
ethyl ester with PyBOP to make dipeptide 2-24. Removal of the Boc-protecting group of 2-
24 and coupling with EDC*HCl to 2-23, allowed us to synthesize the protected hexathiazole 
2-25 in 36% yield. 
 20 
 
Scheme 2.2. Synthesis of the core analogue of thiocillin. HOSu = N-hydroxysuccinimide. 
TFAA = trifluoroacetic anhydride. DME = 1,2-dimethoxyethane. PyBOP = (Benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate. EDC = N-(3-Dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride. DMAP = 4-dimethylaminopyridine. NMM = N-
methylmorpholine. 
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2.3.3 Native Chemical Ligation and Dehydroalanine formation 
Final deprotections with trifluoroacetic acid (TFA) in the presence of triisopropyl 
silane and removal of the N,S-dimethylthiazolidine moiety with 50% (aq.) ethanol of 2-25 
allowed us to obtain the hexathiazole-ethyl ester coupling partner 2-26 for native chemical 
ligation. Buffer exchanging the LP-MESNa thioester 2-4 to a native chemical ligation buffer 
consisting of 200 mM sodium phosphate (pH = 7.5), 6 M guanidinium, 20 mM tris(2-
carboxyethyl)phosphine, and 0.5% (v/v) thiophenol40 and reacting it with excess 2-26 for 3 
days at room temperature showed full conversion to the ligated product 2-27 (Scheme 2.3). 
Elimination of the cysteine side chains to their corresponding Dha was accomplished with 
excess meso-2,5-dibromohexanediamide (2-28),41  and the final substrate for TclM was 
produced 2-29 upon dialysis of excess 2-28. 
 
 
Scheme 2.3. Preparation of TclM substrate. NaPi = sodium phosphate. Gn = guanidine. 
TCEP = tris(2-carboxyethyl)phosphine. 
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2.4 TclM Assay 
Having TclM and its putative linear substrate 2-29, we tested to see if we could effect 
the formal [4+2] cycloaddition in a 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) buffer with 150 mM sodium chloride (Figure 2.8). A characteristic 
absorbance of the tri-substituted pyridine is observed at λ = 350 nm; hence, we monitored the 
reaction over the course of 16 h at 4 h intervals and noticed an increase in the signal at this 
wavelength (Figure 2.8a) over time. Additionally, analytical HPLC shows complete 
consumption of starting material (rt = 7.8 min) after 20 h and the appearance of a new peak at 
(rt = 9.0 min). 
 
     
Figure 2.8. Formation of thiocillin analogue by TclM. a) UV-Vis absorbance from 250 nm to 
450 nm. b) Analytical HPLC traces monitored at λ = 254 nm. c) 1H NMR showing pyridine 
protons. 
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LC/MS analysis of the newly formed product showed a mass corresponding to an m/z 
of 962.1171, which is within instrumental error of the expected [M+H]+ of 2-30 (m/z  
962.1118). Further characterization by MS/MS showed the expected pattern of the cyclized 
thiazolyl peptide; but in order to unequivocally assign the product as the pyridine core, we 
scaled the assay to isolate milligram quantities of the product for NMR analysis. 1H NMR 
showed the appearance of the expected two doublets from the aromatic protons of the 
pyridine core (Figure 2.8c) along with the six singlets from the thiazole scaffolds. Additional 
1D and 2D NMR analyses (13C, dqf-COSY, coupled-HSQC, and HMBC) confirmed the 
structure of the thiocillin analogue 2-30. Intriguingly, the search for intermediates or the 
ultimate fate of the leader peptide in our LC/MS runs did not yield any intermediates or side 
products. This suggests that the intermediates are either short-lived or TclM itself catalyzes 
both the formal [4+2] cycloaddition and aromatization. The lack of presence of the leader 
peptide from our worked-up assays intimates that it might be strongly held by TclM or that it 
might aggregate with the surface of TclM. 
 
2.5 Mutagenesis Studies of TclM 
Identifying the key residues for TclM will be important to understand and propose 
plausible mechanism for enzymatic transformation. Nonetheless, TclM is an enzyme with 
very low homology to proteins of known function. Even within the family of thiazolyl 
peptides, TclM homologues have low sequence similarity. We began our studies by 
attempting to crystallize apo-TclM, TclM + leader peptide, and TclM with thiocillin. 
Unfortunately, our efforts proved to be unsuccessful. Hence, we decided to focus on 
identifying potential key residues that might be important for catalysis and trying to obtain 
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biochemical information from their assays. A sequence alignment of TclM and its 
homologues in other thiazolyl peptide biosynthetic pathways (Figure 2.9a) allowed us to 
identify eight conserved amino acids at the C-termini.  Quickchange mutagenesis facilitated 
mutating these resides to alanines, yielding the TclM mutants E128A, F155A, Y173A, 
H242A, F261A, R265A, R285A, and E297A. These constructs and the native TclM sequence 
were introduced to the M-KO strain of Bacillus cereus ATCC 14579, and the bacteria grown 
with thiocillin producing conditions and 0.2 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) to induce expression from the plasmid utilized, pHT01. Pellet extraction with 
methanol, followed by LC/MS analyses of the extracts showed that the mutants E128A, 
F155A, Y173A, F261A, and E297A produced equal amounts of thiocillin when compared to 
unmodified TclM. Interestingly, the mutants H242A and R285A had great reduction in 
thiocillin production (<50% for H242A and <15% for R285A when compared to unmodified 
TclM, Figure 2.9b), while the mutant R265A completely halted thiocillin production in vivo. 
These results lead us to modify our TclM alignments to further explore other residues that 
might be important for function. An alignment of only TclM-homologues that produce a 
pyridine core were considered. Six more conserved residues were identified and mutated to 
alanines and tested for thiocillin production as done for the previous mutants. The six new 
mutants, S147A, S150A, H151A, S239A, Y272A, and C289A, did not have a substantial 
change in thiocillin production when compared to the wild type enzyme (data not shown). 
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Figure 2.9. Probing conserved residues in TclM and its homologues. a) Alignment of 
residues 231-310 from TclM with its homologues. b) In vivo production of thiocillins by 
TclM and TclM-mutants at 350 nm. 
 
We next cloned the mutants H242A, R265A, and R285A into our TclM expression 
vector pMCSG9 and heterologously expressed them in E. coli RIPL cells. Purifications 
follow the same procedure as for wild type TclM. Subjecting substrate 2-29 to our standard 
TclM-assay conditions with our three mutants showed that conversion was poorer for all 
three (Figure 2.10).  The in vivo result from R265A can be correlated in vitro, but H242A 
and R285A cannot, although no production of cyclized product was observed for H242A. It 
is noteworthy that the substrate utilized is not the native linear one, which might explain the 
lack of correlation for the latter two mutants. We hoped that the decrease in efficiency would 
allow us to visualize by LC/MS analyses potential intermediates, but we were again 
unsuccessful at detecting new species. 
 
a) b) 
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Figure 2.10. In vitro production of thiocillins by TclM and TclM-mutants at 350 nm. 
 
2.6 Probing The Leader Peptide Requirement of TclM 
 The LP requirement for TclM was probed by truncating the N-terminal peptide 
sequence of our linear thiazolyl peptide until no cyclization could be observed by LC/MS 
analysis. The LP sequences are described in Table 2.1 and show a gradual decline in the the 
number of amino acid residues in the peptide chain. Substrate containing the ΔN18 truncate 
was prepared according to our previously described method in Section 2.3. The ΔN18 
truncate did not require the addition of an extra Gly-Ala for MESNa mediated intein 
cleavage. Substrates with LP truncations ΔN28, ΔN30, ΔN31, and ΔN32 were prepared by 
solid phase peptide synthesis (described in further detail in Section 2.7) utilizing H-Rink-
Amide ChemMatrix®.  
 
 
 
 
 
 
 
TclM 
TclM-H242A 
TclM-R265A 
TclM-R285A 
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 Table 2.1. Leader peptide truncations of TclE-H 
Leader Peptide  
(amino acids) 
Leader Peptide Sequence 
ΔN18 (19-38) MIEMVDVDAMPENEALEIMGA 
ΔN28 (29-38) ENEALEIMGA 
ΔN29 (30-38) NEALEIMGA 
ΔN30 (31-38) EALEIMGA 
ΔN31 (32-38) ALEIMGA 
ΔN32 (33-38) LEIMGA 
 
 Interestingly, when we subjected the truncated substrates with TclM, all tested 
versions yielded the cyclized compound except for the ΔN32 truncate (Figure 2.11). The 
ΔN31 and ΔN30-LPs yielded very low amounts of product, while the ΔN29 and ΔN28-LPs 
were similar in yield to the ΔN18. It is noteworthy that the ΔN28-LP provided cleaner 
conversion than the smaller constructs; the smaller ones tended to yield even further 
truncated versions of the substrate, presumably due to low efficiency and background 
hydrolysis of the Dha moieties. This result has the great advantage of allowing for a modular 
combinatorial synthesis of thiopeptide cores that can be readily tested for cyclization by 
attaching a more amenable 10-residue LP, in contrast to the native 38-residue LP, by 
chemical methods such as solid phase peptide synthesis. 
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Figure 2.11. Production of thiocillin analogue by truncated leader peptide sequences. 
 
2.7 Probing TclM and TbtD by Solid Phase Peptide Synthesis of Thiazolyl Peptides 
We wanted to take advantage of the shorter 10-residue recognition sequence (RS) by 
TclM to probe the substrate promiscuity of the enzyme in the residues adjacent to the Dhas 
that will become the pyridine ring. To expedite the process, we wanted to take advantage of a 
modular synthesis by fluorenylmethyloxycarbonyl (Fmoc) solid phase peptide synthesis 
(SPPS, Figure 2.12). The cores could be coupled by successive microwave assisted SPPS 
(step 1, Figure 2.12) with N-Fmoc protected amino acids thiazoles. Similar to our solution 
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phase synthesis, cores would have an N-terminal cysteine thiazole to facilitate Native 
Chemical Ligation. We explored the literature for NCL procedures on-bead and found a 
method by Dawson et al. where they made use of a N-methylbenzimidazolidinone strategy as 
thioester surrogates (step 2, Figure 2.12) to ligate two fragments.42 This provides the 
advantage of making the LP independently from the cores, and it would allow us to build 
core libraries on-bead and ligate them to the LP in a single step. Subsequent cleavage of the 
precursor peptides and desulfhydrylation of cysteine side chains to Dhas would provide 
substrates for TclM (steps 3-4, Figure 2.12). Two key transformations during the synthesis 
included the selective deprotection of the S-trityl groups without peptide cleavage from the 
resin with 0.1 N HCl in hexafluoroisopropanol (HFIP)43 of the N-terminal cysteine thiazole 
from the cores in order to liberate them for NCL, and the desulfhydrylation with methyl 2,5-
dibromopentanoate (2-31) as the desulfhydrylation agent 44  to avoid intramolecular 
“stapling.” With a versatile synthesis in hand, we decided to extend our probes to synthesize 
cores that would resemble the one for the thiopeptide thiomuracin. The pyridine synthase 
from the thiomuracin biosynthetic pathway, TbtD, has recently been characterized;45 it will 
allow us to test the formation of 29-atom macrocycles, complementing the 26-atom 
macrocycle from thiocillin. Just like with TclM, we anticipated that a similar 10-residue LP 
from the precursor peptide, TbtA, would be sufficient for TbtD to cyclize linear substrates. 
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Figure 2.12. Overall SPPS scheme for thiazolyl peptide analogues. 
 
 By this strategy, a total of eleven cores and their sequences are summarized in Table 
2.2. There are interesting trends that can be discerned from these results: a 10-LP from TbtA 
is sufficient for TbtD to perform the cyclization (entries 6,8, and 10), albeit the conversion is 
much poorer and most of the starting material remains (data not shown). We hypothesize that 
there is a [4+2] recognition sequence near the C-terminus of thiazolyl peptides LPs, but 
additional experiments are needed to confirm this trend. Additionally, the environment 
surrounding the downstream 4π-system involved in the pyridine formation seems to be 
important. TclM can tolerate expanding the macrocycle to a 29-atom macrocycle (entry 5), 
but when the exocyclic bisthiazole is changed to a monothiazole, the cyclization does not 
occur (entry 4). Likewise, TbtD needs a C-terminal Dha in order to cyclize the core (entry 6 
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vs. entry 7), but, surprisingly, it can also cyclize in the presence of both an endocyclic and 
exocyclic bisthiazole moieties (entry 10). Finally, while TclM was able to expand the 
macrocycle, TbtD could not tolerate ring compression when the tyrosine residue was 
removed from the core (entry 11). 
 
Table 2.2. Results of constructed cores by SPPS with TclM and TbtD 
  
Dha = dehydroalanine. Thz =  thiazole. Asn = N-methyl asparagine. 
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2.8 TclM Homologues 
 Recently, Mitchell et al. described the presence of a RiPPs-recognition element 
(RRE) found in many of the prokaryotic RiPP biosynthetic pathways;46 these domains have 
homology to PqqD, an accessory protein needed for leader peptide binding of the precursor 
PqqA in the pyrroloquinoline quinone biosynthesis. We queried the amino acid sequences of 
TclM and TbtD for the presence of the RRE through the homology predictor HHpred, but did 
not find one. Our studies suggest that there is a recognition sequence (RS) at the C-terminus 
of the LPs in the precursor peptides. Thus, the putative RS can be a new RRE involved in the 
recognition of the C-terminal sequence of LPs, along with the presence of the highly 
modified core, by TclM and its homologues as a late stage effector of thiazolyl peptide 
maturation and release. 
We set up to clone, overexpress, and purify homologues from the family of 
pyridine/tetrahydropyridine synthases from known thiazolyl peptides. As with TclM, all 
enzymes were cloned into the LIC vector pMCSG9 and expressed as N-terminal 6xHis-
MBP-TEV-constructs (Figure 2.13) to enhance solubility and to assist with purification. 
Having all these enzymes would allows us to extend our knowledge of leader peptide 
requirements and provide access to different sizes of macrocycles in thiopeptides with the 
ultimate goal of finding new avenues to make them bioavailable for use in therapeutics. 
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Figure 2.13. Purified TclM and homologues as 6xHis-MBP-TEV-Fusions. 
 
2.9 Summary 
 We have characterized the function of TclM as a formal [4+2] heterocyclase from the 
thiocillin biosynthetic pathway in B. cereus ATCC 14579. We obtained a linear, highly 
modified substrate through ligation of the leader peptide thioester to a synthetic hexathiazole 
core through native chemical ligation and subsequent conversion of cysteine side chains to 
dehydroalanines. The thiocillin analogue was characterized by 1D and 2D NMR, LC/MS, 
and MS/MS analyses. Residues H242, R265, and R285 in TclM are important for thiocillin 
production in vivo and in vitro. Leader peptide truncation from the TclE precursor peptide 
showed a minimal 7-residue sequence needed to effect cyclization of linear thiopeptides. A 
75 kDa 
50 kDa 
37 kDa 
1 2 3 4 5 6 7 
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modular solid phase peptide synthesis was established to probe for requirements around the 
4π system in the downstream dehydroalanine involved in the formation of the central 
pyridine core in thiocillin and thiomuracin GZ. Homologues of TclM were cloned and 
purified for future studies. 
 
2.10 Experimental 
2.10.1 General Methods 
 All reactions were carried out in an oven-dried round-bottomed-flask under an inert 
nitrogen atmosphere with stirring. Solvents, reagents, and chemicals were purchased through 
Fisher Scientific and used as received unless otherwise noted. Amino acids and their 
protected derivatives, 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HATU), and 1-Ethyl-3-(3-dimethyllaminopropyl)carbodiimide 
hydrochloride (EDC*HCl) were purchased from ChemPep. N,N-diisopropylethyl amine 
(DIPEA), 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), 
and 1-Hydroxybenzotriazole hydrate (HOBt*H2O) were purchased from Sigma-Aldrich. 
Spectra for 1H and 13C NMR were recorded at room temperature, unless otherwise noted, 
with a Varian Inova 400 (400 MHz and 100 MHz, respectively) or Varian Inova 500 (500 
MHz and 125 MHz, respectively) spectrometers. Chemical shifts are reported in δ (ppm) 
relative units to residual solvent peaks CDCl3 (7.26 ppm for 1H and 77.0 ppm for 13C) and 
DMSO-d6 (2.50 ppm for 1H and 39.5 ppm for 13C).  Splitting patterns are assigned as s 
(singlet), d (doublet), t (triplet), q (quartet), quint (quintet), multiplet (m), dd (doublet of 
doublets), and td (triplet of doublets). LC/MS measurements were recorded using an Agilent 
6520 Accurate-Mass Q-TOF ESI positive in high-resolution mode, 350 oC temperature and 
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250 V fragmentor, with a 100 x 2.10 mm Kinetex® 2.6 m C8 100 Å column or a 50 x 2.1 
mm Kinetex® 2.6 m C18 100 Å column; both were purchased from Phenomenex. MS-MS 
was performed with a collision energy of 45 V or 60 V. Predicted masses were extracted to + 
5 ppm. Two methods were utilized: 
 
Method A:  
Time % Solvent B 
0 - 2 min 2% 
2 - 5 min 2 - 45% 
5 – 22 min 45 - 60% 
22 - 23 min 60 – 95% 
23 - 24 min 95% 
24 – 25 min 95 - 2% 
 
 
Method B: 
Time % Solvent B 
0 -2 min 2% 
2- 13 min 2 - 98% 
13– 15 min 98% 
 
Microwave assisted peptide couplings were programmed and synthesized in a Biotage 
Initiator + AlstraTM with Rink Amide ChemMatrix purchased from Biotage. Solutions 
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utilized were freshly prepared just before synthesis. Couplings were monitored utilizing the 
Kaiser test. Flash chromatography was performed on a Biotage IsoleraTM system with a 
hexanes/ethyl acetate solvent system or a dichloromethane/methanol system. Thin-layer-
chromatography glass plates were purchased from Sorbent Technologies, Inc.® with a 
fluorescent indicator at l = 254 nm. Preparatory HPLC was performed in a Shimadzu UFLC 
CBM-20A with a dual channel wavelength detector at 220 nm and 254 nm with a LUNA 10 
m C18(2) 100 Å, AXIA (Phenomenex) semi-preparatory column with a 15 mL/min flow 
rate. Purifications were carried out with a two solvent system (solvent A = 0.1% 
trifluoroacetic acid in water; solvent B = 0.1% trifluoroacetic acid in acetonitrile). 
 
Method A: 
Time % Solvent B 
0 -2 min 5% 
2- 8 min 5 - 35% 
8 – 23 min 35-55% 
23- 25 min 55 – 100% 
25 – 28.5 min 100% 
28.5 – 30 min 100 – 5% 
30 – 32 min 5% 
 
Method B: 
Time % Solvent B 
0 -2 min 5% 
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2- 25 min 5 - 95% 
25 - 27 min 95% 
27 - 28 min 95 – 5% 
28 – 30 min 5% 
 
2.10.2 Synthesis 
Ethyl-(S)-2-(3-(tert-butoxycarbonyl)-2,2-dimethylthiazolidin-4-yl)thiazole-4-carboxylate 
(2-11). Compound 2-11 was prepared as a white solid according to a literature procedure 
from L-cysteine28c (4.54 g, 24% overall yield, 5 steps). 1H is in agreement with that 
previously reported.1 1H NMR (400 MHz, DMSO-d6, 70 oC): δ 8.37 (s, 1H), 5.64 (d, J = 6.4 
Hz, 1H), 4.31 (q, J = 7.2 Hz, 2H), 3.65 (dd, J = 6.8, 12.4 Hz, 1H), 3.09 (d, J = 12.4 Hz, 1H), 
1.88 (s, 3H), 1.80 (s, 3H), 1.35 (s, 9H), 1.32 (t, J = 7.2 Hz, 3H). HR-MS (ESI): Calculated 
C16H25N2O4S2+ [M + H]+ = 373.1250; found [M + H]+ = 373.1255. [a]D20.4  = -44.76o (c = 
0.1, CHCl3). 
 
tert-Butyl-(S)-4-(4-carbamothioylthiazol-2-yl)-2,2-dimethylthiazolidine-3-carboxylate 
(2-12). Compound 2-11 (0.50 g, 1.34 mmol) is dissolved in MeOH (11.5 mL) and cooled to 0 
oC. 30% NH4OH (6.9 mL) is added dropwise and solution is allowed to warm to rt and stir 
for 16 h under N2. Reaction is concentrated to dryness under reduced pressure. Crude mixture 
is dissolved in DCM and Lawesson’s reagent (0.27 g, 0.671 mmol) is added. Reaction is 
allowed to stir for 36 h at rt under N2. Mixture is evaporated to dryness and purified by flash 
chromatography with silica gel (~60 mesh) with a hexanes (Hex) / ethyl acetate (EtOAc) 
mixture (Rf = 0.25, 30 % EtOAc in Hex) to afford the corresponding thioamide as a pale 
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yellow solid (2-12, 0.35 g) in 73% yield (2 steps). 1H NMR (400 MHz, DMSO-d6, 70 oC): δ 
9.71 (s, br, 1H), 9.16 (s, br, 1H), 8.34 (s, 1H), 5.61 (d, J = 6.4 Hz, 1H), 3.63 (dd, J = 6.0, 12.2 
Hz, 1H), 3.27 (d, J = 12.4 Hz, 1H), 1.87 (s, 3H), 1.80 (s, 3H), 1.37 (s, 9H). 13C NMR (100 
MHz, DMSO-d6, 70 oC): δ 189.21, 173.27, 152.71, 151.34, 126.26, 80.22, 71.77, 70.68, 
64.97, 32.69, 28.87, 27.56. HR-MS (ESI): Calculated C14H22N3O2S3+ [M + H]+ = 360.0869; 
found [M + H]+ = 360.0851. [a]D20.4  = -50.98o (c = 0.1, CHCl3). 
 
Ethyl(S)-2'-(3-(tert-butoxycarbonyl)-2,2-dimethylthiazolidin-4-yl)-[2,4'-bithiazole]-4-
carboxylate (2-13). Compound 2-12 (0.50 g, 1.40 mmol) is dissolved in DME (8.0 mL) and 
cooled to -40 oC. Anhydrous KHCO3 (0.56 g, 5.59 mmol) is added followed by dropwise 
addition of 80-85% ethylbromo pyruvate (0.85 mL, 5.59 mmol) and reaction stirred for 24 h 
at -15 oC. Precipitate is removed by vacuum filtration and washed with DME (2 mL). 
Solution is cooled to -20 oC and 2,6-lutidine (1.13 mL, 9.66 mmol) is added dropwise 
followed by TFAA (0.643 mL, 4.63 mmol). Reaction is stirred for 2 h at this temperature. 
Mixture is evaporated to dryness and partitioned between CHCl3 (10 mL) and H2O (10 mL). 
Collected organic layer and extracted aqueous layer two more times with CHCl3 (5 mL 
each). CHCl3 layer is washed with 10% CuSO4 (2 x 10 mL), 0.05 M citric acid (2 x 10 mL), 
and brine (10 mL). Mixture is purified by flash chromatography with silica gel (~60 mesh) 
with a hexanes (Hex) / ethyl acetate (EtOAc) mixture (Rf = 0.30, 25 % EtOAc in Hex) to 
afford the corresponding bis-thiazole ethyl ester  as a white solid (2-13, 0.493 g) in 77% 
yield. 1H NMR (400 MHz, DMSO-d6, 70 oC): δ 8.48 (d, J = 0.8 Hz,  1H), 8.25 (d, J  = 
0.8Hz, 1H), 5.70 (d, J = 6.4 Hz, 1H), 4.35 (q, J = 6.8 Hz, 2H), 3.67 (dd, J = 6.4, 12.4 Hz, 
1H), 3.16 (t, J = 15.6 Hz, 1H), 1.91 (s, 3H), 1.81 (s, 3H), 1.36 (s, 9H), 1.35 (t, J = 7.2 Hz, 
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3H) . 13C NMR (100 MHz, DMSO-d6, 70 oC): δ 174.68, 162.18, 160.33, 146.85, 146.54, 
128.63, 117.76, 80.09, 70.62, 70.58, 64.86, 60.42, 32.99, 28.90, 27.74, 27.55, 13.78. HR-MS 
(ESI): Calculated C19H26N3O4S3+ [M + H]+ = 456.1080; found [M + H]+ = 456.1099. [a]D20.4  
= -69.38o (c = 0.1, CHCl3). 
 
tert-Butyl (S)-(1-amino-1-thioxopropan-2-yl)carbamate (2-15). Boc-Ala-OSu (10.0 g, 
34.9 mmol) is dissolved in EtOAc (450 mL) and cooled to 0 oC 30% NH4OH (12 mL) is 
added dropwise over a 15 min period and reaction stirred at 0 oC for 1 h. 200 mL of sat. (aq.) 
NaHCO3 are added and the organic layer collected, dried with Na2SO4, and concentrated to 
dryness under reduced pressure. Crude reaction mixture is dissolved in DCM (250 mL) and 
Lawesson’s reagent (7.17 g, 17.7 mmol) is added and reaction stirred for 36 h at rt under N2. 
Mixture is evaporated to dryness and purified by flash chromatography with silica gel (~60 
mesh) with a hexanes (Hex) / ethyl acetate (EtOAc) mixture (Rf = 0.65, 50 % EtOAc in Hex) 
to afford the corresponding thioamide as a pale yellow solid (2-15, 6.01 g) in 82% yield (2 
steps). 1H NMR (400 MHz, DMSO-d6, 26 oC): δ 9.54 (s, br, 1H), 9.08 (s, br, 1H), 6.79 (d, J 
= 6.4 Hz, 1H), 4.22-4.27 (m, 1H), 1.37 (s, 9H), 1.23 (d, J = 6.8 Hz, 3H). 13C NMR (100 
MHz, DMSO-d6, 26 oC): δ 209.37, 154.52, 78.13, 55.62, 28.16, 21.07. HR-MS (ESI): 
Calculated C8H16N2O2SNa+ [M + Na]+ = 227.0830; found [M + H]+ = 227.0838. [a]D20.4  = -
48.14o (c = 0.1, CHCl3). 
 
Ethyl(S)-2-(1-((tert-butoxycarbonyl)amino)ethyl)thiazole-4-carboxylate (2-16). 
Compound 2-15 (4.27 g, 20.9 mmol) is dissolved in DME (113 mL) and cooled to -40 oC. 
Anhydrous KHCO3 (8.37 g, 83.6 mmol) is added followed by dropwise addition of 80-85% 
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ethylbromo pyruvate (13.1 mL, 83.6 mmol) and reaction stirred for 24 h at -15 oC. Precipitate 
is removed by vacuum filtration and washed with DME (20 mL). Solution is cooled to -20 oC 
and 2,6-lutidine (16.82 mL, 144 mmol) is added dropwise followed by TFAA (9.62 mL, 69.2 
mmol). Reaction is stirred for 2 h at this temperature. Mixture is evaporated to dryness and 
partitioned between CHCl3 (10 mL) and H2O (10 mL). Collected organic layer and extracted 
aqueous layer two more times with CHCl3 (5 mL each). CHCl3 layer is washed with 10% 
CuSO4 (2 x 10 mL), 0.05 M citric acid (2 x 10 mL), and brine (10 mL). Mixture is purified 
by flash chromatography with silica gel (~60 mesh) with a hexanes (Hex) / ethyl acetate 
(EtOAc) mixture (Rf = 0.30, 25 % EtOAc in Hex) to afford the corresponding alanine-
thiazole ethyl ester as a white solid (2-16, 2.97 g) in 47% yield. 1H NMR (400 MHz, DMSO-
d6, 26 oC): δ 8.38 (s, 1H), 7.82 (d, J = 7.2 Hz, 1H), 4.85-4.88 (m, 1H), 4.30 (t, J = 6.8 Hz, 
2H), 1.46 (d, J = 7.2 Hz, 3H), 1.40 (s, 9H), 1.29 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, 
DMSO-d6, 26 oC): δ 176.65, 160.69, 155.00, 145.79, 128.59, 78.49, 60.59, 48.58, 28.11, 
20.39, 14.14. HR-MS (ESI): Calculated C13H21N2O4S+ [M + H]+ = 301.1217; found [M + 
H]+ = 301.1244. [a]D20.4  = -28.10o (c = 0.1, CHCl3). 
 
General Procedure A 
Corresponding ester (1.0 equiv.) is dissolved in THF (9.43 mL/mmol) and MeOH (7.86 
mL/mmol) and cooled to 0 oC. 0.4 M NaOH (3.13 equiv.) is added dropwise and reaction 
stirred for 4 h at rt. Concentrated until about a third of solvent is left and the aqueous layer is 
acidified with 0.5 M citric acid until pH = 3.0. Extracted compound with ethyl acetate, unless 
otherwise noted, (3 x 12 mL/mmol). Washed with H2O (12 mL/mmol) and brine (12 
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mL/mmol). Dried with Na2SO4 and concentrated to dryness under reduced pressure to afford 
the corresponding acid, which was utilized without further purification. 
 
General Procedure B 
Corresponding Boc-protected amine (1.0 equiv.) is dissolved in DCM (3.45 mL/mmol) and 
cooled to 0 oC. Trifluoroacetic acid (3.45 mL/mmol) is added dropwise over a 10 min period 
and reaction warmed to rt over a 2 h period. Mixture is concentrated to dryness under 
reduced pressure. EtOAc is added (5 mL) and reaction concentrated to dryness. Crude amine 
salt was utilized without further purification. 
 
General Procedure C 
Corresponding acid (1.05 equiv.) is dissolved in DCM (9.32 mL/mmol). PyBOP (1.05 
equiv.) and N,N-diisopropylethylamine (2.5 equiv.) are added and mixture stirred for 15 min 
at rt. Meanwhile, amine salt (1.0 equiv.) is dissolved in DCM (1.43 mL/mmol) and MeCN 
(1.43 mL/mmol) and added dropwise to the above acid solution at 0 oC. Reaction is 
monitored by TLC until complete consumption of starting amine. Reaction is concentrated to 
dryness under reduced pressure and purified by silica gel (~60 mesh). 
 
General Procedure D: Adapted from a literature procedure.28c Compound (1.0 equiv.) is 
dissolved in methanol (MeOH, 7.8 mL/mmol) and tetrahydrofuran (THF, 9.4 mL/mmol) and 
cooled to 0 oC. 0.4 M NaOH (3.13 equiv.) is added dropwise and reaction stirred for 4 hrs at 
rt. Organics are removed by rotary evaporation under reduced pressure. Aqueous layer is 
acidified with 1 N HCl until pH = 3.0. Acid derivative is extracted with ethyl acetate (EtOAc, 
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3 x 10 mL/mmol), unless otherwise noted, dried with Na2SO4 and concentrated to dryness. 
Crude acid is dissolved in dichloromethane (DCM, 3.7 mL/mmol) and cooled to 0 oC; 
trifluoroacetic acid (TFA, 3.7 mL/mmol) is added dropwise and reaction stirred for 2 h at 0 
oC and 1h at rt. Concentrated. 50% (aq.) ethanol (3.7 mL/mmol) is added and removed by 
concentration; repeated this process 3 more times. Dried under vacuum to dryness. Crude 
compound is dissolved in TFA (4.6 mL/mmol) and trityl chloride (1.0 equiv.) is added and 
reaction stirred for 10 min at rt. Concentrated. Added DCM (9.2 mL/mmol) and 
concentrated; repeated three more times. Added DCM (18.4 mL/mmol) and washed with 
H2O (3.7 mL/mmol). Dried with Na2SO4 and concentrated to dryness. Crude compound is 
dissolved in THF (3.7 mL/mmol) and H2O (3.7 mL/mmol) and cooled to 0 oC. NaHCO3 (2.5 
equiv.) is added scoop wise, followed by Fmoc-OSu (1.0 equiv.) over a 20 min period. 
Reaction is stirred for 20 h at rt. Concentrated to remove THF. Extracted with EtOAc (14.8 
mL/mmol), unless otherwise noted, and collected organic layer; repeated the extraction one 
more time. Dried organics with Na2SO4 and concentrated. Desired compound was purified by 
flash chromatography with silica gel. 
 
General Procedure E: Compound (1.0 equiv.) is dissolved in methanol (MeOH, 7.8 
mL/mmol) and tetrahydrofuran (THF, 9.4 mL/mmol) and cooled to 0 oC. 0.4 M NaOH (3.13 
equiv.) is added dropwise and reaction stirred for 4 hrs at rt. Organics are removed by rotary 
evaporation under reduced pressure. Aqueous layer is acidified with 1 N HCl until pH = 3.0. 
Acid derivative is extracted with ethyl acetate (EtOAc, 3 x 10 mL/mmol), unless otherwise 
noted, dried with Na2SO4 and concentrated to dryness. Crude acid is dissolved in 
dichloromethane (DCM, 3.7 mL/mmol) and cooled to 0 oC; trifluoroacetic acid (TFA, 3.7 
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mL/mmol) is added dropwise and reaction stirred for 2 h at 0 oC and 1h at rt. Concentrated. 
Extracted with EtOAc (14.8 mL/mmol), unless otherwise noted, and collected organic layer; 
repeated the extraction one more time. Dried organics with Na2SO4 and concentrated. 
Desired compound is purified by flash chromatography with silica gel. 
 
General Procedure F: Adapted from a literature procedure.47 Compound (1.0 equiv.) is 
suspended in benzene (2.5 mL/mmol) and Lawesson’s reagent is added (0.5 equiv.); reaction 
is refluxed for 1 h and then cooled to rt. EtOAc is added (5 mL/mmol) and organics washed 
with sat. NH4Cl (aq., 2 x 1.25 mL/mmol), sat. NaHCO3 (2.4 mL/mmol), and brine. Dried 
organics with Na2SO4 and concentrated. Crude mixture is dissolved in 1,2-dimethoxyethane 
(DME, 3.6 mL/mmol) and cooled to -40 oC. KHCO3 (4.0 equiv.) is added followed by 
dropwise addition of ethylbromopyruvate (4.0 equiv.). Reaction is let to react for 16 hrs 
while warming to -20 oC then to rt. Solid is filtered and washed with DME. Filtrate is cooled 
to -15 oC and 2,6-lutidine added (6.91 equiv.), followed by trifluoroacetic anhydride (3.31 
equiv.) over a 20 min period. Reaction is allowed to stir at this temperature for 3 hrs. 
Reaction is concentrated to dryness and EtOAc added (4 mL/mmol). Organic layer is washed 
with 0.1 N HCl (4 x 2 mL/mmol) and brine. Dried organic layer with Na2SO4 and 
concentrated. Desired compound is purified by flash chromatography on silica gel. 
 
tert-Butyl-(S)-4-(4-(((2S,3R)-3-hydroxy-1-methoxy-1-oxobutan-2-yl)carbamoyl)thiazol-
2-yl)-2,2-dimethylthiazolidine-3-carboxylate (2-18). Acid of compound 2-11 was prepared 
according to General Procedure A. Coupling of acid and amine hydrochloride salt of L-
threonine methyl ester was done according to General Procedure C for 2 h. Mixture was 
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purified by flash chromatography with silica gel (~60 mesh) with a hexanes (Hex) / ethyl 
acetate (EtOAc) mixture (Rf = 0.45, 50 % EtOAc in Hex) to afford the corresponding coupled 
product as a white solid (2-18, 0.34 g) in 65% yield. 1H NMR (400 MHz, DMSO-d6, 70 oC): 
δ 8.21 (s, 1H), 7.89 (d, J = 8.4 Hz, 1H), 5.68 (d, J = 6.4 Hz, 1H), 4.47 (dd, J = 2.8, 8.6 Hz, 
1H), 4.23-4.27 (m, 1H), 3.68 (s, 3H), 3.65 (d, J = 6.8 Hz, 1H), 3.14 (d, J = 12.4 Hz, 1H), 1.90 
(s, 3H), 1.80 (s, 3H), 1.35 (s, 9H), 1.13 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 
70 oC): δ 174.07, 170.38, 160.20, 151.25, 148.01, 123.90, 80.10, 70.60, 65.83, 64.87, 57.42, 
51.54, 51.50, 32.93, 28.83, 27.54, 19.94. HR-MS (ESI): Calculated C19H30N3O6S2+ [M + H]+ 
= 460.1571; found [M + H]+ = 460.1585. [a]D20.4  = -44.76o (c = 0.1, CHCl3). 
 
Ethyl-2-((S)-1-(2-((S)-1-((tert-butoxycarbonyl)amino)ethyl)thiazole-4-
carboxamido)ethyl)thiazole-4-carboxylate (2-20) 
 Acid of compound 2-16 was prepared according to General Procedure A and extracted with 
chloroform. Amine salt of compound 2-16 was prepared according to General Procedure B. 
Coupling of acid and amine salt was done according to General Procedure C for 3 h. Mixture 
was purified by flash chromatography with silica gel (~60 mesh) with a hexanes (Hex) / ethyl 
acetate (EtOAc) mixture (Rf = 0.6, 50 % EtOAc in Hex) to afford the corresponding coupled 
product as a pale yellow solid (2-20, 0.43 g) in 49% yield. 1H is in agreement with that 
previously reported.48  1H NMR (400 MHz, DMSO-d6, 70 oC): δ 9.03 (t, 11.6 Hz, 1H), 8.41 
(d, J = 0.8 Hz, 1H), 8.22 (s, 1H), 7.84 (d, J = 6.4 Hz, 1H), 5.38-5.45 (m, 1H), 4.86-4.93 (m, 
1H), 4.29 (q, J = 7.2 Hz, 2H), 1.65 (d, J = 6.8 Hz, 3H), 1.50 (d, J = 6.8 Hz, 3H), 1.41 (s, 9H), 
1.30 (t,  J = 7.2 Hz, 3H). HR-MS (ESI): Calculated C19H27N4O5S2+ [M + H]+ = 455.1417; 
found [M + H]+ = 455.1416. [a]D20.4  = -27.94o (c = 0.1, CHCl3). 
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Ethyl 2'-((S)-1-(2-((S)-1-((tert-butoxycarbonyl)amino)ethyl)thiazole-4-carboxamido)-2-
(tritylthio)ethyl)-[2,4'-bithiazole]-4-carboxylate (2-24). Compound 2-13 (0.50 g, 1.10 
mmol) is dissolved in DCM (6 mL) and cooled to 0 oC. Trifluoroacetic acid (6 mL) is added 
dropwise and reaction stirred for 4 h at rt. Reaction is concentrated under reduced pressure. 
50 % (aq.) EtOH (5 mL) is added and mixture concentrated again; repeated four more times. 
Dried under vacuum. Crude mixture is dissolved in trifluoroacetic acid (5 mL) and trityl 
chloride (0.306g, 1.10 mmol) is added and reaction stirred for 10 min at rt. Concentrated. 
Added 10 mL of DCM and concentrated. Repeated three more times. Added 10 mL of DCM 
and 5 mL of H2O. Collected organic layer, dried with Na2SO4 and concentrated to dryness 
under reduced pressure. Compound was utilized without any further purification. 
The coupling to the acid of compound 2-16, prepared via General Procedure A, was 
performed according to General Procedure C for 3 h. Mixture was purified by flash 
chromatography with silica gel (~60 mesh) with a hexanes (Hex) / ethyl acetate (EtOAc) 
mixture (Rf = 0.65, 50 % EtOAc in Hex) to afford the corresponding coupled product as a 
yellow solid (2-24, 0.44 g) in 65% yield (4 steps). 1H NMR (400 MHz, DMSO-d6, 70 oC): δ 
8.81 (d, J = 8.0 Hz, 1H), 8.47 (s, 1H), 8.22 (s, 1H), 8.20 (s, 1H), 7.53 (s, br, 1H), 7.30-7.38 
(m, 12 H), 7.22-7.26 (m, 3H), 5.21-5.27 (m, 1H), 4.93-4.99 (m, 1H), 4.35 (t, J = 6.8 Hz, 2H), 
3.18 (dd, J = 8.8, 12.6 Hz, 1H), 2.95 (dd, J = 5.2, 12.8 Hz, 1H), 1.55 (d, J = 6.8 Hz, 3H), 1.41 
(s, 9H), 1.34 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 70 oC): δ 176. 13, 171.72, 
161.95, 160.28, 159.95, 154.56, 148.30, 146.83, 143.93, 128.79, 128.70, 127.61, 126.42, 
124.06, 118.04, 78.25, 66.60, 60.38, 50.63, 48.58, 35.30, 27.84, 20.26, 13.75. HR-MS (ESI): 
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Calculated C41H41N5O5S4+ [M + H]+ = 812.2063; found [M + H]+ = 812.2064. [a]D20.4  = -
33.88o (c = 0.1, CHCl3). 
 
Ethyl-2-((S)-1-(2-((S)-1-((2S,3R)-2-(2-((S)-3-(tert-butoxycarbonyl)-2,2-
dimethylthiazolidin-4-yl)thiazole-4-carboxamido)-3-hydroxybutanamido)ethyl)thiazole-
4-carboxamido)ethyl)thiazole-4-carboxylate (2-22). Acid of compound 2-18 was prepared 
according to General Procedure A. Amine salt of compound 2-20 was prepared according to 
General Procedure B. Amine salt (0.198 g, 0.423 mmol) is dissolved in CHCl3 (2 mL) and 
cooled to 0 oC. N-methylmorpholine (0.146 mL, 1.33 mmol) is added very slowly dropwise. 
Meanwhile, acid (0.237 g, 0.532 mmol) is dissolved in CHCl3 (4 mL) and THF (0.75 mL) 
and added to the above cooled solution dropwise. EDC*HCl (0.102 g, 0.532 mmol) is added 
followed by 2 crystals of N,N-4-dimethylaminopyridine (DMAP) and reaction stirred for 18 
h at rt. Reaction is washed with 0.05 M citric acid (2 x 5 mL), dried with Na2SO4, and 
concentrated. Mixture was purified by flash chromatography with silica gel (~60 mesh) with 
a hexanes (Hex) / ethyl acetate (EtOAc) mixture (Rf = 0.50, 100%  EtOAc) to afford the 
corresponding coupled product as a white solid (2-22, 0.275 g) in 54% yield. 1H NMR (400 
MHz, DMSO-d6, 70 oC): δ 8.72 (d, J = 7.6 Hz, 1H), 8.62 (d, J  = 8.0 Hz, 1H), 8.36 (s, 1H), 
8.21 (s, 1H), 8.19 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 5.68 (d, J = 6.4 Hz, 1H), 5.40-5.47 (m, 
1H), 5.25-5.32 (m, 1H), 4.46 (dd, J = 3.2, 8.2, 1H), 4.32 (q, J = 7.2 Hz, 2H), 4.17-4.22 (m, 
1H), 3.67 (dd, J = 6.4, 12.4 Hz, 1H), 3.12 (d, J = 12.4 Hz, 1H) 1.90 (s, 3H), 1.80 (s, 3H), 1.68 
(d, J = 7.2 Hz, 3H), 1.60 (d, J = 6.8 Hz, 3H), 1.35 (s, 9H), 1.32 (t, J = 7.2 Hz, 3H), 1.12 (d, J 
= 6.4 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 70 oC): δ 174.21, 173.95, 173.87, 169.31, 
160.36, 160.06, 159.90, 148.48, 148.40, 145.47, 128.25, 124.07, 123.57, 80.14, 70.62, 66.36, 
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64.91, 60.23, 57.79, 46.79, 46.76, 46.72, 32.93, 28.81, 27.78, 27.55, 20.15, 19.87, 19.82, 
13.76. HR-MS (ESI): Calculated C32H44N7O8S4+ [M + H]+ = 782.2129; found [M + H]+ = 
782.2120. [a]D20.4  = -46.34o (c = 0.1, CHCl3). 
 
Ethyl-2'-((S)-1-(2-((S)-1-(2-((S)-1-(2-((S)-1-((2S,3R)-2-(2-((S)-3-(tert-butoxycarbonyl)-
2,2-dimethylthiazolidin-4-yl)thiazole-4-carboxamido)-3-
hydroxybutanamido)ethyl)thiazole-4-carboxamido)ethyl)thiazole-4-
carboxamido)ethyl)thiazole-4-carboxamido)-2-(tritylthio)ethyl)-[2,4'-bithiazole]-4-
carboxylate (2-25). Acid of compound 2-22 was prepared according to General Procedure 
A. Amine salt of compound 2-24 was prepared according to General Procedure B. Amine salt 
(0.26 g, 0.326 mmol) is dissolved in CHCl3 (2 mL) and cooled to 0 oC. N-methylmorpholine 
(0.11 mL, 1.00 mmol) is added very slowly dropwise. Meanwhile, acid (0.25 g, 0.332 mmol) 
is dissolved in CHCl3 (4 mL) and added to the above cooled solution dropwise. EDC*HCl 
(63 mg, 0.328 mmol) is added followed by 2 crystals of N,N-4-dimethylaminopyridine 
(DMAP) and reaction stirred for 20 h at rt. Mixture was purified by flash chromatography 
with silica gel (~60 mesh) with a dichloromethane (DCM) / methanol (MeOH) mixture (Rf = 
0.30, 5%  MeOH in DCM) to afford the corresponding coupled product as a white solid (2-
25, 0.165 g) in 36% yield. 1H NMR (400 MHz, DMSO-d6, 70 oC): δ 8.85 (d, J = 8.4 Hz, 
1H), 8.80 (d, J = 7.6 Hz, 1H), 8.74 (d, J = 7.6 Hz, 1H), 8.64 (d, J = 7.2 Hz, 1H), 8.48 (s, 1H), 
8.24 (s, 1H), 8.22 (s, 1H), 8.212 (s, 1H), 8.207 (s, 1H), 8.20 (s, 1H), 7.95 (d, J = 8.0 Hz, 1H), 
7.30-7.37 (m, 12H), 7.23-7.26 (m, 3H), 5.68 (d, J = 6.0 Hz, 1H), 5.42-5.53 (m, 2H), 5.28-
5.33 (m, 1H), 5.20-5.26 (m, 1H), 4.47 (dd, J = 3.6, 8.2 Hz, 1H), 4.35 (q, J = 6.8 Hz, 2H), 
4.18-4.23 (m, 1H), 3.67 (dd, J = 6.4, 12.4 Hz, 1H), 3.18 (t,  J = 9.2 Hz, 1H), 3.12 (d, J = 12.4 
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Hz, 1H), 2.94 (dd, J = 5.2, 12.8 Hz, 1H), 1.89 (s, 3H), 1.80 (s, 3H), 1.74 (d, J = 6.8 Hz, 3H), 
1.72 (d, J = 8.8 Hz, 3H), 1.60 (d, J = 7.2 Hz, 3H), 1.35 (s, 9H), 1.33 (t, J = 4.4 Hz, 3H), 1.14 
(d,  J = 6.4 Hz, 3H). 13C NMR (100 MHz, DMSO-d6, 70 oC): δ 174.29, 174.17, 174.03, 
173.96, 171.75, 169.34, 161.96, 160.30, 160.08, 160.01, 159.99, 159.93, 151.29, 148.60, 
148.48, 148.42, 148.23, 146.82, 146.79, 143.94, 128.80, 127.65, 126.46, 124.40, 124.08, 
123.58, 118.10, 80.14, 70.61, 66.62, 66.38, 64.90, 60.41, 57.80, 50.70, 46.93, 46.80, 35.29, 
32.93, 28.84, 27.80, 27.56, 20.20, 19.94, 19.87, 19.84, 19.80, 13.77. HR-MS (ESI): 
Calculated C66H71N12O10S8+ [M + H]+ = 1447.3176; found [M + H]+ = 1447.3216. [a]D20.4  = 
-50.98o (c = 0.1, CHCl3). 
 
 
(S)-1-(4-(((2S,3R)-1-(((S)-1-(4-(((S)-1-(4-(((S)-1-(4-(((S)-1-(4-(ethoxycarbonyl)-[2,5'-
bithiazol]-2'-yl)-2-mercaptoethyl)carbamoyl)thiazol-2-yl)ethyl)carbamoyl)thiazol-2-
yl)ethyl)carbamoyl)thiazol-2-yl)ethyl)amino)-3-hydroxy-1-oxobutan-2-
yl)carbamoyl)thiazol-2-yl)-2-mercaptoethan-1-aminium 2,2,2-trifluoroacetate (2-26). 
Compound 2-25 (49.2 mg, 34.6 mmol) is dissolved in DCM (1 mL) and cooled to 0 oC. 
Trifluoroacetic acid (1 mL) is added dropwise followed by triisopropylsilane (7.5 mL, 34.6 
mmol). Reaction is stirred for 4 h at rt. Mixture is concentrated in vacuo and 50% (aq.) EtOH 
is added (3 mL) and concentrated again. Repeated 3 more times. Dried overnight in vacuo 
NH
S
N
SN
NH
NH
O
Me
HN
O
Me S
N O
HN
N S
Me
HO
Me
N
S
O
OEt
O
NS
O
HS
H3N
HS
2-26
F3C O
O
 49 
and dissolved mixture in 346.5 mL of N,N-dimethylformamide (DMF) to make a 0.10 M 
stock. 
 
2,5-Dibromohexanediamide (2-28). Compound 2-28 was prepared as a white solid 
according to a literature procedure from adipic acid.41 1H is in agreement with that previously 
reported. 1H NMR (600 MHz, DMSO-d6): δ 7.69 (s, 2H), 7.31 (s, 2H), 4.33 (q, J = 4.8 Hz, 
2H), 2.01-2.06 (m, 1H), 1.88-2.00 (m, 2H), 1.79-1.84 (m, 1H). 
 
 
 
(S)-2-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-(tritylthio)ethyl)thiazole-4-
carboxylic acid (2-33). Compound was prepared from compound 2-11 according to General 
Procedure D. Compound was purified by flash chromatography with silica gel (~60 mesh) in 
a dichloromethane (DCM) / methanol (MeOH) mixture (Rf = 0.4, 5 % MeOH in DCM) to 
afford the corresponding Fmoc-protected amino acid  as a pale tan solid (2-33) in 66% yield 
(4 steps). 1H NMR (500 MHz, DMSO-d6): δ 8.30 (d, J = 8.5 Hz, 1H), 8.26 (s, 1H), 7.88 (d, J 
= 7.5 Hz, 2H), 7.70 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.31-7.40 (m, 14H), 7.24-
7.28 (m, 4H), 4.51-4.55 (m, 1H), 4.34 (d, J = 7.0 Hz, 2H), 4.23 (t, J = 7.0 Hz, 1H), 2.83 (dd, 
J = 9.5, 12.25 Hz, 1H), 2.67 (dd, J = 5.0, 12.5 Hz, 1H). 13C NMR (125 MHz, DMSO-d6): δ 
171.62, 162.06, 155.45, 144.15, 143.64, 140.69, 129.08, 128.12, 127.60, 127.03, 127.01, 
126.85, 125.19, 125.16, 120.08, 66.46, 65.67, 52.48, 46.62, 35.43. HR-MS (ESI): Calculated 
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Me Me
N
S
OEt
O
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C40H32N2NaO4S2+ [M + Na]+ = 691.1696; found [M + Na]+ = 691.1689. [a]D22.4  = +16.0o (c 
= 0.1, MeOH). 
 
 
(S)-2'-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-(tritylthio)ethyl)-[2,4'-
bithiazole]-4-carboxylic acid (2-34). Compound 2-34 was prepared from compound 2-13 
according to General Procedure D. Compound was purified by flash chromatography with 
silica gel (~60 mesh) in a dichloromethane (DCM) / methanol (MeOH) mixture (Rf = 0.1, 5 
% MeOH in DCM) to afford the corresponding Fmoc-protected amino acid pale tan solid (2-
34) in 42% yield (4 steps). 1H NMR (500 MHz, DMSO-d6): δ 13.15 (s, br, 1H), 8.47 (s, 1H), 
8.40 (d, J = 8.5 Hz, 1H), 8.19 (s, 1H), 7.87 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 5 Hz, 2H), 7.32-
7.40 (m, 15H), 7.25-7.30 (m, 4H), 4.55 (q, J = 6 Hz, 1H), 4.43 (t, J = 6 Hz, 1H), 4.38 (t, J = 7 
Hz, 1H), 4.26 (t, J = 6.5 Hz, 1H), 2.94 (t, J = 6.5 Hz, 1H), 2.69 (dd, J = 3.5, 12.5 Hz, 1H). 
13C NMR (125 MHz, DMSO-d6): δ 173.42, 162.02, 155.61, 148.09, 147.46, 144.17, 143.65, 
140.74, 129.13, 128.24, 128.12, 127.62, 127.06, 126.86, 125.19, 125.12, 120.09, 118.05, 
66.77, 65.68, 53.05, 46.70, 35.74, 25.23. HR-MS (ESI): Calculated C43H33N3NaO4S3+ [M + 
Na]+ = 774.1525; found [M + Na]+ = 774.1526. [a]D22.8  = +14.0o (c = 0.1, MeOH). 
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(S)-2-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)ethyl)thiazole-4-carboxylic acid 
(2-35). Compound 2-35 was prepared from compound 2-16according to General Procedure 
E. Compound was purified by flash chromatography with silica gel (~60 mesh) in a 
dichloromethane (DCM) / methanol (MeOH) mixture (Rf = 0.35, 5 % MeOH in DCM) to 
afford the corresponding Fmoc-protected amino acid as a white solid (2-35) in 83% yield (3 
steps). 1H NMR (500 MHz, DMSO-d6): δ 13.0 (s, br, 1H), 8.35 (s, 1H), 8.28 (d, J = 8 Hz, 
1H), 7.88 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 8 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 8 
Hz, 2H), 4.96 (t, J = 7.5 Hz, 1H), 4.44 (t, J = 7 Hz, 1H), 4.34 (t, J = 6.5 Hz, 1H), 4.24 (t, J = 
6.5 Hz, 1H), 1.51 (d, J = 6.5 Hz, 3H). 13C NMR (125 MHz, DMSO-d6): δ 175.52, 162.11, 
155.67, 147.00, 143.79, 143.73, 140.78, 128.36, 127.66, 127.10, 125.21, 125.14, 120.13, 
65.61, 49.04, 46.75, 20.53. HR-MS (ESI): Calculated C21H19N2O4S+ [M + H]+ = 395.1060; 
found [M + H]+ = 395.1055. [a]D22.5  = +24. 0o (c = 0.1, MeOH). 
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Ethyl (S)-2-(1-((tert-butoxycarbonyl)amino)-2-methylpropyl)thiazole-4-carboxylate (2-
36). Compound 2-36 was prepared according to a literature procedure28c from L-Boc-Val-OH 
as a white solid (3.02 g, 75% overall yield, 3 steps). 1H is in agreement with that previously 
reported.28c 1H NMR (400 MHz, DMSO-d6): δ 8.40 (s, 1H), 7.70 (d, J = 8.4 Hz, 1H), 4.62 (t, 
J = 7.6 Hz, 1H), 4.29 (q, J = 7.2 Hz, 2H), 2.18-2.24 (m, 1H), 1.39 (s, 9H), 0.89 (d, J = 6.8 
Hz, 3H), 0.84 (d, J = 7.2 Hz, 3H). HR-MS (ESI): Calculated C15H25N2O4S+ [M + H]+ = 
329.1530; found [M + H]+ = 329.1524. [a]D22.8  = -14.0o (c = 0.1, MeOH).  
 
(S)-2-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpropyl)thiazole-4-
carboxylic acid (2-37). Compound 2-37 was prepared from compound 2-36 according to 
General Procedure D. Compound was purified by flash chromatography with silica gel (~60 
mesh) in a dichloromethane (DCM) / methanol (MeOH) mixture (Rf = 0.4, 5% MeOH in 
DCM) to afford the corresponding Fmoc-protected amino acid as a pale tan solid  (2-37) in 
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78% yield (3 steps). 1H NMR (500 MHz, DMSO-d6): δ 12.98 (s, br, 1H), 8.36 (s, 1H), 8.23 
(d, J = 8.5 Hz, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 6.0 Hz, 2H), 7.41 (d, J = 6.5 Hz, 
2H), 7.32 (t, J = 7.5 Hz, 2H), 4.67 (t, J = 8 Hz, 1H), 4.31-4.37 (m, 2H), 4.24 (t, J = 7 Hz, 
1H), 2.23-2.28 (m, 1H), 0.93 (d, J = 7 Hz, 3H), 0.86 (d, J = 7 Hz, 3H). 13C NMR (125 MHz, 
DMSO-d6): δ 173.67, 162.08, 156.14, 146.85, 143.72, 140.71, 128.34, 127.63, 127.03, 
125.24, 120.10, 65.66, 58.99, 46.69, 32.18, 19.18, 18.21. HR-MS (ESI): Calculated 
C23H23N2O4S+ [M + H]+ = 423.1373; found [M + H]+ = 423.1352. [a]D22.8  = -20.0o (c = 0.1, 
MeOH). 
 
Ethyl (S)-2'-(1-((tert-butoxycarbonyl)amino)-2-methylpropyl)-[2,4'-bithiazole]-4-
carboxylate (2-38). Compound 2-36 (4.08 g, 12.4 mmol) is dissolved in MeOH (75 mL) and 
cooled to 0 oC. 28% (aq.) NH4OH (50 mL) is added dropwise and reaction stirred for 8 hrs at 
rt. Methanol is removed under reduced pressure and DCM is added (75 mL). Collected 
organic layer, dried with Na2SO4, and concentrated to dryness to afford the amide derivative 
that was subjected to General Procedure F to make compound 2-38. Compound was purified 
by flash chromatography with silica gel (~60 mesh) in a hexanes (Hex) / ethyl acetate 
(EtOAc) mixture (Rf = 0.3, 20% EtOAc in Hex) to obtain 2-38 (2.71 g, 53% yield, 4 steps). 
1H is in agreement with that previously reported.36 1H NMR (400 MHz, DMSO-d6): δ 8.53 
(s, 1H), 8.26 (s, 1H), 7.76 (d, J = 8.4 Hz, 1H), 4.66 (t, J = 7.2 Hz, 1H), 4.33 (q, J = 6.8 Hz, 
2H), 2.22-2.29 (m, 1H), 1.41 (s, 9H), 1.32 (t, J = 6.8 Hz, 3H), 0.93 (d, J = 6.4 Hz, 3H), 0.89 
(d, J = 6.8 Hz, 3H). HR-MS (ESI): Calculated C18H26N3O4S2+ [M + H]+ = 412.1359; found 
[M + H]+= 412 1354. [a]D22.6  = -27.0o (c = 0.1, MeOH). 
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(S)-2'-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpropyl)-[2,4'-
bithiazole]-4-carboxylic acid (2-39). Compound 2-39 was prepared from compound 2-38 
according to General Procedure E. Compound was purified by flash chromatography with 
silica gel (~60 mesh) in a dichloromethane (DCM) / methanol (MeOH) mixture (Rf = 0.35, 
5% MeOH in DCM) to afford the corresponding Fmoc-protected amino acid as a pale tan 
solid (2-39) in % yield (3 steps). 1H NMR (400 MHz, DMSO-d6): δ 8.32 (s, br, 1H), 8.26 (d, 
J = 8.8 Hz, 1H), 8.22 (s, 1H), 7.89 (d, J = 7.6 Hz, 2H), 7.72-7.74 (m, 2H), 7.39-7.43 (m, 2H), 
7.32 (t, J = 7.6 Hz, 2H), 4.70 (t, J = 7.6 Hz, 1H), 4.36 (quint., J = 7.6 Hz, 2H), 4.24 (t, J = 7.4 
Hz, 1H), 2.24-2.31 (m, 1H), 0.96 (d, J = 6.4 Hz, 3H), 0.90 (d, J = 6.4 Hz, 3H). 13C NMR 
(125 MHz, DMSO-d6): δ 174.97, 162.21, 162.02, 156.19, 148.10, 147.31, 143.71, 140.72, 
128.91, 127.64, 127.04, 125.24, 125.18, 120.10, 117.77, 65.67, 58.95, 46.72, 32.30, 19.31, 
18.25. HR-MS (ESI): Calculated C26H24N3O4S2+ [M + H]+ = 506.1203; found [M + H]+ = 
506.1202. [a]D22.8  = -29.0 o (c = 0.1, MeOH). 
 
 
Ethyl (S)-2-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)-3-
oxopropyl)thiazole-4-carboxylate (2-40). Compound 2-40 was prepared as a white solid 
according to a literature method36 from Fmoc-Asp(OtBu)-OH (4.41 g, 58% overall yield, 5 
steps). 1H is in agreement with that previously reported.49 1H NMR (500 MHz, DMSO-d6): δ 
8.44 (s, 1H), 8.33 (d, J = 8 Hz, 1H), 7.89 (d, J = 8 Hz, 2H), 7.70 (d, J = 7.5 Hz, 2H), 7.41 (t, 
J = 7 Hz, 2H), 7.32 (t, J = 7 Hz, 2H), 5.22 (q, J = 6.5 Hz, 1H), 4.36-4.46 (m, 2H), 4.23-4.31 
FmocHN
O
O
N
S
O
OEt
FmocHN
NHMe
O
N
S
O
OEt
i.TIPS, TFA, CH2Cl2, 7 h
ii. i-BuOCOCl, DIPEA, 
   CH2Cl2
iii. DIPEA, MeNH2 (2M, THF)
i. 0.4 M NaOH, THF : MeOH, 
   4h
ii. Fmoc-OSu, NaHCO3, 
   THF : H2O, 16 h
FmocHN
NHMe
O
N
S
O
OH
2-42
84%, 2 steps.
2-40 2-41> 99%, 3 steps
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(m, 3H), 2.99 (dd, J = 6, 15.8 Hz, 1H), 2.77 (dd, J = 9, 15.8 Hz, 1H), 1.37 (s, 9H), 1.29 (t, J = 
7.5 Hz, 3H). HR-MS (ESI): Calculated C28H31N2O6S+ [M + H]+ = 523.1897; found [M + H]+ 
= 523.1903. [α]D22.8  = -2.0o (c = 0.1, MeOH). 
 
Ethyl (S)-2-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(methylamino)-3-
oxopropyl)thiazole-4-carboxylate (2-41). Compound 2-40 (4.41 g, 8.44 mmol) is dissolved 
in DCM (60 mL) and cooled to 0 oC. Triisopropylsilane (1.94 mL, 9.28 mmol) is added 
followed by dropwise addition of TFA (40 mL). Reaction is stirred for 7 h at rt. Reaction is 
concentrated; DCM (50 mL) is added and solution concentrated. DCM is added (80 mL) and 
solution cooled to 0 oC; DIPEA (4.41 mL, 25.3 mmol) is added, followed by dropwise 
addition of iso-butylchloroformate (3.28 mL, 25.3 mmol). Reaction is allowed to stir for 40 
min at 0 oC, then additional DIPEA is added (7.35 mL, 42.2 mmol) followed by a dropwise 
addition of a 2 M MeNH2 solution (in THF, 21.1 mL, 42.2 mmol). Reaction is allowed to stir 
for 40 min at 0 oC and at rt for 80 min. Mixture is partitioned between 1 N HCl & 10% 
MeOH in DCM. Organics are dried with Na2SO4 and concentrated. Mixture was purified by 
flash chromatography with silica gel (~60 mesh) with a dichloromethane (DCM) / methanol 
(MeOH) mixture (Rf = 0.45, 5%  MeOH in DCM) to afford the corresponding coupled 
product as a white solid (2-41, 4.05 g) in > 99% yield (3 steps). 1H NMR (500 MHz, DMSO-
d6): δ 8.41 (s, 1H), 8.23 (d, J = 8.5 Hz, 1H), 7.87-7.90 (m, 3H), 7.69 (t, J = 5.5 Hz, 2H), 7.41 
(t, J = 7 Hz, 2H), 7.32 (t, J = 7 Hz, 2H), 5.25 (q, J = 8 Hz, 1H), 4.39 (t, J = 7 Hz, 1H), 4.27-
4.34 (m, 3H), 4.23 (t, J = 6.5 Hz, 1H), 2.85 (dd, J = 5.5, 15 Hz, 1H), 2.69 (dd, J = 8.5, 15.2 
Hz, 1H), 2.57 (d, J = 4.5 Hz, 3H), 1.29 (t, J = 7 Hz, 3H). 13C NMR (125 MHz, DMSO-d6): δ 
173.88, 168.89, 160.64, 155.50, 145.67, 143.75, 143.60, 140.70, 129.16, 127.60, 127.06, 
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127.03, 125.15, 125.11, 120.09, 120.03, 65.62, 60.67, 50.25, 46.65, 25.52, 14.18. HR-MS 
(ESI): Calculated C25H26N3O5S+ [M + H]+ = 480.1588; found [M + H]+ = 480.1570. [α]D22.7  
= -11.2o (c = 0.1, MeOH). 
 
(S)-2-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(methylamino)-3-
oxopropyl)thiazole-4-carboxylic acid (2-42). Compound 2-41 (1.83 g, 3.82 mmol) is 
dissolved in MeOH (23.9 mL) and THF (28.7 mL) and cooled to 0 oC. 0.5 M NaOH (23.9 
mL, 11.96 mmol) is added dropwise and reaction stirred for 4 hrs at rt. THF and MeOH are 
removed by rotary evaporation and the pH of the aqueous phase is acidified to 7 with 1N 
HCl. Concentrated to dryness. Crude mixture is dissolved in THF (25 mL) and H2O (25 mL) 
and cooled to 0 oC. NaHCO3 (1.12 g, 13.4 mmol) is added scoop-wise followed by Fmoc-
OSu (1.29 g, 3.82 mmol) over a 20 min period. Reactions is let to react for 16 hrs at rt. THF 
is removed by rotary evaporation and water layer is adjusted to pH = 3 with 1 N HCl to form 
a ppt. Solid is collected by filtration and washed with 10% MeOH in DCM (2 x 50 mL) to 
afford the corresponding Fmoc-protected amino acid as a white solid (2-42) in 84% yield (2 
steps). 1H NMR (500 MHz, DMSO-d6): δ 12.98 (s, br, 1H), 8.35 (s, 1H), 8.23 (d, J = 8 Hz, 
1H), 7.89 (d, J = 7 Hz, 2H), 7.84 (s, br, 1H), 7.69 (t, J = 8 Hz, 2H), 7.41 (t, J = 7 Hz, 2H), 
7.32 (t, J = 7 Hz, 2H), 5.26 (q, J = 8 Hz, 1H), 4.39 (t, J = 8 Hz, 1H), 4.32 (t, J = 6.5 Hz, 1H), 
4.24 (t, J = 7 Hz, 1H), 2.86 (dd, J = 5, 15.25 Hz, 1H), 2.70 (dd, J = 9, 15 Hz, 1H), 2.57 (t, J = 
4.5 Hz, 3H). 13C NMR (125 MHz, DMSO-d6): δ 173.59, 168.99, 162.01, 155.54, 146.82, 
143.78, 143.63, 140.73, 128.71, 127.63, 127.10, 127.06, 125.19, 125.15, 120.12, 65.65, 
50.28, 46.67, 25.55. HR-MS (ESI): Calculated C23H22N3O5S+ [M + H]+ = 452.1275; found 
[M + H]+ = 452.1266. [α]D22.7  = -25.0o (c = 0.1, MeOH). 
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(S)-2-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-phenylethyl)thiazole-4-
carboxylic acid (2-44). Compound 2-44 was made as a white solid according to a literature 
procedure50 from Fmoc-Phe-OH in 66% yield (4 steps). 1H is in agreement with that 
previously reported.50 1H NMR (400 MHz, 40 oC, DMSO-d6): δ 13.00 (s, br, 1H), 8.37 (s, 
1H), 8.34 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 7.6 Hz, 2H), 7.61 (d, J = 7.6 Hz, 2H), 7.41 (t, J = 
7.6 Hz, 2H), 7.31-7.34 (m, 3H), 7.26-7.30 (m, 3H), 7.20 (t, J = 7.2 Hz, 1H), 5.02-5.08 (m, 
1H), 4.20-4.30 (m, 2H), 4.15 (t, J = 6.8 Hz, 1H), 3.38 (d, J = 4.4 Hz, 1H), 3.34 (d, J = 4.4 Hz, 
1H), 3.03-3.09 (m, 1H). HR-MS (ESI): Calculated C27H23N2O4S+ [M + H]+ = 471.1373; 
found [M + H]+ = 471.1371 . [a]D22.8  = -12.0o (c = 0.1, MeOH). 
 
 
3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(methylamino)benzoic acid (2-45). 
Compound 2-45 was made as a brown solid according to a literature procedure42 from 4-
fluoro-3-nitrobenzoic acid in 83% yield (3 steps). 1H is in agreement with that previously 
reported.42 1H NMR (400 MHz, 40 oC, DMSO-d6): δ 12.11 (s, br), 8.62 (s, br), 7.89 (d, J = 
7.6 Hz, 2H), 7.69 (t, J = 7.6 Hz, 3H), 7.42 (t, J = 7.6 Hz, 2H), 7.33 (t, J = 7.6 Hz, 2H), 6.61 
(d, J = 8.4 Hz, 1H), 4.37 (d, br, J = 4.4 Hz, 2H), 4.27 (d, br, J = 6 Hz, 1H), 2.79 (s, 3H). 
FmocHN
OH
FmocHN N
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O
OH
2-43 2-44
4 steps, 66%
O
i. i-BuOCOCl, DIPEA, CH2Cl2, 45 min
ii. 28% NH4OH, 0 oC, 1 h
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Methyl 2,5-dibromopentanoate (2-31). Compound 2-31 was made as an oil according to a 
literature procedure44 from δ-valerolactone in 22% yield (2 steps). 1H is in agreement with 
that previously reported.44 1H NMR (500 MHz, DMSO-d6): δ 4.66 (dd, J = 2.4, 8.2 HZ, 1H), 
3.72 (s, 3H), 3.58 (td, J = 1.6, 6.4 Hz, 2H), 2.10-2.19 (m, 1H), 1.81-2.06 (m, 3H). 
 
 
 
(S)-1-(4-(((2S,3R)-1-(((S)-1-(4-(((S)-1-(4-(((S)-1-(4-(((S)-1-(4-carbamoyl-[2,4'-bithiazol]-
2'-yl)-2-mercaptoethyl)carbamoyl)thiazol-2-yl)ethyl)carbamoyl)thiazol-2-
yl)ethyl)carbamoyl)thiazol-2-yl)ethyl)amino)-3-hydroxy-1-oxobutan-2-
yl)carbamoyl)thiazol-2-yl)-2-mercaptoethan-1-aminium 2,2,2-trifluoroacetate (2-46). 
Compound 2-46 was built on solid-phase support utilizing RinkAmide Resin. Detailed 
procedure can be found in Section 2.10.3. 1H NMR (500 MHz, DMSO-d6): δ 9.14 (d, J = 8.5 
Hz, 1H), 9.10 (d, J = 8.0 Hz, 1H), 9.04 (d, J = 8.0 Hz, 1H), 8.96 (d, J = 7.5 Hz, 1H), 8.83 (s, 
br, 3H), 8.46 (s, 1H), 8.28 (t, J = 3 Hz, 2H), 8.24-8.26 (m, 2H), 8.01 (d, J = 8.5 Hz, 1H), 7.81 
(s, 1H), 7.67 (s, 1H), 5.42-5.49 (m, 3H), 5.25 (quint, J = 7.5 Hz, 1H), 4.94-4.95 (m, 1H), 4.52 
(dd, J = 4, 8.8 Hz, 1H), 4.16-4.20 (m, 1H), 3.24-3.35 (m, 2H), 3.09-3.15 (m, 2H), 2.82-2.88 
Br OMe
O
Br
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22%, 2 steps
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(m, 1H), 2.66 (t, J = 8.5 Hz, 1H), 1.72 (d, J = 7.5 Hz, 3H), 1.70 (d, J = 7.5 Hz, 3H), 1.58 (d, J 
= 7 Hz, 3H), 1.14 (d, J = 6 Hz, 3H). 13C NMR (125 MHz, DMSO-d6): δ 174.96, 174.90, 
174.74, 172.84, 169.60, 164.79, 162.14, 161.49, 160.73, 160.39, 160.34, 159.96, 158.20 (q, J 
= 36 Hz), 151.12, 148.81, 148.77, 148.72, 148.59, 148.57, 147.48, 126.69, 124.99, 124.76, 
124.75, 124.49, 119.27, 118.19, 116.95, 114.62, 112.29, 66.94, 57.91, 53.80, 53.19, 47.27, 
47.21, 47.08, 27.62, 27.18, 20.66, 20.61, 20.20. HR-MS (ESI): Calculated C37H42N13O7S8+ 
[M + H]+ = 1036.1090; found [M + H]+ = 1036.1091. [a]D20.4  = +447o (c = 0.1, MeOH). 
 
2.10.3 Solid Phase Peptide Synthesis 
General Microwave SPPS Method 1:  
Resin (50 mg, 0.47 mmol peptide/g resin) is initially swollen in DMF (1.5 mL) for 20 
min at 70°C. 
(i) Coupling: Fmoc-AA-OH (5.0 equiv., 0.5 M in DMF), HATU (5.0 equiv., 0.5 M in 
DMF), and DIEA (10.0 equiv., 1.0 M in DMF) were added to the swollen resin in that order. 
The resulting suspension was heated under microwave irradiation: 5 min at 75 °C. The 
reaction vessel is then drained and resin is thoroughly washed with DMF four times. 
(ii) Fmoc removal: Following coupling, excess 20% piperidine is added to the 
reaction vessel and allowed to incubate for 3 min while stirring at rt. The reaction vessel is 
drained, washed with DMF and excess 20% piperidine is introduced again and allowed to stir 
at rt for 10 min. The reaction vessel is drained and resin is thoroughly washed with DMF four 
times. 
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General Microwave SPPS Method 2:  
(i) Coupling: Fmoc-AA-OH (5.0 equiv., 0.5 M in DMF), TBTU (5.0 equiv., 0.5 M in 
DMF), HOBt (5.0 equiv., 0.5 M in DMF) and DIEA (10.0 equiv., 1.0 M in DMF) were added 
to the resin in that order. The resulting suspension was heated under microwave irradiation: 5 
min at 75 °C. The reaction vessel is then drained and resin is thoroughly washed with DMF 
four times. 
(ii) Fmoc removal: Same as Fmoc removal in Method 1. 
 
A. Leader Peptides 
  
 
 Procedure has been adapted from a literature one.42 The linear synthesis of minimal 
the leader peptides were carried out on a ChemMatrix solid support (0.47 mmol/g) on a 0.188 
mmol scale. To facilitate higher loading of Fmoc-MeDbz-OH, a glycine or alanine spacer 
was coupled to the resin first using Method 1. Coupling of the Fmoc-MeDbz-OH moiety was 
accomplished using Method 2. All following Fmoc-AA-OH were coupled using Method 1. 
All couplings and deprotections were monitored by Kaiser Tests. Last coupling is done with 
the Boc-AA-OH derivative. Subsequently, the peptide was acylated with a solution of p-
nitrophenyl chloroformate (10.0 equiv, 0.5 M in DCM) over 1 hr at 37 °C. The resin was 
filtered, washed with DCM, and treated with a solution of DIEA (0.5 M in DMF) for 30 min. 
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After washing the resin with DMF and DCM, the resin was dried and cleaved using the 
standard cleavage cocktail (TFA/TIS/H2O, 95:2.5:2.5) to yield the LP-MeNbz. 
 
B. Core Peptides 
 
The linear syntheses of the core peptides were carried out on a ChemMatrix solid 
support (0.47 mmol/g) on a 0.01175 mmol scale. With the exception of 2-34, all building 
blocks were coupled using Method 1. Compound 2-34 was coupled using Method 2. All 
couplings and deprotections were monitored by Kaiser test. After washing the resin with 
DMF and DCM, the resin was dried and cleaved using the standard cleavage cocktail 
(TFA/TIS/H2O, 95:2.5:2.5) to yield the core peptides. 
 
C. On-Resin Native Chemical Ligation 
Core Deprotection Protocol (0.5mg resin, 0.00235mM scale):  
(i) Fmoc-protected resin-bound cores were swollen in DMF (0.5mL) for 30min at 
37°C. Fmoc removal was accomplished using 20% Piperidine in DMF (0.5mL) for 4min at 
room temperature. This procedure was repeated twice. Resin was washed 5 times with DMF 
(1.0mL), then 5 times with DCM (1.0mL). 
(ii) Selective trityl group deprotections were done according to a literature 
procedure43  using 0.1 N HCl in HFIP + 1% TIPS (0.2 mL) for 1min at room temperature. 
This procedure was repeated once. Resin was washed 5 times with DMF (1.0mL), then 5 
times with DCM (1.0mL) 
N
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(iii) Reduced cysteines were maintained by incubating the deprotected resin in 1:1 DMF:H2O 
with 1.0 equiv. of tris(2- carboxyethyl)phosphine hydrochloride (TCEP) at 37°C for 30 min. 
 
Ligations: 
All ligations were performed at 37°C in ligation buffer, made fresh before use: 200 
mM sodium phosphate (pH = 7.20), 6 M guanidinium HCl, 200 mM 4-mercaptophenylacetic 
acid (MPAA), 400 mM TCEP. 3.0 equiv. of crude LP-MeNbz-AAs were solubilized in 
buffer to a concentration of 3.5 mM (relative to the resin-bound core peptide) and pH was 
adjusted back to 7.2 with NaOH (aq). Ligations were incubated for 9 hrs at 37 °C and 
mixture decanted. Resin was washed 3 times with buffer, 5 times with DMF, then 5 times 
with DCM. Ligated products were then cleaved with standard cleavage cocktail and purified 
by semi-preparatory HPLC utilizing Method B. Fractions containing ligated products were 
collected and lyophilized. Peptides were fully characterized by LC/MS and MS/MS. 
 
2.10.4 Cloning of tclM and tbtD into Ligation Independent Cloning pMCSG9 vector 
 The gene tclM was amplified from B. cereus ATCC 14579 genomic DNA. The E. 
coli codon optimized gene tbtD was purchased from Integrated DNA Technologies (IDT). 
Genes were amplified by PCR using Q5® High-Fidelity Master Mix with HF-buffer (NEB) 
with GC-enhancer following the manufacturer’s manual. Primers utilized: 
tclM 
Forward (5’à  3’): - TAC TTC CAA TCC AAT GCG ATG GAG CAG TAT CAT AAA 
ATT– 3’ 
Reverse (5’à  3’): - TTA TCC ACT TCC AAT GCG CTA TCA ATA TCT TTG TAA 
GTC– 3’ 
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tbtD 
Forward (5’à  3’): TAC TTC CAA TCC AAT GCG ATG GCA GCA GGT GAA CGT 
TGG TGG 
Reverse (5’à  3’): TTA TCC ACT TCC AAT GCG CTA TTA ACG GGT CGC AAC TTC 
TTC ATG TGC 
The purified PCR products were phosphorylated with T4-PNK, and then treated with 
T4-DNA Polymerase to create LIC-overhangs. pMCSG9 was linearized with SSp1 and 
dephosphorylated with Antarctic Phosphatase, and then treated with T4-DNA Polymerase to 
create LIC-overhangs. Treated PCR product and vector were combined in a 1:1 ratio and 
transformed into One-Shot® Top10 and BL21 (DE3) Competent Cells (Agilent). 
 
2.10.5 Cloning of tclE-H’s Leader Peptide into Sequence and Ligase Independent 
Cloning pETXSH vector 
 
A. Full Length Leader Peptide (38 amino acids) 
The leader peptide sequence from tclE was amplified from B. cereus ATCC 14579 
genomic DNA by PCR using the Phusion ® High-Fidelity Master Mix with HF-buffer 
(NEB) following the manufacturer’s manual. Primers utilized: 
 
Forward (5’à  3’): - TTT AAG AAG GAG ATA TAC CAA TGA GTG AAA TTA AAA 
AAG C– 3’ 
Reverse (5’à  3’): – AGT GCA ATC TCC CGT GAT ACA CGC TCC CAT AAT TTC 
AAG C– 3’ 
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The purified PCR product was treated with T4-DNA Polymerase to create SLIC-
overhangs. pETXSH was linearized with NsiI and dephosphorylated with Antarctic 
Phosphatase, and then treated with T4-DNA Polymerase to create SLIC-overhangs. Treated 
PCR product and vector were combined and transformed into One-Shot® Top10 and BL21-
CodonPlus (DE3)-RIPL Competent Cells (Agilent). 
 
B. Quickchanges into pETXSH containing TclE’s FLeader Peptide 
Due to the removal of the C-terminus GlyAla during cleavage of the intein-tag with 
sodium 2-mercaptoethane sulfonate (MESNa), addition of another GlyAla to the C-terminus 
afforded the desired cleaved leader peptide-thioester. These additions were accomplished by 
first introducing an additional Gly to the C-terminus followed by an addition of Ala. 
Quichanges were performed using Pfu-Turbo (Agilent) according to manufacturer’s manual. 
Primers utilized are as follows: 
 
Glycine addition:  
Forward (5’à 3’): GAA ATT ATG GGA GCG GGA TGT ATC ACG GGA GAT 
Reverse (5’ à 3’): ATC TCC CGT GAT ACA TCC CGC TCC CAT AAT TTC 
 
Alanine addition after glycine addition: 
Forward (5’à 3’): ATT ATG GGA GCG GGA GCA TGT ATC ACG GGA GAT 
Reverse (5’ à 3’): ATC TCC CGT GAT ACA TGC TCC CGC TCC CAT AAT 
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C. ΔN18 Leader Peptide (20 amino acids) 
PCR procedure is the same as in A. 
Forward (5’à  3’): TAC TTC CAA TCC AAT GCG ATG GCA GCA GGT GAA CGT 
TGG TGG 
Reverse (5’à  3’): TTA TCC ACT TCC AAT GCG CTA TTA ACG GGT CGC AAC TTC 
TTC ATG TGC 
 
2.10.6 Protein Expression and Purification 
A. TclM 
TclM protein was heterologously expressed in E. coli RIPL cells. 1 L of Luria-
Bertani (LB) medium, supplemented with ampicillin (100 mg/mL) and chloramphenicol (34 
mg/mL), was inoculated with 5 mL of an overnight culture and grown to an OD600 between 
0.6-0.8 at 37 oC, at which point 200 mL of a 1 M stock of IPTG was added and culture grown 
for 18 h at 16 oC. Cells were pellet and resuspended in 40 mL of lysis/binding buffer (50 mM 
KHPO4 at pH = 7.00, 250 mM KCl, 10 mM imidazole, and 10% glycerol) supplemented with 
250 mg/mL lysozyme, 2 mM PMSF, and 1-protease inhibitor tablet (ROCHE®). Cells were 
lysed by sonicating twice with a 30% maximum amplitude intermittent pulses for 1:30 min. 
Cell debris was removed by centrifugation (40 min at 15,000 rpm at 4 oC) and supernatant 
collected and cold filtered through a 0.44 mm filter. Supernatant was loaded into a 5-mL 
HisTrap (Ni2+) IMAC column and washed (4 CV) to remove non-specific binding. 6xHis-
MBP-TclM was eluted with an elution buffer gradient (50 mM KHPO4 at pH = 7.00, 250 
mM KCl, 500 mM imidazole, and 10% glycerol) from 0 – 100% (5 CV). Fractions 
containing eluted protein are pooled and concentrated to 5 mL utilizing a Centricon (30,000 
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Da MWCO) concentrator (EMD Millipore®). The resulting concentrated protein was buffer-
exchanged into 50 mM KHPO4 at pH = 7.00, 250 mM KCl, and 10% glycerol utilizing a PD-
10 column (GE Healthcare Life Sciences®) to obtain 7 mL of 6xHis-MBP-TclM. Removal of 
the MBP-tag was accomplished with 1% (w/w) TEV-protease and cleavage was left 
overnight at 4 oC. Supernatant was loaded into a 5-mL HisTrap (Ni2+) IMAC column and 
washed with same buffer (3 CV) to elute the cleaved protein. Concentration of the pooled 
fractions containing pure TclM (10,000 Da MWCO) to ~300 mL afforded 8.09 mg/mL of 
protein which was utilized for enzymatic assays.  
 
B. TbtD 
Similarly, TbtD protein was heterologously expressed in E. coli BL21 (DE3) cells. 1 
L of Luria-Bertani (LB) medium, supplemented with ampicillin (100 mg/mL) was inoculated 
with 5 mL of an overnight seed and grown to an OD600 between 0.6-0.8 at 37 oC, at which 
point 200 mL of a 1 M stock of IPTG was added and culture grown for 18 h at 16 oC. Cells 
were pellet and resuspended in 40 mL of lysis/binding buffer (50 mM KHPO4 at pH = 7.00, 
250 mM KCl, 10 mM imidazole, and 10% glycerol) supplemented with 250 mg/mL 
lysozyme, 2 mM PMSF, and 1-protease inhibitor tablet (ROCHE). Cells were lysed by 
sonicating twice with a 20% maximum amplitude intermittent pulses for 1:30 min. Cell 
debris was removed by centrifugation (20 min at 15,000 rpm at 4 oC) and supernatant 
collected and cold filtered through a 0.44 mm filter. Supernatant was loaded into a 5-mL 
HisTrap (Ni2+) IMAC column and washed (4 CV) to remove non-specific binding. 6xHis-
MBP-TbtD was eluted with an elution buffer gradient (50 mM KHPO4 at pH = 7.00, 250 
mM KCl, 500 mM imidazole, and 10% glycerol) from 0 – 100% (5 CV). Fractions 
 67 
containing eluted protein are pooled and concentrated to 5 mL utilizing a Centricon (30,000 
Da MWCO) concentrator (EMD Millipore). The resulting concentrated protein was buffer-
exchanged into 50 mM KHPO4 at pH = 7.00, 250 mM KCl, and 10% glycerol utilizing a PD-
10 column (GE Healthcare Life Sciences) to obtain 7 mL of 6xHis-MBP-TbtD, which was 
concentrated (30,000 Da MWCO concentrator) to 1 mL to yield a 9.8 mg/mL solution of 
protein which was utilized for enzymatic assays. 
 
  
 
C. Leader Peptide Thioesters 
LP-intein protein was heterologously expressed in E. coli RIPL cells. 1 L of Luria-
Bertani (LB) medium, supplemented with ampicillin (100 mg/mL) and chloramphenicol (34 
mg/mL), was inoculated with 5 mL of an overnight culture and grown to an OD600 between 
0.6-0.8 at 37 oC, at which point 200 mL of a 1 M stock of IPTG was added and culture grown 
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for 18 h at 16 oC. Cells were pellet and resuspended in 40 mL of lysis/binding buffer (50 mM 
NaHPO4 at pH = 7.00, 250 mM NaCl, and 10 mM imidazole) supplemented with 250 mg/mL 
lysozyme, 2 mM PMSF, and 1-protease inhibitor tablet (ROCHE®). Cells were lysed by 
sonicating twice with a 30% maximum amplitude intermittent pulses for 1:30 min. Cell 
debris was removed by centrifugation (40 min at 15,000 rpm at 4 oC) and supernatant 
collected and cold filtered through a 0.44 mm filter. Supernatant was loaded into a 5-mL 
HisTrap (Ni2+) IMAC column and washed (4 CV) to remove non-specific binding. LP-intein 
was eluted with an elution buffer gradient (50 mM NaHPO4 at ph = 7.00, 250 mM NaCl, and 
500 mM imidazole) from 0 – 100% (5 CV). Fractions containing eluted protein are pooled 
and concentrated to 5 mL utilizing a Centricon (10,000 Da MWCO) concentrator (EMD 
Millipore®). The resulting concentrated protein was buffer-exchanged into 50 mM HEPES at 
pH = 7.50 and 150 mM NaCl utilizing a PD-10 column (GE Healthcare Life Sciences®) to 
obtain 7 mL of LP-intein. Removal of the intein-tag was accomplished by adding sodium 2-
mercaptoethane sulfonate (MESNa) to 0.5 M. Mixture was left overnight to react at room 
temperature. Dialysis was performed to remove excess MESNa with a 2,000 Da MWCO 
cassette in 2 L of 50 mM HEPES at pH = 7.50 and 150 mM NaCl; after 2 hours, the buffer 
was exchanged for fresh one and dialyzed for 6 h more. Supernatant was loaded into a 5-mL 
HisTrap (Ni2+) IMAC column and washed with same buffer (3 CV) to elute LP-MESNa 
thioester (14). Pooled fractions containing peptide (positive dot blot test), concentrated using 
a 1 kDa MWCO concentration (PALL®) and utilized for next step as it is. Obtained: 
Full length LP-MESNa: 10.5 mL of 0.464 mg/mL. 
ΔN18 LP-MESNa: 2 mL of 2.5 mg/mL. 
Peptides were characterized by LC/MS and MS/MS. 
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2.10.7 Native Chemical Ligations 
LP-thioesters are buffer exchanged to 3.5 mL of buffer (200 mM NaHPO4, pH = 7.50, 6 M 
guanidinium hydrochloride, 20 mM tris(2-carboyxethyl) phosphine, and 0.5% (v/v) 
thiophenol. Meanwhile, 20 µL of core of 2-26 or 2-46 (0.10 M in DMF) was added and 
mixture allowed to incubate for 3 days at room temperature. Crude mixture was purified by 
semi-preparatory HPLC utilizing Method A. Peptides were characterized by LC/MS and 
MS/MS. 
 
2.10.8 Desulhydrylation of Cysteine Side Chains to Dehydroalanines 
A. When 2-28 was utilized 
 Native chemical ligation product was buffered exchanged using a PD-10 into 50 mM 
NaHPO4 (pH = 8.00).  A 500-fold excess of 2,5-dibromohexanediamide (0.50 M in DMF) 
was added and mixture incubated at room temperature for 2 h and at 37 oC for 3.5 h. 
Precipitate was removed by centrifugation (1 min at 15,000 rpm) and supernatant was 
dialyzed into 2 L of 50 mM NaHPO4 (pH = 8.00) utilizing a dialysis cassette (2,000 Da 
MWCO from THERMO®) for 2h, after which the buffer was replaced with fresh one and 
dialysis continued overnight at 4 oC. Supernatant was collected. 
B. When 2-31 was utilized 
Adapted from utilized a previously described method.44 Briefly, in a 1.7 mL 
microcentrifuge tube, cysteine-containing substrate is dissolved to a final concentration of 
0.63 µM in a solution containing 50% (aq.) DMF, 1.26 mM TCEP, and 63 mM K2CO3. 
Mixture is allowed to incubate for 15 min at 37 oC, after which compound 2-31 is added to a 
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final concentration of 63 mM. Reaction is allowed to stir at 37 oC for 3 h. Excess 2-31 is 
removed by washing with diethyl ether (Et2O) twice: Et2O (300 µL / 50 µL reaction) is 
added, mixture vortexed for 3 s, and centrifuged for 10 s at 6,000 rpm. Carefully, top ether 
layer is removed. Microcentrifuge tube is set at 37 oC with the cap open to remove excess 
Et2O for 10 min. Substrates were utilized without further purification. 
 
2.10.9 Cyclization Assays 
Assays were performed in a 50 mM HEPES (pH = 7.20) and 150 mM NaCl buffer 
with final concentrations of 50 µM substrate and 10 µM of the corresponding enzyme (TclM 
or MBP-TbtD) in a total volume of 100 mL. Reactions were incubated at 25 oC and 350 rpm 
for 20 h, after which 200 µL of methanol were added, incubated at rt for 3 min, and 
precipitated protein removed by centrifugation (3 min at 15,000 rpm) and the supernatant 
collected. The supernatants were analyzed by LC/MS with the C18 Kinetex® column by 
injecting 30 µL/sample utilizing Method B. 
 
2.10.10 Leader Peptide Truncations 
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The leader peptide (LP) requirement for TclM was probed by truncating the N-terminal 
peptide sequence of our linear thiazolyl peptide until no product production could be 
observed by LC/MS analysis. Substrates containing the full-length leader peptide and ΔN18 
truncate were prepared according to the method described in Section 2.10.6c, Section 2.10.7, 
and Section 2.10.8b . Substrates with LP truncation ΔN28, ΔN29, ΔN30, ΔN31, and ΔN32 
were prepared by solid phase peptide synthesis (Section 2.10.3 and Section 2.10.8b). 
Peptides were characterized by LC/MS and MS/MS. 
 In a final volume of 100 µL, substrate (10.5 µM) was incubated with TclM (10.5 µM) 
at 25 oC for 24 h. 200 µL of methanol are added and reactions incubated for 3 min at rt; 
precipitated protein is removed by centrifugation (3 min at 15,000 rpm) and supernatant 
collected. Crude supernatant is analyzed by injecting 30 µL into the LC/MS with the 
Kinetex® C8 column utilizing Method A. 
 
2.10.11 Expression of Thiocillin 
 5 mL of Luria-Bertani (LB) broth in 10 mL culture tubes were individually inoculated 
with 5 µL of an overnight seed of Bacillus cereus ATCC 14579, Bacillus cereus ATCC 
14579 tclM-KO, or Bacillus cereus ATCC 14579 tclM-KO with pHT01 containing the 
desired mutant and grown for three days at 30 oC and 250 rpm using a rotary incubator. 
Grow-ups containing pHT01 were grown with 5 µg/mL of chloramphenicol and induced 
after one day with 0.2 mM IPTG. Cells are pelleted and supernatant removed. 500 µL of 
methanol are added and pellet extracted for 30 min. Cell debris is removed by centrifugation 
(5 min at 15,000 rpm), and supernatant collected. Samples for LC/MS analyses were 
prepared by diluting 10 µL of supernatant into 90 µL of 50% (aq.) acetonitrile. 
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2.10.12 Quickchange Mutagenesis of tclM-mutants in pHT01 or pMCSG9 and 
Transformation into B. cereus ATCC 14579 tclM-KO 
 Quichanges were performed using Pfu-Turbo (Agilent) according to manufacturer’s 
manual. Primers utilized: 
 
Plasmid 
 
Mutation 
 
Sequence (5’ à 3’) 
Forward 
Sequence (5’ à 3’) 
Reverse 
pHT01 E128A ATAGAATTTGCGCTAGCTATA
ATGTTAATTTCA 
TGAAATTAACATTATAGCT
AGCGCAAATTCTAT 
pHT01 S147A AAAAAAGGCTACTTAGCTTAT
GCATCTCATGTA 
TACATGAGATGCATAAGCT
AAGTAGCCTTTTTT 
pHT01 S150A GCTACTTATCCTATGCAGCTC
ATGTAAATGGATTT 
AAATCCATTTACATGAGCT
GCATAGGATAAGTAGC 
pHT01 H151A CTTATCCTATGCATCTGCTGTA
AATGGATTTTTT 
AAAAAATCCATTTACAGCA
GATGCATAGGATAAG 
pHT01 F155A TCTCATGTAAATGGAGCTTTT
ACTAGATGGAAA 
TTTCCATCTAGTAAAAGCT
CCATTTACATGAGA 
pHT01 Y173A GATATATTTCATAAGAACGCT
TTAAATAACAAAGAGTAC 
GTACTCTTTGTTATTTAAAG
CGTTCTTATGAAATATATC 
pHT01 S239A GATTTTCTAGAAAAAGCTCAG
TTTCATAAGACG 
CGTCTTATGAAACTGAGCT
TTTTCTAGAAAATC 
pHT01, 
pMCSG9 
H242A GAAAAAAGTCAGTTTGCTAAG
ACGATATTAAAT 
ATTTAATATCGTCTTAGCA
AACTGACTTTTTTC 
pHT01 F261A AATAAAGATATAAACGCTTTA
GGTTCACGCCTA 
TAGGCGTGAACCTAAAGCG
TTTATATCTTTATT 
pHT01, 
pMCSG9 
R265A AACTTTTTAGGTTCAGCTCTA
ATAACTGTATTT 
AAATACAGTTATTAGAGCT
GAACCTAAAAAGTT 
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pHT01 Y272A CGCCTAATAACTGTATTTACG
GCTTTATTAATACGAAAT 
ATTTCGTATTAATAAAGCC
GTAAATACAGTTATTAGGC
G 
pHT01, 
pMCSG9 
R285A ATTCAAAATAAAGATGCTTAT
CTACTTTGCTAC 
GTAGCAAAGTAGATAAGCA
TCTTTATTTTGAAT 
pHT01 C289A GATAGATATCTACTTGCTTAC
TATTCATATAAA 
TTTATAGATATAGTAAGCA
AGTAGATATCTATC 
pHT01 E297A CTATATCTATAAAATTATTGC
TGAAAAATATAATATAG 
CTATATTATATTTTTCAGCA
ATAATTTTATAGATATAG 
 
 Transformations into B. cereus ATCC 14579 tclM-KO were done according to a 
literature procedure.51 Cells were recovered in 1 mL of LB for 1 h and then pelleted by 
centrifugation for 5 min at 3,500 rpm. 900 µL of supernatant are removed and cells 
resuspended in 100 µL. 50 µL were plated in an LB-agar plate containing 5 µg/mL 
chloramphenicol for 36 h at 30 oC. 
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CHAPTER III 
CHEMOENZYMATIC SYNTHESIS OF THIOMARINOL AND STRUCTURE-
ACTIVITY-RELATIONSHIP OF ITS DITHIOLOPYRROLONE CONSTITUENT 
3.1 Introduction 
  Antibiotic resistance has become a great concern worldwide, and the search for new 
antibacterial compounds or natural products can be time-consuming. This process can be 
shortened by taking advantage of known natural products and create hybrid antibiotics in 
which two bioactive molecules are covalently linked to each other. This strategy has the 
advantage of improving bioactivity against bacterial strains that are resistant to one of the 
individual components1 and by improving pharmacokinetics and pharmacodynamics.2,3 A 
potentially useful class of naturally occurring hybrid antibiotics is the thiomarinols (3-5, 
Figure 3.1). Thiomarinols were first discovered from Pseduoalteromonas spp. SANK73394,5 
and they consist of two scaffolds, linked via an octanoyl fatty chain, related to two individual 
antibiotic moieties. First, it possesses the monic acid side chain of the molecule mupirocin, 
an FDA approved antibacterial mixture of pseudomonic acids under the name Bactroban 
(GlaxoSmithKline), which is known to be active against methicillin-resistant S. aureus 
(MRSA) by inhibiting isoleucyl tRNA synthetase. Second, the thiomarinols contain a 
holothin core from the dithiolopyrrolone (DTP) family of natural products, bioactive 
molecules shown to have activity against rifamycin-resistant bacteria and MRSA.6,7  
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Figure 3.1. Structures related to thiomarinol biosynthesis. a) Structure of pseudomonic acids. 
b) Structure of dithiolopyrrolones. c)  Thiomarinol biosynthetic cluster from P. spp. 
SANK73390. Open arrows indicate ORFs with significant homology to the mupirocin 
pathway; blue ORFs are homologous to DTP biosynthetic genes; black ORFs are unique to 
the thiomarinol pathway, and the red ORFS, TmlU and HolE, have counterparts in the 
mupirocin and holomycin pathway, respectively, and predicted to be involved in the ligation 
of the two moieties. 
 
The thiomarinol gene cluster was discovered by whole genome sequencing from P. 
SANK73390 and found to be encoded in a 97 kb plasmid comprising of genes related to non-
ribosomal peptide synthesis (NRPS), which produce the holothin core, and polyketide 
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synthesis (PKS), which produces the marinolic acid scaffold.5 Gene knockout experiments 
showed that the enzyme TmlU was the one responsible for linking holothin to marinolic 
acid.5,8 TmlU was assigned as an amide ligase based on sequence identity with enzymes 
involved in the biosynthesis of aminocoumarins by linking different functionalities to the 
coumarin core through amide linkages. The ligase utility of TmlU could be harnessed in vitro 
to test for substrate promiscuity. Moreover, it would provide a platform by which structure-
activity-relationship models can be pursued for both the marinolic acid and holothin 
moieties. 
 
3.2 Synthesis of Pseudomonic acid C, Holothin, and Pseudomonyl C Holothinamide 
In order to test TmlU in vitro, we needed to access the individual components of 
thiomarinol. The marinolic acid component is not readily available, but a closely related 
compound, the antibiotic mupirocin, is commercially available. It differs to the marinolic 
acid moiety in thiomarinol by having one extra methylene group in the octanoyl linker. Thus, 
in our subsequent studies, we focused on utilizing the pseudomonic acid moiety over the 
marinolic acid. Mupirocin consists mostly of pseudomonic acid A (PAA, >90%) with small 
amounts of pseudomonic acid B (PAB), and C (PAC), yet PAC is the predominant species 
found in thiomarinol. We utilized a known method by King et al. 9 to convert PAA to PAC 
(Scheme 3.1) in 62% overall yield. They key transformation relied on the use of potassium 
selenocyanate in the reduction of the epoxide of PAA to yield the trans-alkene in PAC. 
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Scheme 3.1. Synthesis of pseudomonic acid C from pseudomonic acid A. PTSA = p-toluene 
sulfonic acid. EtOAc = ethyl acetate. AcOH = acetic acid. 
 
The second component, thiolutin, was accessed by utilizing a previously reported 
method in the expedient total synthesis of dithiolopyrrolones (Scheme 3.2).10 Starting from 
1,3-dichloroacetone (3-6), displacement with p-methoxybenzylthiol (PMBSH) of the 
chlorides yields compound 3-7. Condensation with PMB-NH2 and cyclization with oxalyl 
chloride yields the pyrrolone ring 3-8. Aminolysis with ammonium acetate and deprotection 
of the PMB-protecting groups with refluxing trifluoroacetic acid (TFA) in the presence of m-
cresol yielded the trifluoroacetyl holothin 3-10. The trifluoroacetyl group was removed by 
addition of concentrated HCl in refluxing methanol to afford holothin as the hydrochloride 
salt 3-3. All subsequent reactions were done with this salt of holothin in order to improve 
aqueous solubility and compound stability. 
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Scheme 3.2. Synthesis of holothin hydrochloride. PMB = p-methoxybenzyl. EtOH = ethanol. 
TFA = trifluoroacetic acid. 
 
We additionally synthesized the ligated product pseudomonyl C holothinamide 
(PAC-holothin) 3-13 (Scheme 3.3) to obtain a standard for our enzymatic assays. The 
hydroxyl groups at position 6,7, and 13 in PAC (3-2) were protected with trichloroacetyl 
chloride to obtain 3-11. Formation of the acyl chloride with oxalyl chloride allowed the 
coupling of holothin in 60% yield for the 3 steps. Removal of the protecting groups with 7 N 
NH3 (MeOH) afforded our standard 3-13.  This standard was provided to our collaborators in 
Dr. Bo Li’s laboratory in the department of Chemistry at the University of North Carolina at 
Chapel Hill to test the chemoenzymatic ligation of holothin (3-3) with PAC (3-2). Their 
results are summarized in Figure 3.2. It was found that TmlU acted as an acetyl coenzyme A 
ligase to yield the CoA thioester of PAC (3-14), and HolE ligated the thioester to holothin. 
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Scheme 3.3. Synthesis of pseudomonyl C holothinamide. DMAP = 4-dimethylamino 
pyridine. DMF =  N,N-dimethylformamide. THF =  tetrahydrofuran. MeOH = methanol. 
 
 
Figure 3.2. Pseudomonic acid C and holothin ligation by TmlU and HolE. a) Hypothesized 
ligation mechanism. b) Standard 3-13. c) Ligation with TmlU and HolE. d) No CoASH. e) 
No TmlU. f) No HolE. ATP = adenosine 5’-triphosphate. AMP = adenosine monophosphate. 
PPi = pyrophosphate.   Assay conditions: 20 mM KHPO4 (pH = 7.5), 1 mM ATP, 2 mM 
MgCl2, 1 mM CoASH, 0.1 mM PAC, 0.1 mM holothin, 1 µM TmlU, and 1 µM HolE. 
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3.3 Dithiolopyrrolone Natural Products 
Of the two constituents found in thiomarinol, we became interested in exploring the 
holothin moiety as a standalone antibiotic. Holothin belongs to the family of natural products 
called dithiolopyrrolones (DTPs), first discovered in the early 1940s. These antibiotics 
contain a unique pyrrolone structure fused to a 5-membered ene-disulfide ring.11  Within this 
class of compounds, thiolutin (3-15), 12  isolated from Streptomyces luteosporeus, and 
holomycin (3-4),13  isolated from Streptomyces clavuligerus, are two of the most well 
characterized; other congeners include aureothricin (3-16), xenorhabdin I (3-17), tigloyl 
holothin (3-18, Figure 3.4). Recently, it has been shown that Photobacterium halotolerans14 
and Yersinia ruckeri7 produce holomycin biosynthetically as well, making it somewhat of an 
ubiquitous natural product found in both marine and soil systems. 
 
 
Figure 3.3. Representative members of the dithiolopyrrolone family of natural products. 
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DTPs gained interest from the research community by showing activity against 
Gram-positive and Gram-negative bacteria,15 with important bioactivity against Neisseria 
gonorrhoeae and MRSA.6,7 Moreover, DTPs have been extensively tested against cancer cell 
lines; they were found to be involved in many biological pathways such as effecting 
phosphorylation levels of Hsp27 in cell adhesion, and inhibition of angionesis and tumor 
growth in endothelial cells.16  The exact mechanism of action of DTPs has not been well 
established. One pathway that has been suggested involves the arrest in production of mRNA 
and proteins by interacting with DNA-dependent RNA polymerases.17, 18 Experiments have 
shown that in vivo inhibition of RNA synthesis cannot be correlated in vitro, suggesting a 
mode of action where DPTs can act as prodrugs and need to be modified by living systems.18 
In contrast, the holomycin producing species Y. ruckeris encodes for an RNA 
methyltransferase that confers self-resistance for the antibiotic itself, and when the gene 
encoding for this protein is knocked-out, the bacterium becomes susceptible towards the 
compound.7 The mechanism by which Y. ruckeris protects itself from holomycin suggests a 
pathway in which DTPs interact with important RNA nucleotides and can lead to disruption 
of ribosomal related processes such as translation. 
 
3.4 Syntheses and Biological Activities of Dithiolopyrrolone Analogues 
We have envisioned that changing the substituents and electronics of the bicyclic 
system in DTPs would allow us to further study solubility, susceptibility towards oxidation, 
possible disulfide exchange, and metal chelation properties (Figure 3.5). Holomycin and 
thiolutin are sparingly soluble in water, thus finding substitution patterns that enhance 
aqueous solubility are important; we envision that the introduction of functional groups such 
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as a mesyl moiety would assist with this property. Additionally, we wanted to synthesize 
analogs similar to those found in nature to probe their physical properties. We further look to 
determine the possibility of having a Michael acceptor to determine if there are any 
nucleophiles that might interact with this functional group and mimic possible covalent 
bonds or transient interactions with protein partners in vivo. Next, we wanted to change the 
steric factors involved with the N-endocyclic amide and N-exocyclic amide; we speculated 
that introducing bulky groups would allow for a structure-activity-relationship model to be 
identified since these natural products differ only by different N-acylations and/or N-
methylation.  
 
 
Figure 3.4. Rational design of dithiolopyrrolone analogs. 
 
We took advantage of the previously described synthesis of holothin (Scheme 3.2) to 
access analogues by acylating at the exocyclic amine (Scheme 3.4a). All acylating partners 
were either commercially available or could be easily accessed by conversion of their 
carboxylic acid to their acyl chloride by treatment with oxalyl chloride. Making substitutions 
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at the endocyclic amide proved to be limited to electron rich arylated amines due to 
displacement of the alkylated amine moiety during the aminolysis step with ammonium 
acetate (Scheme 3.2) with ammonia to yield the pyrrolone without N-substitution at the 
endocyclic amide. Likewise, the presence of the disulfide moiety led us to speculate the 
redox potential and/or metal chelating properties of this scaffold since earlier reports have 
shown that the oxidized thiosulfinate from holothin can be found in thiomarinol B and has 
comparable bioactivity to non-oxidized ones.19  Thus, we synthesized oxidized analogs 
through the use of oxone (Figure 3.4b) as previously shown to occur.20 
 
 
Scheme 3.4. Syntheses of dithiolopyrrolone derivatives. a) Acylating strategy from 
trifluoroacetyl intermediate. b) Oxidation strategy for thiosulfinate production. 
 
The derivatives synthesized were probed for antibiotic activity against Neisseria 
gonorrhoeae FA19 and for cytotoxicity in HeLa cells. Disk-diffusion-assays on N. 
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exocyclic amide is replaced by an ester and where the disulfide is oxidized to the 
thiosulfinate. Unfortunately, no structure-activity-relationship could be extracted from our 
dataset since no clear pattern can be discerned.  
 
Table 3.1. Biological activities against HeLa cells and N. gonorrhoeae FA19 of 
DTPderivatives. 
  
Entry Compound 
# 
X R1 R2 CC50a,b 
(µM) 
Activity 
Diameterc (mm) 
1 µg 
1 3-4 NH acetyl acetyl 5.05 21 
2 3-15 NH methyl acetyl 1.15 17 
3 3-17 NH H pentanoyl 2.50 17 
4 3-18 NH H tigloyl ND 20 
5 3-19 NH H mesyl 26.8 10 
6 3-20 NH H 6-heptynoyl 5.75 21 
7 3-21 NH H 5-hexynoyl 19.7 21 
8 3-22 NH H hexanoyl 18.5 24 
9 3-23 NH H octanoyl 6.05 21 
10 3-24 NH H crotonyl ND 21 
11 3-25 NH H methacryloyl ND 22 
12 3-26 NH H 3,3-dimethylacryloyl ND 21 
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O
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13 3-27 NH H 6-azidohexanoyl ND 22 
14 3-28 NH Bn acetyl ND 19 
15 
16 
17 
18 
19 
3-29 
3-30 
 
3-31 
 
3-32 
 
3-33 
O 
NH 
NH 
NH 
NH 
PMP 
H 
H 
H 
H 
acetyl 
pivaloyl 
benzoyl 
acetyl 
trifluoroacetyl 
ND 
ND 
ND 
ND 
ND 
8 
ND 
ND 
6 
6 
        
aThe cytotoxicity values correspond to HeLa cells in which ATP contents equals 50% of the vehicle controls. 
bAverage of two separate determinations. cActivity on Neisseria gonorrhoeae FA19 on disk diffusion assays. 
Disk diameter is 6 mm. ND = not determined. Bn = benzyl. PMP = p-methoxyphenyl. 
 
3.5 Pull-down Assay with Stable Isotope Labeling by Amino Acids 
 While DTPs have been studied since the 1940s, their mechanism of action is still not 
well understood, in part because the in vivo results cannot be correlated in vitro. Hence, we 
designed a pull-down experiment where we could be able to detect binding partners and 
obtain a better understanding of the type of interactions these small molecules can have with 
potential targets. We decided to utilize the Stable Isotope Labeling by Amino acids (SILAC) 
technique21 because it provides a robust, quantitative approach for measuring protein binders 
by mass spectrometry. We immobilized 6-azidohexanoyl holothin (Table 3.1, entry 13) on a 
cyclooctyne-containing bead through click-chemistry. We then grew two sets of E. coli 
MG1655 cultures with defined MOPS media to early stationary phase: the first culture 
contained all standard amino acids, while the second culture contained heavy L-lysine (13C6) 
and heavy L-arginine (13C615N4). Cultures were lysed and protein concentration standardized 
to 2 mg/mL according to protein concentration standardization by bicinchoninic acid assay 
(BCA). Next, we incubated 6-azidohexanoyl with the “light” lysate (i.e. no heavy amino 
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acids utilized), followed by the beads containing our immobilized compound (Figure 3.6). 
After three rounds of bead washing, elution of binding proteins was accomplished by boiling 
the beads and running them on 12% SDS PAGE. Proteins bands were cut, trypsinized, and 
analyzed by LC/MS-MS. 
 
Figure 3.5. Workflow for SILAC pull-down assay with dithiolopyrrolones.  
 
 Interestingly, our pull-down returned the association of our DTP with a 
cyclodioxygenase (Figure 3.7), although a secondary test such as isothermal titration 
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calorimetry is needed to confirm the specific binding affinity. This result can be attributed to 
the presence of the disulfide moiety being recognized by enzymes that oxidize sulfides to 
sulfonic acids. Moreover, the disulfide bond can be reduced inside the cell and provide the 
putative iron-chelating properties of thiols, which cyclodioxygenases need to add oxygen to 
their oxidizing species. Upon close inspection of the holomycin biosynthetic cluster, we find 
that the origin of replication fork (ORF) 3493 from S. clavuligerus encodes for a cupin like 
protein; cupins are known oxidases of cysteine side chains and cysteamine to their metabolic 
products.22  
       
 
 
Figure 3.6. SILAC pull-down results. 
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3.6 Oxidized Holomycin Reactivity 
 The reactivity of thiosulfinate and thiosulfonate derivatives of ester-substituted DTP 
analogs has been explored by Schachtner et al.,20 and they found them to be reactive to 
nucleophiles; however, holomycin and thiolutin are much more electron-rich, and similar 
reactivity was not examined. With the possibility that the thiosulfinate version of DTPs can 
be important, we made use of dioxoholomycin (Table 3.1, entry 18) and exposed it to the 
thiol nucleophile N-acetylcysteine in sodium phosphate buffer at various pHs. Surprisingly, 
we did not detect adducts were there was nucleophilic displacement or disulfide mixing, yet 
we did see the appearance of what appeared to be N-acetyl cysteamine and holomycin. We 
further monitor this reaction by UV-Vis due to the characteristic λmax = 300 nm of 
dioxoholomycin and λmax = 390 nm for holomycin. Our studies showed that, indeed, there is 
a shift from 300 nm to 390 nm over our time-course experiment (Figure 3.8), and that this 
change is strongly pH-dependent, with acidic conditions promoting the oxidation. This effect 
was also observed when reduced-glutathione was used. 
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Figure 3.7. Dioxoholomycin reactivity towards thiols. Red line corresponds to t = 0 h. Blue 
line corresponds to t = 14 h. Intermediate lines are separated by 2 h. 
 
 Oxidative-sensitive cysteines are important for regulatory processes in the cell.23 
They can act as on/off switches when in a certain oxidation state. We searched the literature 
for proteins sensitive to oxidative conditions to test whether 3-32 could oxidize cysteines in 
proteins. Recent reports focusing on the arginine phosphatase YwlE24 and the adenosyl-5’-
phosphosulfate kinase AtAPSK25  have been shown, by simple analytical tools, how these 
proteins contain cysteines that are labile towards redox conditions. We found that the 
arginine phosphatase YwlE is inactivated by a redox-active inhibitor that promotes the 
intramolecular disulfide formation between its Cys9 and Cys14, which are the only two 
cysteines in the protein, and thus leading to its inactivation. We heterologously expressed and 
purified YwlE and subjected it to our standard reaction conditions with 3-32 and found by 
mass spectrometry a mass change of -2 Dalton, corresponding to the disulfide (Figure 3.9a). 
Likewise, AtAPSK has been shown to dimerize at appropriate redox conditions, and thus 
inactivating the enzyme by linking Cys86 in one monomer to Cys119 in the other monomer. 
Ravilious et al have expressed a truncated form of the protein AtAPSK (AtAPSKΔ77) and 
NH
S S
OH
N
O O
CO2HAcHN
SH various pH
excess
50 mM NaH2PO4/
Na2HPO4 buffer
rt, overnight
0"
0.2"
0.4"
0.6"
0.8"
1"
1.2"
1.4"
1.6"
1.8"
250" 300" 350" 400" 450" 500"
A
bs
or
ba
nc
e*
U
ni
ts
*
Wavelength*(nm)*
pH*=*7.0*
0"
0.2"
0.4"
0.6"
0.8"
1"
1.2"
1.4"
1.6"
1.8"
250" 300" 350" 400" 450" 500"
A
bs
or
ba
nc
e/
A
u,
Wavelength/nm,
pH,=,8.0,
0"
0.2"
0.4"
0.6"
0.8"
1"
1.2"
1.4"
1.6"
1.8"
250" 300" 350" 400" 450" 500"
A
bs
or
ba
nc
e*
U
ni
ts
*
Wavelength*(nm)*
pH*=*4.5*
Me
O
NH
S S
OH
NMe
O
CO2HAcHN
S
S
AcHN CO2H
3-32 3-4
 94 
shown that its oxidation state is affected by the presence of the oxidant L-glutathione, dimer 
(GSSG) or the reductant L-glutathione, reduced (GSH).25 AtAPSKΔ77 has the advantage of 
being able to be visualized by simple SDS-PAGE by monitoring the bands at 22 kDa 
(monomer, reduced sate) and 44 kDa (dimer, oxidized state). Our results confirm the 
GSSG/GSH redox effect (Figure 3.9b) and show that oxo-holomycin can oxidize the protein 
into its dimeric isoform; moreover, the introduction of GSH and oxo-holomycin prevents 
AtAPSK from being fully oxidized. 
 
 
Figure 3.8. Dioxoholomycin oxidation of YwlE and AtAPSKΔ77: a) YwlE at z = 14 
(reduced YwlE = 17233 Da ; oxidized YwlE= 17231 Da) and b) AtAPSKΔ77 (reduced 
monomer = 22 kDa, oxidized dimer = 44 kDa). 
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3.7 In vivo Reduced Glutathione Analysis of Holomycin Treated in Escherichia coli 
 The SILAC pull-down experiment and our oxidation studies on the dioxoholomycin 
(3-32) presented evidence that DTPs can be involved in redox cycling inside the cells. Hence, 
we sought to test this hypothesis by measuring the in vivo effect of holomycin in GSH/GSSG 
levels in E. coli MG1655 at the literature MIC of 2 µg/mL.18 We decided to utilize 
holomycin and not dioxoholomycin because the latter lacked antibiotic activity in our disk 
diffusion assays previously described. To complement our experiment, we utilized the known 
redox active compound Paraquat as a positive control, chloramphenicol due to its effect on 
glutathione,26 and rifampicin as an inhibitor of glutathione biosynthesis.27 E. coli cultures 
were grown to half log-phase (OD600 = 0.3) at 37 oC, and the controls or antibiotics were 
added to the following final concentrations: 0.5% DMSO, 2 µg/mL holomycin, 300 µg/mL 
Paraquat, 5 µg/mL chloramphenicol, and 10 µg/mL rifampicin. Cells were incubated for 1h 
afterwards and then pelleted and lyophilized. Dried cells were utilized to measure glutathione 
content by using monobromobimane according to a literature procedure.28 As expected, 
Paraquat, and rifampicin did increase the amount of GSSG with respect to their control by 
lowering the amount of GSH (Figure 3.10). Similarly, chloramphenicol greatly increased the 
GSSG content, but the amount of GSH increased significantly as well, possibly due to the 
fact that glutathione is used to detoxify this antibiotic by dechlorinating it.26 Holomycin, on 
the other hand, did not have an effect on the ratio of GSH to GSSG when compared to its 
control, although, like chloramphenicol, the actual concentrations of both were higher. 
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Ratio DMSO(1) Holomycin DMSO(2) Paraquat Chloramphenicol Rifampicin 
GSH 77 77 82 49 54 46 
GSSG 1 1 1 1 1 1 
 
Figure 3.9. Quantifying reduced and oxidized glutathione in treated E. coli MG1655. 
DMSO(1) corresponds to DMSO control for holomycin treated cells; DMSO(2) corresponds 
to DMSO control for Paraquat, chloramphenicol, and rifampicin. *p < 0.05. ** p < 0.01. 
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3.8 Summary 
 TmlU and HolE from the thiomarinol biosynthetic pathway are the enzymes that 
ligate individual components of the hybrid antibiotic; TmlU activates pseudomonic acid C by 
converting it to the CoA thioester, and HolE is the transferase that ligates holothin to the 
CoA thioester. TmlU does not show high substrate promiscuity, with preference for long, 
complex alkyl chains. HolE does allow for multiple CoA thioesters as coupling partners, but 
not the use of aryl amines. Multiple analogs of holothin were synthesized and tested for 
biological activity against N. gonorrhoeae and found to be active, except for the oxidized 
thiosulfinates. SILAC pull-down experiments showed that DTPs can associate with iron-
dependent cyclodioxygenases. Dioxoholomycin can oxidize thiols from small molecules as 
well as from redox-sensitive cysteines in proteins. Holomycin does not have an effect on the 
redox status of E. coli MG1655 in vivo, although the concentration of GSH and GSSG are 
increased overall. The reactivity of dioxoholomycin reveals a plausible mechanism of action 
of dithiolopyrrolones where redox homeostasis can be disturbed through thiol oxidation or 
iron sequestration. 
 
3.9 Experimental 
3.9.1 General Methods 
 All reactions were carried out in an oven-dried round-bottomed-flask under an inert 
nitrogen atmosphere. Solvents and reagents were used as received unless otherwise noted. 
Mupirocin was purchased from Applichem through Fisher scientific. Thiolutin was 
purchased from commercial sources. Spectra for 1H and 13C NMR were recorded at room 
temperature with a Bruker AvanceIII (500 MHz and 125 MHz or 600 MHz and 150 MHz, 
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respectively) or a Varian Inova 400 (400 MHz and 100 MHz, respectively). Chemical shifts 
are reported in δ (ppm) relative units to residual solvent peaks CDCl3 (7.26 ppm for 1H and 
77.0 ppm for 13C) and DMSO-d6 (2.50 ppm for 1H and 39.5 ppm for 13C).  Splitting patterns 
are assigned as s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), multiplet (m), dd 
(doublet of doublets), and td (triplet of doublets). Mass spectrometry measurements were 
recorded using an Agilent 6520 Accurate-Mass Q-TOF ESI positive in high-resolution mode. 
Predicted masses were extracted to + 5 ppm. 
 
3.9.2 Synthesis 
9-(((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-((4R,5S,E)-5-hydroxy-4-methylhex-2-en-1-
yl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoic acid (3-2, 
Pseudomonic acid C). Pseudomonic acid C was prepared according to a literature method.9 
Mupirocin (3-1, 1.02 g, 2.04 mmol) was dissolved in 2,2-dimethoxypropane (20 mL) and 
ethyl acetate (20 mL). p-Toluenesulfonic acid monohydrate (102 mg, 0.54 mmol) was added 
and reaction stirred at rt for 1 h. Mixture was washed with brine (40 mL), dried with 
anhydrous Na2SO4, and concentrated under reduced pressure to dryness. The resulting 6,7-O-
isopropylidenepseudomonic acid A was dissolved in 50 % aqueous methanol (40 mL) and 
converted to its potassium salt by addition of potassium bicarbonate (0.204 g, 2.04 mmol). 
After concentration to dryness under reduced pressure, the resulting potassium salt was 
dissolved in 90 % aqueous tert-amylalcohol (30 mL) and potassium selenocyanate (0.88 g, 
6.11 mmol) was added. The resulting mixture was refluxed for 2 days under nitrogen. After 
cooling to rt, the reaction was filtered with celite and washed with additional 90 % aqueous 
tert-amylalcohol (20 mL) and concentrated to dryness to afford. The crude compound was 
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dissolved in water (40 mL) and ethyl acetate was added (40 mL); 5 M HCl was added, while 
stirring, until pH = 2. The organic layer was collected and the aqueous layer further extracted 
with ethyl acetate (2 x 20 mL). The combined extracts were dried with Na2SO4 and 
evaporated to dryness. The crude oil was dissolved in 80 % acetic acid (20 mL) and stirred 
for 12 h at rt. Mixture was evaporated to dryness and purified by silica gel (60 mesh) with a 0 
– 6 % methanol gradient in chloroform (Rf = 0.30, 5 % MeOH in CHCl3) to afford 
pseudomonic acid C (#, 0.61 g) in 62% overall yield. 1H and 13C NMRs are in agreement 
with those previously reported.9 HR-MS (ESI): Calculated C26H44NaO8+ [M + Na]+ = 
507.2928; found [M + Na]+ = 507.2911. 
 
2,2,2-trifluoro-N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)acetamide (3-10 
Trifluoroacetyl holothin) was prepared according to a literature method.10 The residue was 
purified by flash column chromatography (Hex/EtOAc 1:2, Rf = 0.40) to obtain a yellow 
solid (5 steps, 13% overall yield). 1H NMR (500 MHz; DMSO-d6) δ 7.32 (s, 1H), 10.92 (s, 
1H), 11.60 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 112.0, 112.2, 115.4 (q, J = 285 Hz), 
133.5, 140.3, 153.8 (q, J = 37.5 Hz), 167.5. HR-MS (ESI): Calculated C7H4F3N2O2S2+ [M + 
H]+ = 268.9661; found [M + H]+ = 268.9664. 
 
6-amino-[1,2]dithiolo[4,3-b]pyrrol-5(4H)-one hydrochloride (3-3, holothin 
hydrochloride) 
3-10 (5.00 mg, 18.6 mmol) was dissolved in MeOH (1.0 mL) and 37% HCl (25 mL) was 
added dropwise. Reaction was refluxed for 2.5 h, cooled to rt, and concentrated to dryness 
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under reduced pressure to afford holothin hydrochloride (3-3) as a yellow solid which was 
utilized without any further purification. 
(2S,3S,4R,5S)-2-((E)-2-methyl-4-oxo-4-((9-oxo-9-((5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-
b]pyrrol-6-yl)amino)nonyl)oxy)but-2-en-1-yl)-5-((4R,5S,E)-4-methyl-5-(2,2,2-
trichloroacetoxy)hex-2-en-1-yl)tetrahydro-2H-pyran-3,4-diyl bis(2,2,2-trichloroacetate) 
(3-12). Pseudomonic acid C (0.267g, 0.55 mmol) was dissolved in CH2Cl2 (9.2 mL) and 
cooled to 0 oC. Trichloroacetyl chloride (0.31 mL, 2.75 mmol) and pyridine (0.19 mL, 2.38 
mmol) were added dropwise, followed by addition of 4-N,N-dimethylaminopyridine (6.7 mg, 
0.055 mmol). Reaction was warmed to rt and stir for 2.5 h. Mixture was diluted with CH2Cl2 
(10 mL) and washed with 1N HCl (2 x 5 mL). Organic layer was dried with Na2SO4 and 
concentrated to dryness under reduced pressure to afford S9, which was utilized without any 
further purification. 
Crude compound (0.385g, 0.42 mmol) was dissolved in CH2Cl2 (7.0 mL) and cooled to 0 oC. 
Oxalyl chloride (71 mL, 0.84 mmol) was added dropwise followed by one drop of N,N-
dimethylformamide. Reaction was stirred at rt for 3 h and concentrated to dryness under 
reduced pressure. The resulting crude acyl chloride was utilized without any further 
purification.  
Crude acyl chloride was dissolved in THF (2.13 mL) and added dropwise to a 0 oC 
suspension of holothin hydrochloride (87.1 mg, 0.418 mmol) in THF (19 mL). Et3N (0.13 
mL, 0.931 mmol) was added dropwise to the mixture and reaction stirred at rt for 45 min. 
Mixture was concentrated to dryness under reduced pressure. Silica gel (60 mesh) 
purification with a methanol gradient (0-5%) in chloroform (Rf = 0.75, 5% MeOH in CHCl3) 
afforded 3-12 (0.271g, 0.252 mmol) as a yellow foam in 60 % overall yield. 1H NMR (600 
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MHz; CDCl3) δ 8.77 (s, 1H), 7.61 (s, 1H), 6.81 (s, 1H), 5.73 (s, 1H), 5.55 (m, 2H), 5.48 (t, J 
= 3.0 Hz, 1H), 4.98 (m, 1H), 4.92 (dd, J = 3.0, 9.9 Hz, 1H), 4.07 (t, J = 6.9 Hz, 2H), 3.87 (dd, 
J = 3.0, 12.0 Hz, 1H), 3.71 (d, J = 12.0 Hz, 1H), 2.50 (m, 1H), 2.45 (dd, J = 2.4, 14.4 Hz, 
1H), 2.34 (m, 5H), 2.20 (d, J = 1.2 Hz, 3H), 2.03 (m, 1H), 1.69 (m, 2H), 1.63 (m, 3H), 1.32 
(m, 9H), 1.25 (m, 2H), 1.11 (d, J = 7.2 Hz, 3H). 13C NMR (150 MHz; CDCl3) δ 171.65, 
168.47, 166.41, 161.41, 160.83, 160.80, 154.13, 134.44, 133.06, 127.68, 118.74, 114.39, 
112.06, 90.29, 89.53, 89.05, 79.85, 74.40, 73.53, 72.55, 65.56, 63.95, 42.69, 41.92, 40.01, 
36.42, 32.01, 29.71, 29.16, 29.07, 29.05, 28.65, 25.92, 25.32, 19.04, 16.76, 16.31. Calculated 
C37H44Cl9N2O11S2+ [M + H]+ = 1070.9578; found [M + H]+ = 1070.9887. [a]D20.4  = +9.54o (c 
= 0.1, CHCl3). 
 
9-oxo-9-((5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)amino)nonyl (E)-4-
((2S,3R,4R,5S)-3,4-dihydroxy-5-((4R,5S,E)-5-hydroxy-4-methylhex-2-en-1-
yl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoate (3-13). 3-12 (0.230 g, 0.214 mmol) 
was dissolved in MeOH (4 mL) and cooled to 0 oC. NH3 (7 N in MeOH, 0.245 mL, 1.72 
mmol) was added dropwise. Reaction was stirred for 3 h at rt and concentrated to dryness 
under reduced pressure. Silica gel (60 mesh) purification with a methanol gradient (0-6%) in 
chloroform (Rf = 0.5, 5% MeOH in CHCl3) afforded 3-13 (0.103g, 0.161 mmol) as an 
orange-yellow solid in 75 % yield. 1H NMR (600 MHz; CDCl3) δ 9.17 (s, 1H), 8.01 (s, 1H), 
6.88 (s, 1H), 5.76 (s, 1H), 5.45 (m, 2H), 4.07 (t, J = 6.3 Hz, 2H), 3.92 (t, J = 3.3 Hz, 1H), 
3.79 (dd, J = 3.0, 11.4 Hz, 1H), 3.73 (td, J = 3.0, 9.0 Hz, 1H), 3.64 (m, 2H), 3.56 (m, 1H), 
3.51 (dd, J = 1.8, 11.4 Hz, 1H), 3.47 (dd, J = 3.0, 8.4 Hz, 1H), 2.62 (dd, J = 2.4, 15.0 Hz, 
1H), 2.44 (s, br, 3H), 2.36 (t, J = 7.5 Hz, 2H), 2.28 (dd, J = 8.1, 14.7 Hz, 1H), 2.23 (m, 1H), 
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2.20 (d, J = 0.6 Hz, 3H), 2.16 (m, 1H), 2.09 (m, 1H), 1.86 (m, 1H), 1.69 (m, 1H), 1.62 (m, 
1H), 1.32 (m, 8H), 1.16 (d, J = 6.0 Hz, 3H), 0.99 (d, J = 7.2 Hz, 3H). 13C NMR (150 MHz; 
CDCl3) δ 171.93, 168.49, 166.79, 156.76, 134.38, 133.14, 129.44, 117.51, 113.95, 112.49, 
74.85, 71.24, 70.53, 70.37, 68.92, 64.82, 63.74, 44.71, 42.88, 41.73, 36.30, 32.32, 28.81, 
28.75, 28.70, 28.40, 25.73, 25.56, 20.41, 19.22, 16.71. Calculated C31H47N2O8S2+ [M + H]+ = 
639.2768; found [M + H]+ =  639.2765. [a]D20.4  = +21.74o (c = 0.1, CHCl3). 
 
General Procedure for the preparation of dithiolopyrrolone analogs: Trifluoroacetyl 
holothin (3-10, 0.050g, 0.186mmol) is dissolved in MeOH (7.25 mL) and HCl (37% 
aqueous, 0.24 mL) is added dropwise. Reaction is refluxed for 2.5 h. Mixture is allowed to 
cool to room temperature and concentrated in vacuo yielding compound 3-3 as a yellow-
orange solid that is used without further purification (Rf = 0, Hex/EtOAC 1:2). The residual 
solid is suspended in THF (16.5 mL) and cooled to 0 oC. The corresponding acid chloride is 
added dropwise (0.231 mmol) followed by Et3N (57.8 µL, 0.415mmol). Reaction is allowed 
to warm to room temperature and stirred for 30 minutes. Mixture is concentrated in vacuo 
and purified by flash column chromatography. 
 
N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)acetamide (3-4, Holomycin). 
Prepared according to the general procedure. Acetyl chloride (16.4 µL, 0.231 mmol) was 
utilized as the acid chloride source. Flash column chromatography (Rf = 0.67, EtOAc/MeOH 
9:1) yielded compound 3-4 as an orange solid (57 % yield). 1H NMR (500 MHz; DMSO-d6) 
δ 2.00 (s, 3H), 7.04 (s, 1H), 9.89 (s, 1H), 10.71 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 
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22.4, 110.7, 115.4, 133.7, 134.0, 167.9, 168.9. HR-MS (ESI): Calculated [M + H]+ = 
214.9943; found [M + H]+ = 214.9946. 
 
N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)pentanamide (3-17, Pentanoyl 
Holothin). Prepared according to the general procedure. Pentanoyl chloride was utilized as 
the acid chloride source. Flash column chromatography (Rf = 0.10, Hex/EtOAc 1:2) yielded 
compound as a yellow solid (84% yield). 1H NMR (500 MHz; DMSO-d6) δ 0.86 (t, J = 7.0 
Hz, 3H), 1.22-1.30 (m, 2H), 1.46-1.52 (quint, J = 7.5 Hz, 2H), 2.33 (t, J = 7.0 Hz, 2H), 7.04 
(s, 1H), 9.84 (s, 1H), 10.71 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 13.7, 21.7, 27.2, 34.4, 
110.5, 115.3, 133.7, 133.9, 167.9, 171.8. HR-MS (ESI): Calculated [M + H]+ = 257.0413; 
found [M + H]+ = 257.0418. 
 
(E)-2-methyl-N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)but-2-enamide (3-18, 
Tigloyl Holothin). Prepared according to the general procedure. Tigloyl chloride was 
utilized as the acid chloride source. Flash column chromatography (Rf = 0.35, Hex/EtOAc 
1:2) yielded compound as an orange solid (66% yield). 1H NMR (500 MHz; DMSO-d6) δ 
1.73 (dd, J = 1.0 and 7.0 Hz, 3H), 1.80 (t, J = 1.0 Hz, 3H), 6.53 (qq, J = 1.0 and 7.0 Hz, 1H), 
7.09 (s, 1H), 9.07 (s, 1H), 10.77 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 12.2, 13.9, 110.8, 
115.3, 130.1, 132.9, 133.7, 134.9, 166.9, 168.0. HR-MS (ESI): Calculated [M + H]+ = 
255.0256; found [M + H]+ = 255.0267. 
 
N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)methanesulfonamide (3-19, Mesyl 
Holothin).  
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Prepared according to the general procedure. Mesyl chloride (22.2µL, 0.231 mmol) was 
utilized as the acid chloride source. Flash column chromatography (Rf = 0.5, EtOAc/MeOH 
9:1) yielded compound as a brown solid (15% yield). 1H NMR (500 MHz; DMSO-d6) δ 2.99 
(s, 3H), 7.19 (s, 1H), 9.36 (s, 1H), 10.83 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 40.8, 
111.4, 113.1, 133.9, 141.8, 168.7. HR-MS (ESI): Calculated [M + H]+ = 250.9613; found [M 
+ H]+ = 250.9633. 
 
N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)hept-6-ynamide (3-20, 6-Heptynoyl 
Holothin). Prepared according to the general procedure. 6-heptynoyl chloride was utilized as 
the acid chloride source. Flash column chromatography (Rf = 0.15 Hex/EtOAc 1:2) yielded 
compound as a brown solid (24% yield). 1H NMR (500 MHz; DMSO-d6) δ 1.42 (quint, J = 
7.5 Hz, 2H), 1.59 (quint, J = 7.5 Hz, 2H), 2.16 (td, J = 2.5 and 7.0 Hz, 2H), 2.34 (t, J = 7.5 
Hz, 2H), 2.77 (t, J = 2.5 Hz, 1H), 7.05 (s, 1H), 9.87 (s, 1H), 10.72 (s, 1H). 13C NMR (125 
MHz; DMSO-d6) δ 17.9, 24.7, 27.9, 34.5, 71.8, 84.8, 111.1, 115.8, 134.1, 134.5, 168.4, 
172.1. HR-MS (ESI): Calculated [M + H]+ = 281.0413; found [M + H]+ = 281.0423. 
 
N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)hex-5-ynamide (3-21, 5-Hexynoyl 
Holothin) Prepared according to the general procedure. 5-hexynoyl chloride was utilized as 
the acid chloride source. Flash column chromatography (Rf = 0.5, Hex/EtOAc 1:2) yielded 
compound as a brown-orange solid (16% yield). 1H NMR (500 MHz; DMSO-d6) δ 1.68 
(quint, J = 7.0 Hz, 2H), 2.16 (td, J = 2.5 and 7.0 Hz, 2H), 2.43 (t, J = 7.0 Hz, 2H), 2.78 (t, J = 
3 Hz, 1H), 7.04 (s, 1H), 9.88 (s, 1H), 10.68 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 17.3, 
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24.0, 71.6, 83.9, 110.5, 115.3, 133.7, 134.1, 167.9, 171.1. HR-MS (ESI): Calculated [M + 
H]+ = 267.0256; found [M + H]+ = 267.0260. 
 
N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)hexanamide (3-22, Hexanoyl 
Holothin). Prepared according to the general procedure. Hexanoyl chloride was utilized as 
the acid chloride source. Flash column chromatography (Rf = 0.60, EtOAc) yielded 
compound as a yellow solid (77% yield). 1H NMR (500 MHz; DMSO-d6) δ 0.85 (t, J = 7.0 
Hz, 3H), 1.19-1.31 (m, 4H), 1.50 (quint, J = 7.0 Hz, 2H), 2.32 (t, J = 7.5 Hz, 2H), 7.04 (s, 
1H), 9.84 (s, 1H), 10.71 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 13.8, 21.8, 24.7, 30.8, 
34.6, 110.5, 115.3, 133.7, 133.9, 167.9, 171.8. HR-MS (ESI): Calculated [M + H]+ = 
271.0569; found [M + H]+ = 271.0590. 
 
N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)octanamide (3-23, Octanoyl 
Holothin). Prepared according to the general procedure. Octanoyl chloride was utilized as 
the acid chloride source. Flash column chromatography (Rf = 0.45, Hex/EtOAc 1:2) yielded 
compound as a yellow solid (77% yield). 1H NMR (500 MHz; DMSO-d6) δ 0.84 (t, J = 7.0 
Hz, 3H), 1.18-1.29 (m, 8H), 1.50 (quint, J = 7.0 Hz, 2H), 2.32 (t, J = 7.5 Hz, 2H), 7.04 (s, 
1H), 9.83 (s, 1H), 10.70 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 13.9, 22.0, 25.1, 28.4, 
28.5, 31.1, 34.6, 110.5, 115.4, 133.7, 133.9, 167.9, 171.8. HR-MS (ESI): Calculated [M + 
H]+ = 299.0882; found [M + H]+ = 299.0887. 
 
(E)-N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)but-2-enamide (3-24, Crotonyl 
Holothin). Prepared according to the general procedure. Crotonyl chloride was utilized as the 
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acid chloride source. Flash column chromatography (Rf = 0.20, Hex/EtOAc 1:2) yielded 
compound as an orange solid (39% yield). 1H NMR (500 MHz; DMSO-d6) δ 1.81 (dd, J = 
1.5 and 7.0 Hz, 3H), 6.33 (dd, J = 1.5 and 15.2 Hz, 1H), 6.74 (dq, J = 6.5 and 15.5 Hz, 1H), 
7.08 (s, 1H), 9.97 (s, 1H), 10.75 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 17.7, 111.0, 
115.3, 124.2, 133.8, 134.4, 163.5, 167.9. HR-MS (ESI): Calculated [M + H]+ = 241.0100; 
found [M + H]+ = 241.0103. 
 
N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)methacrylamide (3-25, 
Methacryloyl Holothin). Prepared according to the general procedure. Methacryloyl 
chloride was utilized as the acid chloride source. Flash column chromatography (Rf = 0.15, 
Hex/EtOAc 1:2) yielded compound as an orange solid (39% yield). 1H NMR (500 MHz; 
DMSO-d6) δ 1.92 (s, 3H), 5.50 (t, J = 1.0 Hz, 1H), 5.89 (s, 1H), 7.12 (s, 1H), 9.34 (s, 1H), 
10.80 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 18.4, 111.0, 114.9, 121.8, 133.7, 135.7, 
138.1, 166.1, 168.0. HR-MS (ESI): Calculated [M + H]+ = 241.0100; found [M + H]+ = 
241.0103. 
 
3-methyl-N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)but-2-enamide (3-26, 3,3-
Dimethylacryloyl Holothin) Prepared according to the general procedure. 3,3-
dimethylacryloyl chloride was utilized as the acid chloride source. Flash column 
chromatography (Rf = 0.4, Hex/EtOAc 1:2) yielded compound as an orange solid (54% 
yield). 1H NMR (500 MHz; DMSO-d6) δ 1.81 (d, J = 1.0 Hz, 3H), 2.12 (d, J = 1.0 Hz, 3H), 
6.07-6.09 (m, 1H), 7.04 (s, 1H), 9.73 (s, 1H), 10.72 (s, 1H). 13C NMR (125 MHz; DMSO-d6) 
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δ 19.8, 27.2, 110.5, 115.5, 117.5, 133.7, 133.8, 152.8, 164.6, 168.0. HR-MS (ESI): 
Calculated [M + H]+ = 255.0256; found [M + H]+ = 255.0266. 
 
6-azido-N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)hexanamide (3-27, 6-
Azidohexanoyl Holothin) Prepared according to the general procedure. 6-azidohexanoyl 
chloride was utilized as the acid chloride source. Flash column chromatography (Rf = 0.3 
Hex/EtOAc 1:2) yielded compound as an orange solid (19%). 1H NMR (500 MHz; DMSO-
d6) δ 1.26-1.33 (m, 2H), 1.53 (quint, J = 7.0 Hz, 4H), 2.34 (t, J = 7.5 Hz, 2H), 3.31 (t, J = 7.0 
Hz, 2H), 7.05 (s, 1H), 9.86 (s, 1H), 10.71 (s). 13C NMR (125 MHz; DMSO-d6) δ 24.6, 25.7, 
27.9, 34.5, 50.5, 110.6, 115.3, 133.7, 134.0, 167.9, 171.7. HR-MS (ESI): Calculated [M + 
H]+ = 312.0583; found [M + H]+ = 312.0592. 
 
N-(4-benzyl-5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)acetamide. (3-28). Flash 
column chromatography (Rf = 0.45, Hex/EtOAc 1:1) yielded compound as an orange solid 
(61% yield). 1H NMR (500 MHz; DMSO-d6) δ 2.02 (s, 3H), 4.95 (s, 2H), 7.21-7.27 (m, 3H), 
7.29 (s, 1H), 7.30-7.34 (m, 2H), 10.07 (s, 1H). 13C NMR (125 MHz; DMSO-d6) δ 22.3, 44.0, 
111.8, 114.5, 127.2, 127.4, 128.6, 133.4, 134.6, 137.2, 166.0, 168.8. HR-MS (ESI): 
Calculated [M + H]+ = 305.0413; found [M + H]+ = 305.0414. 
 
tert-Butyl (5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)carbamate (3-30, Pivaloyl 
Holothin). Prepared according to the general procedure. Pivaloyl chloride was utilized as the 
acid chloride source. Flash column chromatography (Rf = 0.10, Hex/EtOAc 1:2) yielded 
compound as a yellow solid (77% yield). 1H NMR (400 MHz; DMSO-d6) δ 1.20 (s, 9H), 
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7.08 (s, 1H), 8.73 (s, 1H), 10.76 (s, 1H). 13C NMR (100 MHz; DMSO-d6) δ 26.94, 110.70, 
115.11, 133.61, 134.87, 168.05, 176.60.  
 
N-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)benzamide (3-31, Benzoyl 
Holothin). Prepared according to the general procedure. Pivaloyl chloride was utilized as the 
acid chloride source. Flash column chromatography (Rf = 0.10, Hex/EtOAc 1:2) yielded 
compound as a yellow solid (72% yield). 1H NMR (400 MHz; DMSO-d6) δ 7.16 (s, 1H), 
7.47-7.51 (m, 2H), 7.56-7.60 (m, 1H), 7.97-99 (m, 2H), 10.02 (s, 1H), 10.81 (s, 1H). 
 
N-(2,2-dioxido-5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)acetamide (3-32, 
Dioxyholomycin). 3-4 (64.1 mg, 0.299 mmol) is dissolved in a mixture of acetone (12.8 mL) 
and water (12.8 mL) and cooled to 0 oC. Oxone® is added scoopwise (0.46 g, 1.49 mmol) and 
solution stirred at this temperature for 30 minutes. Reaction is quenched by addition of three 
drops of a saturated (aqueous) NaHCO3 solution and stirred for an additional 30 minutes. 
Solids are filtered off and filtrate is concentrated. Flash column chromatography (Rf = 0.75, 
EtOAc/MeOH 9:1) yielded compound as a light yellow solid (40% yield). 1H NMR (500 
MHz; DMSO-d6) δ 2.08 (s, 3H), 7.27 (s, 1H), 10.57 (s, 1H), 11.35 (s, 1H). 13C NMR (125 
MHz; DMSO-d6) δ 22.6, 109.5, 115.2, 123.3, 143.2, 165.8, 170.6. Calculated [M + H]+ = 
246.9842; found [M + H]+ = 246.9843. 
 
N-(2,2-dioxido-5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)-2,2,2-
trifluoroacetamide (3-33, Dioxytrifluoroacetyl holothin). 3-10 (0.050 g, 0.186 mmol) is 
dissolved in a mixture of acetone (10 mL) and water (5 mL) and cooled to 0 oC. H2O2 (1.02 
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mmol), 30% solution in H2O, is added dropwise and reaction stirred at 0 oC for 5 min, 
followed by 45 min at rt. Reaction is quenched by addition of two drops of a saturated 
(aqueous) NaHCO3 solution and stirred for an additional 5 minutes. Concentrated. 
Purification of the mixture by flash column chromatography (Rf = 0.45, Hex/EtOAc 1:2) 
yielded compound as a light yellow solid (64% yield, b.r.s.m.). 1H NMR (500 MHz; DMSO-
d6) δ 7.46 (s, 1H), 11.53 (s, 1H), 12.24, (s, broad, 1H). 13C NMR (125 MHz; DMSO-d6) δ 
111.6, 117.3 (q, J = 285 Hz), 121.5, 123.8, 142.1, 155.5 (q, J = 38.8 Hz), 165.0. Calculated 
[M + H]+ = 300.9559; found [M + H]+ = 300.9563. 
 
3.9.3 Ywle Expression, Purification, and Assay 
E. coli BL21, transformed with pET21a(+) plasmid containing the YwlE gene, are 
grown in 1.0 L of LB broth supplemented with 100 µg/mL of ampicillin to an OD600 = 0.8 at 
37 oC. Induced with 0.5mM IPTG for 2 h at 37 oC. Centrifuged cells at 4,000rpm for 15 min 
and removed supernatant. Resuspended cells in 35 mL lysis buffer (50mM Tris, pH = 7.5, 
and 300mM NaCl) supplemented with 2 mM PMSF, 10 mM MgCl2, 250 µg/mL lysozyme, 2 
U/mL DNase I, and 2 EDTA-free protease inhibitor tablets from ROCHE. Disrupted cells by 
sonicating twice for 1.5 min at 30% max burst intensity intervals. Centrifuged debris for 1 h 
at 15,000rpm. Lysate was filtered with a 0.45µm sterile filter and loaded into a Ni2+ column, 
previously equilibrated with lysis buffer. Washed off non-specific proteins by washing with 
lysis buffer first, followed by lysis buffer with 100mM imidazole. Eluted YwlE protein with 
lysis buffer supplemented with 250mM imidazole. Phosphatase-containing fractions were 
loaded on a Superdex®-75 column equilibrated with 20mM Tris (pH = 7.5) and 100mM 
NaCl. Fractions containing YwlE were pooled and concentrated to 9.25 mg/mL using a 
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Centricon concentrator with a 10kDa nominal molecular weight mass cutoff. Buffer-
exchanged protein using a PD-10 desalting column (GE Healthcare) to 50mM NH4HCO3 (pH 
= 8.0). 
Enzymatic assays were carried out in 50 mM NH4HCO3 (pH = 4.5) with final volumes of 
100 µL: 
1. 3.5 mg/mL YwlE + DMSO 
2. 3.5 mg/mL YwlE + 10mM Oxo-holomycin 
Incubated for 1 h at rt. Analyzed protein redox state with the LTqFT-ESI+ high-resolution 
mass spectrometer. 
 
3.9.4 AtAPSK Expression, Purification, and Assay 
E. coli BL21, transformed with pET28a(+) plasmid containing the AtAPSKΔ77 gene, 
were grown in 1.0 L of terrific broth supplemented with 50 µg/mL of kanamycin to an OD600 
= 0.8 at 37 oC. Induced with 1.0mM IPTG overnight at 20 oC. Centrifuged cells at 4,500rpm 
and remove supernatant. Resuspend cells in 35 mL of lysis buffer (50mM Tris, pH = 8.0, 
500mM NaCl, 20 mM imidazole, 1mM 2-mercaptoethanol, 10% (v/v) glycerol, 1% Tween-
20, 2 mM PMSF, 10 mM MgCl2, 250 µg/mL lysozyme, 2 U/mL DNase I, and 2 protease 
inhibitor tablets from ROCHE). Disrupted cells by sonicating twice for 1.5 min with 30% of 
max burst intensity. Centrifuged debris for 1 h at 15,000rpm. Lysate is filtered with a 0.45 
µm sterile filter and loaded into the Ni2+ column, previously equilibrated with equillibration 
buffer (lysis buffer without 1% Tween-20). Washed off non-specific proteins by washing 
with equilibration buffer. Eluted YwlE protein with equilibration buffer with 250mM 
imidazole. Kinase-containing fractions are loaded on a Superdex-200 column equilibrated 
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with 25mM Hepes, pH = 7.5, 200mM KCl, 5mM 2-mercaptoethanol, 5% (v/v) glycerol, 
Fractions containing AtAPSKΔ77 are pooled and concentrated to 1.3 mg/mL using a 
Centricon concentrator with a 3 kDa nominal molecular weight mass cutoff. Buffer 
exchanged protein using a PD-10 column to 50mM NaH2PO4/Na2HPO4 (pH = 4.5) and 
concentrated to a final concentration of 2.01 mg/mL. Enzymatic reactions are carried out in 
22.8 µM AtAPSKΔ77 in 50 mM sodium phosphate buffer (pH = 4.5). Final volume of 
reactions is 100 µL. Reactions are stirred for 1 h at rt while stirring. Oxo-holomycin stock is 
200 mM in DMSO. L-Glutathione, reduced, stock is 200 mM in H2O. L-Glutathione dimer 
stock is 100mM in H2O. H2O2 stock is 0.3% in H2O (98 mM). 
 
3.9.5 Dioxoholymycin Reactivity with N-Acetylcysteine 
To a 2 mL screw-cap HPLC vial with septum was added 50 mM NaHPO4  buffer, at 
the indicated pH, followed by 3-32 from a freshly prepared 10 mM DMSO stock, and N-
Acetylcysteine from a freshly prepared 10 mM pH = 7.0 NaHPO4 stock, such that the total 
volume was 1 mL and the concentrations of oxo-holomycin and N-Acetylcysteine were 0.5 
mM and 1.0 mM, respectively. Reactions were monitored with UV/Vis in 384-well Greiner 
UV-star plates and were analyzed using a TECAN M1000 Infinite Pro microplate reader. 
 
3.9.6 Measuring Glutathione Content in E. coli MG1655 
Each experiment was done by growing 1.5 L of freshly prepared Luria-Bertani (LB) 
broth, in 2.8 L baffled-flasks with 1.5 mL inoculation from overnight seed, with E. coli 
MG1655 and 2 drops of antifoam at 37 oC until half log-phase was reached (OD600 = 0.3, ~ 
3.5 h). Then, DMSO, holomycin (3-4, DMSO, final concentration 2 mg/mL), Paraquat (H2O, 
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final concentration 300 mg/mL), chloramphenicol (MeOH, final concentration 5 mg/mL), or 
rifampicin (DMSO, final concentration 10 mg/mL) solutions were added. Cells were grown 
for one more hour at 37 oC and cells pelleted for 15 min at 4,500 rpm. Pellets were 
lyophilized to obtain dry cells. 
Each pellet was split into 6 equal portions of ~50 mg residual dry weight each. Three 
cell pellets were extracted with 1 ml of pre-warmed (60 °C) 50% aqueous-acetonitrile 
containing 2 mM monobromobimane (mBBr) and 20 mM 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) pH 8.0. These thiol samples were incubated at 60 °C for 15 
min, cooled on ice and acidified with 5 µl of 5M methanesulfonic acid. The cell debris was 
removed by centrifugation (13,000g for 10 min). The other three cell pellets were extracted 
with 1 ml of pre-warmed (60 °C) 50% aqueous-acetonitrile containing 5 mM N-
ethylmaleimide (NEM) and 20 mM HEPES pH 8.0. These disulfide samples were incubated 
at 60 °C for 15 min and cooled on ice. The cell debris was removed by centrifugation (same 
as above). A 0.8 mL aliquot of the supernatant was mixed with 2.5 mM dithiothreitol (DTT) 
to react with residual NEM. The 0.8 mL supernatant was reduced with 2 mM DTT for 20 
min at 23 °C and mBBr was added to a final concentration of 6 mM and reacted in the dark 
for an additional 10 min. The labeling reaction was quenched with 5 µl 5 M methanesulfonic 
acid. Analysis was done on LC/MS by injecting 15 µL of non-NEM treated samples and 30 
µL of NEM-treated samples. Concentrations were calculated according to a previously made 
standard curve: 
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CHAPTER IV 
VISIBLE LIGHT O-GLYCOSYLATION OF THIOGLYCOSIDES 
4.1 Introduction 
 Natural products containing O-sugar linkages are often found in nature,1 with 
aminoglycosides being the first class of naturally occurring antibiotics discovered through 
systematic screening of naturally occurring scaffolds.2 Erythromycin is amongst the most 
well studied antibiotics containing a sugar moiety and having strong activity against 
Staphylococcus aureus and Streptococcus pyogenes3 (Figure 4.1). It is often the substitute 
for patients possessing allergy to penicillin. Moreover, the thiopeptide nocathiacin I from 
Nocardia sp. ATCC 202099 has been found to be active against Gram-positive bacteria and a 
multi-drug resistant strain of Enterococcus faecium (Figure 4.1).4 Sugar moieties can often 
increase solubility and aid in targeted drug delivery by allowing recognition of specific 
interactions within the cell surface.5 Therefore, a method by which sugars could be linked to 
natural products is highly desirable. We envisioned the design of a method that would be 
mild and selective for activating glycosides in the presence of other functional groups, and 
then trapping it with an alcohol-containing acceptor molecule. The field of visible light 
catalysis has provided an avenue in which to pursue the glycosylation reaction. 
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Figure 4.1. O-Linked sugar containing antibiotics. 
 
Visible light catalysis has found increasing use in organic chemistry for the activation 
of key moieties towards nucleophilic trapping by utilizing substoichiometric photoredox 
catalysts6,7 involved in the formation of carbon-carbon, carbon-hydrogen, carbon-oxygen, 
and carbon-halogen bonds. This is best exemplified by the catalysts involved in singly 
occupied molecular orbital (SOMO) enantioselective additions into chiral 3π 
imidazolidinones developed by the MacMillan group.8,9 In parallel, visible light catalysis has 
been harnessed for light activated metal-ligand complexes to access radical pathways that 
activate redox cycles by single-electron-transfer (SET) from a co-reductant (reductive 
quenching) or co-oxidant (oxidative quenching, Figure 4.2).10,11  
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Figure 4.2. Commonly utilized visible light photoredox cycles. M = metal. L = ligand. 
 
Visible light catalysis has allowed for transformation of alcohols to alkyl halides12, 
formation of iminium intermediates for the Strecker reaction7 and other nucleophilic 
additions, C-H activation at benzylic positions,13 alkyl halide addition to olefins14, and many 
other transformations. Due to the ability of photocatalysts to both receive and donate 
electrons, they can be fine-tuned to access various excitation wavelengths by the ligands 
associated with the metal center, allowing for the utilization of various visible light resources 
to promote redox cycling. 
 Amongst the most well studied photocatalysts are Ru(bpy)3Cl2 (4-1) and 
Ir[dF(CF3)ppy]2-(dtbbpy)PF6 (4-2, Figure 4.3). These compounds have the advantage of 
having long-lived photoexcited states and inherent stability. Moreover, the Ru (II) and Ir (III) 
centers are able to take part in metal to ligand charge transfer (MLCT), resulting in a species 
where the metal center is formally oxidized while the ligand is formally reduced. Rapid 
intersystem crossing between the excited singlet state to the triplet state, allows for a relative 
long-lived state that can relay electrons since its decay to the singlet ground state is spin 
forbidden. 15   
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Figure 4.3. Commonly utilized visible light catalysts. 
 
A key area where visible light catalysis can be extremely useful is in glycosylation 
chemistry. Selective activation of redox active moieties can be readily advantageous in the 
production of key synthetic methods by complementing protection/deprotection strategies. 
Thioglycosides, important starting blocks in carbohydrate chemistry, 16 can be considered 
ideal candidates for visible light catalysis. Preliminary work by Yoshida et al 17 has utilized 
this moiety in electron relay cycles for the activation of the anomeric position in 
electrochemical cells, showing the potential for thioglycosides to be activated towards 
oxidation and hence promising compatibility with visible light catalysis.  
The complexity of oligosaccharides found in nature has spurred a great interest in 
developing chemical transformations that can link one or more carbohydrates together. For 
many years, chemical transformations have relied on the premise that the anomeric position 
of an acceptor glycoside can become active upon having an electronic demanding moiety that 
polarizes the σ* of the bond by which the oxygen in the pyran ring can promote dissociation 
and form an oxocarbenium ion, an elusive intermediate that has just been recently observed 
in superacid media18 by nuclear magnetic resonance (NMR). An incoming nucleophile donor 
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can then trap the oxocarbenium ion (Figure 4.4a). The use of rationally designed protecting 
groups for selective protection/deprotection at specific positions in the ring (Figure 4.4b) 
when the glycosylation does not involve the anomeric position is of equal importance. We 
envisioned a method by which we could combine both visible light catalysis and 
oxocarbenium chemistry to develop a mild method for O-glycosylation of thioglycosides that 
would be amenable for synthetic glycochemistry. 
 
Figure 4.4 Glycochemistry reactivity. a) Formation of oxocarbenium ion and trapping by 
nucleophile at either α or β anomeric position. b) Representation of selective 
glucopyranoside reaction with different protecting groups at each hydroxyl position. 
 
4.2 Visible Light Activation of Thioglycosides 
 We speculated that catalysts 4-1 and 4-2 would be able to generate oxocarbenium 
ions from electron rich thioglycosides through MLCT; these reactive intermediates could 
then be trapped with an alcohol donor. Our initial studies led us to synthesize S-phenyl (SPh, 
4-3) and S-p-methoxyphenyl (SPMP) β-glucose tetra-O-benzyl-thioglycoside (4-4) and to 
effect their activation with blue visible light irradiation in the presence of the co-oxidant 
BrCCl3, catalyst 1 or 2, and methanol as the trapping nucleophile under the conditions 
described in Table 4.1. Ru-catalyst 4-1 did not effect the activation of either SPh (4-3) or 
SPMP (4-4, entries 1 and 2) and trapping by methanol, but the Ir-catalyst 4-2 did allow for 
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the production of methoxylated product (4-5) when 4-4 was employed as substrate (Table 
4.1, entries 4-10). The differential activity of the two thioglycoside donors can be attributed 
to the oxidation potentials of 4-3 and 4-4 measured at 1.31 eV and 1.16 eV (vs Ag/AgCl), 
respectively, and the oxidation potential of 4-2 at 1.21 eV (vs Ag/AgCl). 
 
Table 4.1. Optimizing glycosidation conditions*. 
 
Entry Substrate MeOH (equiv.) Catalyst (5 mol%) Co-oxidant (equiv.) Additive Yield 
1 4-3 10 4-1 BrCCl3 (2.0) -- 0 
2 4-4 10 4-1 BrCCl3 (2.0) -- 0 
3 4-3 10 4-2 BrCCl3 (2.0) -- 0 
4 4-4 10 4-2 BrCCl3 (2.0) -- 96 
5 4-4 2 4-2 BrCCl3 (2.0) -- 12 
6 4-4 2 4-2 BrCCl3 (2.0) TFE 37 
7 4-4 2 4-2 BrCCl3 (2.0) HFIP 51 
8 4-4 2 4-2 CBr4 (2.0) HFIP 58 
9 4-4 2 4-2 CBr4 (0.25) HFIP 65 
10 4-4 2 4-2 BrCCl3 (0.25) HFIP 61 
*Reactions were carried in 0.1 M MeCN and 10 equiv. of additive. 
 
The equivalents of alcohol were reduced from 10.0 equiv. to 2.0 equiv. to make it 
more amenable for future glycosidic reactions, but the reaction yield decreased substantially 
(Table 4.1, entry 5). Previous work has shown the positive influence of adding a polar, protic 
O
BnO
BnO
BnO
OBn
SPh
co-oxidant, MeOH, 4-1 or 4-2
MeCN, HFIP or TFE, 6 h,
blue light
O
BnO
BnO
BnO
OBn
SPMP
or
4-3 4-4
O
BnO
BnO
BnO
OBn
OMe
4-5α,β
 122 
acid to aid in solvation of the charge transfer complex; 19  hence, we utilized 2,2,2-
trifluoroethanol (TFE) as an additive and found that although the yield did increase, we 
would see trapping of the oxocarbenium ion by TFE (Table 4.1, entry 7). We next tried the 
additive 1,1,1,3,3,3,-hexafluoroisopropanol (HFIP) and found that no trapping could be seen 
by this alcohol and the yield increased to 51% (Table 4.1, entry 7). We further explored the 
use of CBr4 as co-oxidant (Table 4.1, entry 8) and found it to be efficient in promoting the 
reaction. Notably, the use of substoichiometric amounts of co-oxidant led to similar yields 
(Table 4.1, entries 9-10), suggesting a pathway where the X3CBr species acts as an initial 
electron relay compound but it is not needed to propagate the reaction. All subsequent 
experiments were run with conditions in entries 9 and 10 from Table 4-1. 
 The substrate scope of the reaction was further explored and the use of primary, 
secondary, and tertiary alcohols as trapping agents were examined as well as different 
protecting groups on the glycosyl donor. 
 
Table 4.2. Substrate scope and compatibility for glycosylation. 
Entry Donor Acceptor (R’OH) Product % Yield  (α:β) 
1 
	
CH3OH 
	
65% [a] 
(0.9:1) 
 
2 
	
	
66% [a] 
(1:1.5) 
3 
	
CH3OH N/A	 NR 
 
4 
	
CH3OH 
	
72% [a] 
(1.6:1) 
OBnO
OBn
BnO SPMP
OBn
4-4
OBnO
OBn
BnO OMe
OBn 4-5 (α:β)
OH OBnO
OBn
BnO O
OBn 4-6 (α:β)
OAcO
OAc
AcO SPMP
OAc
4-7
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OMe
MeO SPMP
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OMe
MeO OMe
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5 
	
CH3(CH2)7OH 
	
71% [a,c] 
(0.75:1) 
 
6 	
	
87% [a] 
(1.6:1) 
 
7 	 	
71%[b,d] 
(1.1:1) 
 
8 
	
	
71% [b,e] 
(1.6:1) 
 
9 
	
	
23% [b] 
(1.2:1) 
10 
	
	
61% [b,f] 
(1.6:1) 
 
11 
	
CH3OH 
	
82% [b] 
(1:4.1) 
 
12 
	
	
42% [b] 
(1:2.9) 
Reactions carried out at 0.1M  thioglycoside with 5 mol% catalyst and irradiated for 6 h with blue LEDs unless 
otherwise stated.  Yields are reported for isolated products.  [a] CBr4 used. [b] BrCCl3 used.  [c] Irradiated for 23 h. 
[d] 18h. [e] 9h. [f] 10h. NR = No reaction. 
 
Primary, secondary, and tertiary alcohols were all permissive nucleophiles for this 
glycosylation chemistry and afforded the desired products as a mixture of anomers with high 
yields. Our initial conditions proved to be amenable towards activating thioglycosides with 
electron rich O-protecting groups and 2-deoxyrhamnal (Table 4.2, entries 1, 4, and 11). The 
use of greasy, alkyl alcohols are allowed (Table 4.2, entry 3). The secondary alcohols 
cyclohexanol and (-)-mentol were also tolerated (Table 4.2, entries 2, 6, and 7). The tetra-O-
acetyl protected thioglycoside 4-7 is not active towards our photocatalyst, presumably due to 
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a higher oxidation potential due to the inactivating nature of the protecting group (Table 4.2, 
entry 3). Yet, acetyl groups are in fact tolerated in the redox cycle as exemplified by the use 
of 2-deoxy-L-rhamnothioglycoside 4-18 (Table 4.2, entries 11-12). Most of our studies were 
done with the more electron rich tetra-O-methyl thioglycoside 4-8, which allowed for 
conversions to expand into bulky, tertiary alcohols (Table 4.2, entry 8), and an enolizable 
stereocenter without loss of chirality (Table 4.2, entry 10). It is noteworthy that glycosyl 
acceptors bearing aryl protecting group are amenable to this chemistry and 1,6-linkages can 
be readily accessed (Table 4.2, entries 9 and 12). 
 
4.3 Mechanistic Studies 
 Having established conditions for thioglycoside activation and intermediate trapping, 
we wanted to investigate the individual components of the reaction by using thioglycoside 4-
4 and methanol. When the catalyst is removed from the reaction, there is no glycosylation 
product; furthermore, when the co-oxidant alkyl halide is removed, the reaction does 
proceed, albeit at a much slower rate (only ~21% after 4 h of irradiation).  The dependence of 
the reaction towards exposure to blue light was monitored by 1H NMR. The symmetric 
disulfide byproduct can be recovered quantitatively after the reaction is complete, and it can 
serve as a measuring point for time-dependent conversion of starting material to product. We 
were able to visualize the disappearance of the starting SPMP aryl thiol peak at 7.52 ppm and 
the appearance of a new peak corresponding to the symmetric disulfide at 7.41 ppm. As seen 
in Figure 4.5a, the reaction is completely dependent on blue light as no reaction progression 
is seen when the blue LEDs are turned off, even after 1 h. Interestingly, the reaction can be 
readily turned off and on intermittently until full consumption of starting material. Further 
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NMR studies focused on the role of HFIP probed by 19F NMR to ensure that no HFIP is 
consumed during the reaction.  Trifluorotoluene was utilized as an internal standard to 
compare and quantify the amount of additive before and after blue light irradiation for 6 h 
(Figure 4.5b); 19F NMR showed that no HFIP is expended during the process, enhancing its 
role as a stabilizer of the CLMT complex. 
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a) 
 
b)  
 
Figure 4.5. Mechanistic studies probed by NMR. a) Monitoring of blue light irradiance on 
thioglycoside activation by 1H NMR. b) Monitoring of HFIP consumption by 19F NMR with 
trifluorotoluene as standard. 
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 An intriguing observation of this reaction is the lack of anomeric selectivity seen 
upon completion. We expected to see a “nitrile effect” where the solvent acetonitrile 
stabilized the oxocarbenium cation by stabilizing the α-position, thus obtaining β-selective 
addition. Indeed, pronounced β-selectivity can be seen early but degrades over the course of 
the reaction (Figure 4.6). This isomerization can be attributed to the low pH of the finalized 
reaction (pH = 4.0) with the expected formation of acidic byproducts from co-oxidant 
consumption and the 10.0 equiv. of HFIP. Efforts at utilizing non-nucleophilic bases during 
the reaction such as N,N-diisopropylethyl amine, 2,6-di-tert-butyl-4-methyl pyridine, and 
2,4,6-tri-tert-butylpyridine to neutralize acidic byproducts were unsuccessful due to 
inhibition of reaction progression from the electron rich bases. 
 
 
Figure 4.6. Loss of anomeric selectivity during reaction progress. t = time in hours. 
 
   Hα  = 4.83 Hβ  = 
4.13 
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Consideration of the possible mechanism suggested that H2 may be produced as a by-
product of the reaction. To test this hypothesis, we scaled the reaction 200-fold and attached 
a H-sensing polymer20 to the cap of the reaction vessel. A positive test was observed only 
when the reaction was treated with light (Figure 4.7). 
 
 
Figure 4.7. Hydrogen detection during reaction. A = Untreated polymer. B = Reaction, no 
light. C = H2-treated polymer. D = Reaction with light. E = Reaction with light, no catalyst. 
 
4.4 Proposed Mechanism 
 
 
Figure 4.8. Proposed mechanism for O-glycosylation of thioglycosides mediated by visible 
light catalysis.  
 
 129 
With the data in hand regarding the mechanistic studies in our SET system activation 
of thioglycosides, we have proposed the mechanism shown in Figure 4.8. The initial step 
involves excitation with visible light of our Ir-catalyst and transfer of an electron from it to 
the C-Br bond. The oxidized catalyst can now be oxidatively quenched by the SPMP moiety 
in the thioglycoside, forming a radical cation. This radical cation can be released from the 
anomeric position assistance from the oxygen pyran and an oxocarbenium ion is produced, 
which can be trapped by our alcohol nucleophiles. The key propagation step relies on the 
through the formation of an SPMP disulfide, that serves as the co-oxidant after the initial 
X3CBr has been consumed, through release of hydrogen. 
 
4.5 Summary 
 We have designed method by which O-glycosides can be accessed from thioglycoside 
donors via visible-light catalysis. We found that the catalyst Ir[dF(CF3)ppy]2 (dtbbpy)PF6 
achieves the condensation of primary, secondary, and  tertiary alcohols with O-protected S-p-
methoxyphenyl (SPMP) thioglycosides in the presence of a substoichiometric amount of the 
co-oxidant bromotrichloromethane, the protic co-solvent hexafluoroisopropanol (HFIP), and 
activation with blue light in acetonitrile. The reaction proceeds via the formation of an 
oxocarbenium ion during a single-electron-transfer (SET) event and subsequent breakdown 
of the carbon-SPMP bond. We see a preference for making the β-anomer over the α-anomer 
early in the reaction. The anomeric selectivity can be attributed to the solvent nitrile effect 
stabilizing the oxocarbenium ions, but the selectivity erodes over the course of the reaction 
presumably due to the increasing acidity of the reaction from byproducts. Future experiments 
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will allow testing this methodology in creating linkages between thioglycosides and natural 
products containing alcohol moieties. 
 
4.6 Experimental 
4.6.1 General Methods 
Solvents and reagents were purchased from commercial vendors and were used 
without any further purification, except for 1-adamantanol, which was purified by column 
chromatography and recrystallization from EtOAC/hexanes and (–)-menthol, which was 
azeotroped with toluene twice and crystallized under vacuum prior to use. 1H NMR spectra 
were recorded at 300 MHz, 13C NMR spectra were recorded at 75 MHz, and 19F NMR 
spectra were recorded at 282 MHz, all using a Bruker ARX300 spectrometer with a QNP 
probe. 13C NMR spectra for mechanistic studies were recorded at 125 MHz, both using a 
Bruker Avance 500 (BBO probe). All NMR spectra were recorded in CDCl3. Mass spectral 
analyses were performed at the Purdue University Campus-Wide Mass Spectrometry Center. 
ESIMS was performed using a FinniganMAT LCQ Classic mass spectrometer system. 
GCMS was performed using an Agilent 9575 GC-MS with a db5 column, heating from 40 to 
320 ˚C; analysis was performed in electron impact mode. Optical rotations were determined 
using an Autopol I automatic polarimeter (Rudolph Research Analytical) in a polarimeter cell 
with a path length of 50 mm. Silica gel flash chromatography was performed using 200-400 
mesh (40-75 µm) silica gel. Preparative thin-layer chromatography was performed on 
Analtech silica gel G1200 uM glass plates. Compounds 4-3,21  4-4,21 4-7,21 4-9,22  and 4-1023  
were prepared according to literature methods. Ir[dF(CF3)ppy]2(dtbbpy)PF6 (4-2) was 
prepared by the method of Lowry et al.24  and was purified by flash column chromatography 
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prior to use, eluting with a gradient of 10% EtOAc in hexanes to 25% hexanes in EtOAc. 
Alternatively, the catalyst can be purified by recrystallization from acetone-hexane vapor 
diffusion. Percent conversion was calculated by 1H NMR using the formula [Integral value 
for disulfide produced]/[Combined integral values for disulfide and starting S-PMP protons] 
x 100.  Hydrogen sensing was performed using a catalyzed molybdenum tri-oxide pigment 
(100 µm) embedded in a silicone matrix deposited on a transparent PET substrate (Element 
One Inc., Boulder, CO).6-7 Reactions were performed in sealed screw-cap vials where the 
polymer was affixed to the inside of the cap. 
 
4.6.2 Experimental Procedures 
p-Methoxyphenyl 2,3,4,6-tetra-O-methyl-1-thio-β-D-glucopyranoside (4-8). 25 
Acetyl thioglycoside 4-7 (1.4 g, 2.97 mmol) was diluted in MeOH (30 mL), and the mixture 
was cooled to 0 ˚C. NaOMe (0.160 g, 2.97 mmol) was added, and the mixture was warmed to 
room temperature and stirred for 1 h, after which it was neutralized by the addition of 
DOWEX 50WX8-100 ion-exchange resin. The mixture was filtered and the filtrate was 
concentrated to yield an orange semisolid, confirmed as the intermediate tetraol by 1H NMR. 
The semisolid was diluted in anhydrous DMF (20 mL) and the mixture was cooled to 0 ˚C. 
NaH (0.713 g, 17.82 mmol, 60% dispersion) was added in portions, and the mixture was 
stirred for 15 min before methyl iodide (2.11 g, 14.8 mmol) was added. The mixture was 
allowed to warm to room temperature and was stirred for 18 h before it was quenched by the 
addition of 5 mL MeOH. Concentration afforded a residue that was partitioned between 
EtOAc and H2O (100 mL of each). The organic layer was separated and the aqueous layer 
was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with brine 
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(50 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by 
flash column chromatography (SiO2), eluting with 3:1 hexanes: EtOAc to yield the title 
compound as a clear syrup (1.02 g, 96%). 1H NMR (CDCl3, 300 MHz) δ 1H NMR (300 
MHz; CDCl3): δ 7.53-7.48 (m, 2 H), 6.86-6.81 (m, 2 H), 4.33 (d, J = 9.8 Hz, 1 H), 3.80 (s, 
3H), 3.64 (s, 3H), 3.60 (d, J = 2.1 Hz, 1 H), 3.57 (d, J = 4.3 Hz, 1H), 3.52 (s, 3 H), 3.39 (s, 
3H), 3.26-3.09 (m, 3H), 2.98 (dd, J = 9.7, 8.4 Hz, 1H); 13C NMR δ 159.6, 135.1, 123.6, 
114.2, 88.6, 88.0, 82.4, 79.3, 78.7, 71.3, 60.9, 60.7, 60.4, 59.3, 55.2; [α]26.7D (c 0.83, CHCl3): 
-24 ˚. ESIMS m/z (rel. intensity) 381 (MNa+, 97/100). 
 
p-Methoxyphenyl 3,4-O-acetyl-2,6-dideoxythio-β-L-arabino-hexopyranoside (4-18). 26 L-
Rhamnal (1.5 g, 7.00 mmol) was diluted in anhydrous toluene (12 mL) and cooled to 0 ˚C. A 
solution of dry gaseous HCl was bubbled through the mixture for 30 min, and the mixture 
was stirred an additional 30 min at 0 ˚C. The mixture was purged with dry nitrogen for 45 
min and then concentrated. The resultant white solid was dissolved in anhydrous toluene (12 
mL) and 4-methoxythiophenol (1.46 g, 10.5 mmol) was added, followed by DIEA (1.35 g, 
10.5 mmol). The mixture was stirred at room temperature for 22 h and then diluted with 
CH2Cl2, washed with H2O, dried over anhydrous sodium sulfate, and concentrated. The 
residue was purified by flash column chromatography, eluting with 4:1 hexanes: EtOAc to 
yield the title compound as a colorless semisolid (1.4 g, 56%), contaminated with trace 
amounts of the α-anomer. 
 
General Procedure for Visible Light-Mediated Glycosylation. Thioglycoside 4-3, 4-4, 4-
8, 4-7, or 4-18 (0.050 g-0.080 g, 0.0754-0.223 mmol), or a mixture of thioglycoside and 
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glycosyl acceptors (sugar alcohol 4-9, 1-adamantanol, or (–)-menthol 0.150-0.446 mmol, 1.5-
2 eq.) was diluted with anhydrous acetonitrile (1-2 mL). 1,1,1,3,3,3-Hexafluoro-2-propanol 
(HFIP, 0.754-2.23 mmol), Ir[dF(CF3)ppy]2(dtbbpy)PF6 (5 mol%) and either CBr4 (0.25 
mol% to stoichiometric, for preparing compounds 4-5α ,β , 4-6α ,β , 4-11α ,β  and 4-13α ,β) or 
CBrCl3 (0.25 mol%, for examples 4-12α ,β , 4-14α ,β , 4-15α ,β , 4-16α ,β , 4-17α ,β , and 4-
20α ,β ,) were added. To those reaction mixtures containing only thioglycoside, the glycosyl 
acceptor (methanol, n-octanol, or cyclohexanol, 0.151-0.446 mol, preparation of compounds 
4-5α ,β , 4-6α ,β , 4-11 - 4-13α ,β) was added. The mixture was placed under an argon 
atmosphere, sealed securely with a rubber septum, and with stirring at room temperature, was 
irradiated using blue LEDs (~452 nm) for 6 h (9 h for adamantanol, 18 h for menthol, 10 h 
for the amide 4-10 and 23 h for n-octanol). Reactions were judged as complete by 1H NMR. 
The crude mixtures were concentrated and the resulting residues were purified as described 
under the headings for individual compounds. 
 
Methyl 2,3,4,6-tetra-O-benzyl-D-glucopyranoside (4-5α  and 4-5β). Using thioglycoside 4-
4 (0.050 g, 0.0754 mmol) and MeOH (0.151 mmol), the general procedure afforded the title 
compound after flash column chromatography (10:1 hexanes:EtOAc- 6:1 hexanes:EtOAc), as 
a mixture of the α-anomer 4-5α  (yellow syrup, 0.013 g) and β-anomer 4-5β  (yellow syrup, 
0.014 g). A total of 0.027 g (65%) of products (α:β ratio: 0.9:1) was obtained. The 1H NMR 
data for 4-5α  and 4-5β  are in good agreement with the literature values. 27 
 
Cyclohexyl 2,3,4,6-Tetra-O-benzyl-D-glucopyranoside (4-6α  and 4-6β).  Using 
thioglycoside 4-4 (0.080 g, 0.1206 mmol) and cyclohexanol (0.2413 mmol), the general 
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procedure afforded the title compound after flash column chromatography (15:1 
hexanes:EtOAc- 10:1 hexanes:EtOAc), as a mixture of inseparable anomers (colorless 
syrup). A total of 0.050 g (66%) of products (α:β ratio: 1:1.5, estimated by 1H NMR) was 
obtained. The 1H NMR data for 4-6α  and 4-6βare in good agreement with the literature 
values. 28 
 
Methyl 2,3,4,6-tetra-O-methyl-D-glucopyranoside (4-11α  and 4-11β). Using thioglycoside 
4-8 (0.080 g, 0.223 mmol) and MeOH (0.446 mmol), the general procedure afforded the title 
compound after purification by flash column chromatography (8:1 hexanes:EtOAc-3:1 
hexanes:EtOAc) as a mixture of the β-anomer 4-11β  (yellow syrup, 0.015 g) and α-anomer 
4-11α  (yellow syrup, 0.025 g). A total of 0.040 g (72%) of products (α:β ratio: 1.6:1) was 
obtained. The 1H NMR data for 4-11α  are in good agreement with the literature values; 29 4-
11β  is also known. 30 1H NMR (300 MHz; CDCl3 11β): δ 4.13 (d, J = 7.7 Hz, 1H), 3.65-3.60 
(m, 1 H), 3.61 (s, 4 H), 3.57-3.53 (m, 1 H), 3.56 (s, 4 H), 3.52 (s, 3 H), 3.51 (s, 3 H), 3.40 (s, 
3 H), 3.29-3.24 (m, 1H), 3.16-3.13 (m, 2 H), 3.00-2.94 (m, 1H). 
 
n-Octyl 2,3,4,6-Tetra-O-methyl-D-glucopyranoside (4-12α  and 4-12β). 31  Using 
thioglycoside 4-8 (0.080 g, 0.223 mmol) and n-octanol (0.446 mmol), the general procedure 
afforded the title compound after purification by flash column chromatography (10:1 
hexanes:EtOAc-5:1 hexanes:EtOAc) as a mixture of the 4-12β  anomer  (yellow syrup, 0.034 
g) and 4-12α  anomer (yellow syrup, 0.025 g). A total of 0.059 g (77%) of products (α:β 
ratio: 0.75:1) was obtained. 1H NMR (300 MHz; CDCl3, 4-12α): δ 4.91 (d, J = 3.6 Hz, 1 H), 
3.64-3.41 (m, 5 H), 3.62 (s, 3 H), 3.53 (s, 3 H), 3.47 (s, 3 H), 3. 40 (s, 3 H), 3.21-3.15 (m, 2 
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H), 1.66-1.57 (m, 2 H), 1.34-125 (m, 10 H), 0.86 (t, J = 6.8 Hz, 3 H). 1H NMR (300 MHz; 
CDCl3 , 4-12β): δ 4.19 (d, J = 7.7 Hz, 1 H), 3.88 (dt, J = 9.4, 6.5 Hz, 1 H), 3.60 (s, 3 H), 
3.60-3.51 (m, 2 H), 3.56 (s, 3 H), 3.51 (s, 3 H), 3.44 (dt, J = 9.4, 6.9 Hz, 1 H), 3.38 (s, 3H), 
3.27-3.22 (m, 1 H), 3.17-3.07 (m, 2 H), 2.99-2.94 (m, 1 H), 1.62-1.54 (m, 2 H), 1.38-1.21 (m, 
10 H), 0.86 (t, J = 6.7 Hz, 3 H). 
 
Cyclohexyl 2,3,4,6-Tetra-O-methyl-D-glucopyranoside (4-13α  and 4-13β). Using 
thioglycoside 4-8 (0.080 g, 0.223 mmol) and cyclohexanol (0.446 mmol), the general 
procedure afforded the title compound after purification by flash column chromatography 
(10:1 hexanes:EtOAc-7:1 hexanes:EtOAc) as a mixture of the β-anomer 4-13β  (yellow 
syrup, 0.024 g) and α-anomer 4-13α  (yellow syrup, 0.038 g). A total of 0.052 g (87%) of 
products (α:β ratio: 1.6:1) was obtained. The 1H NMR data for 13α  and 13β  are in good 
agreement with the literature values. 32 
 
(–)-Menthyl 2,3,4,6-Tetra-O-methyl-D-glucopyranoside (4-14α  and 4-14β).  Using 
thioglycoside 4-8 (0.080 g, 0.223 mmol) and (–)-menthol (0.446 mmol), the general 
procedure afforded the title compound after purification by flash column chromatography 
(11:1 hexanes:EtOAc - 6:1 hexanes:EtOAc) as a mixture of the β-anomer 4-14β  (yellow 
syrup, 0.028 g) and α-anomer 4-14α  (yellow syrup, 0.032 g). A total of 0.060 g (71%) of 
products (α:β ratio: 1.1:1) was obtained. 1H NMR (300 MHz; CDCl3, 4-14α) δ 5.00 (d, J = 
3.7 Hz, 1 H), 3.76 (ddd, J = 10.1, 3.4, 2.3 Hz, 1 H), 3.61 (s, 3 H), 3.52 (s, 3 H), 3.57-3.45 (m, 
3 H), 3.42 (s, 3 H), 3.39 (s, 3 H), 3.31 (td, J = 10.6, 4.4 Hz, 1 H), 3.22-3.18 (m, 1H), 3.12 
(dd, J = 9.7, 3.7 Hz, 1 H), 2.40-2.30 (m, 1 H), 2.09 (br dtd, J = 9.5, 4.9, 2.5 Hz, 1H), 1.61 (br 
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dt, J = 12.9, 3.1 Hz, 2 H), 1.42-1.27 (m, 2 H), 1.06-0.84 (m, 9 H), 0.76 (d, J = 6.9 Hz, 3 H); 
13C NMR (75 MHz; CDCl3) δ 97.9, 82.8, 82.2, 81.0, 79.5, 71.0, 69.8, 60.5, 60.3, 59.1, 58.5, 
48.6, 42.9, 34.2, 31.7, 24.6, 22.9, 22.2, 21.1, 16.0; [α]21.6D (c 1.32, CHCl3): 50.4˚; ESIMS m/z 
(rel. intensity) 771 (2M+Na+, 100), 397 (MNa+, 52). 1H NMR (300 MHz; CDCl3, 4-14β): δ 
4.27 (d, J = 7.8 Hz, 1H), 3.61 (s, 3 H), 3.57-2.55 (m, 2 H), 3.56 (s, 3 H), 3.52 (s, 3 H), 3.44-
3.36 (m, 1 H), 3.38 (s, 3 H), 3.24-3.09 (m, 3 H), 2.94 (td, J = 7.3, 1.9 Hz, 1 H), 2.34-2.24 (m, 
1 H), 2.10-2.03 (m, 1 H), 1.62 (dt, J = 9.6, 3.1 Hz, 2 H), 1.38-1.16 (m, 3 H), 0.99-0.86 (m, 8 
H), 0.76 (d, J = 6.9 Hz, 3 H); 13C NMR (75 MHz; CDCl3) δ 100.9, 86.6, 83.6, 79.4, 78.0, 
74.6, 71.5, 60.7, 60.45, 60.34, 59.4, 47.9, 40.7, 34.4, 31.5, 25.0, 23.0, 22.2, 21.1, 15.5; [α]21D 
(c 1.16, CHCl3): -46.5˚; ESIMS m/z (rel. intensity) 397 (MNa+, 100). 
 
1ʹ-Adamantyl 2,3,4,6-Tetra-O-methyl-D-glucopyranoside (4-15α  and 4-15β). Using 
thioglycoside 4-8 (0.070 g, 0.223 mmol) and 1-adamantanol (0.446 mmol), the general 
procedure afforded the title compound after purification by flash column chromatography 
(10:1 hexanes:EtOAc-3:1 hexanes:EtOAc) as the α-anomer 4-15α   (yellow syrup, 0.033 g) 
and the β-anomer 4-15β . Compound 4-15β  co-eluted with unreacted adamantanol, which 
was removed by trituration of the obtained crude solid with cold hexanes (4 x 1 mL). 
Concentration of the filtrate afforded pure 4-15β   (yellow syrup, 0.021 g). A third fraction 
(0.005 g) containing a 1.4:1 mixture of 4-15β:4-15α  was also collected; a total of 0.059 g 
(71%) of products (overall α:β ratio: 1.6:1) was obtained. 1H NMR (300 MHz; CDCl3, 4-
15α): δ 5.31 (d, J = 3.7 Hz, 1 H), 3.80 (dt, J = 10.1, 2.7 Hz, 1 H), 3.61 (s, 3 H), 3.57-3.55 (m, 
1H), 3.53 (s, 3 H), 3.52-3.47 (m, 2 H), 3.45 (s, 3 H), 3.39 (s, 3 H), 3.22 (dd, J = 10.0, 8.9 Hz, 
1 H), 3.14 (dd, J = 9.7, 3.7 Hz, 1 H), 2.12 (br s, 3 H), 1.86-1.76 (m, 6 H), 1.65-1.56 (m, 6 H). 
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13C NMR (75 MHz; CDCl3) δ 89.1, 83.0, 81.7, 79.6, 74.3, 80.0, 69.3, 60.7, 60.3, 59.1, 58.2, 
42.3, 36.2, 30.6; [α]24.7D (c 1.15, CHCl3): 97˚; ESIMS m/z (rel. intensity) 393 (MNa+, 100); 
1H NMR (300 MHz; CDCl3, 4-15β): δ 4.49 (d, J = 7.8 Hz, 1 H), 3.62 (s, 3 H), 3.60-3.50 (m, 
2 H), 3.57 (s, 3 H), 3.51 (s, 3 H), 3.38 (s, 3 H), 3.27-3.21 (m, 1 H), 3.16-3.03 (m, 2 H), 2.95 
(t, J = 8.3 Hz, 1H), 2.14 (s, 3 H), 1.81 (br q, J = 16.3 Hz, 7 H), 1.61 (br s, 6 H). 13C NMR δ 
95.8, 86.6, 83.8, 79.6, 74.9, 74.3, 71.7, 60.7, 60.5, 60.3, 59.3, 42.5, 36.2, 30.6; [α]25D (c 1.08, 
CHCl3): 3.7˚; ESIMS m/z (rel. intensity) 393 (MNa+, 100). 
 
Methyl-2,3,4-tri-O-benzyl-6-O-(2,3,4,6-Tetra-O-methyl-D-glucopyranosyl)-D-
glucopyranoside (4-16α  and 4-16β). Using thioglycoside 6 (0.080 g, 0.223 mmol) and 
methyl glycoside 4-9  (0.130 g, 0.446 mmol), the general procedure afforded (4-16α  and 4-
16β) after purification by chromatotron (2:1 hexanes:EtOAc-1:1 hexanes:EtOAc).  0.022 g 
of 4-16α  eluted first, followed by 0.018 g 4-16β  (23% yield, 1.2:1 anomeric ratio).  Spectral 
data closely matched previously reported values.33 
 
O-Methyl-(N-benzenecarboxamido)-L-serinyl 2,3,4,6-Tetra-O-methyl-D-
glucopyranoside (4-17α  and 4-17β). Using thioglycoside 6 (0.070 g, 0.223 mmol) and 
serine derivative 4-10 (0.334 mmol), the general procedure afforded the title compound after 
after purification by flash column chromatography (3:1 hexanes:EtOAc-1.5:1 
EtOAc:Hexanes) as the α-anomer 4-17α  (yellow syrup, 0.037 g) and the β-anomer 4-17β . 
Compound 4-17β  was further purified by preparative TLC (2% MeOH in CH2Cl2) and was 
obtained as a pale yellow syrup (0.023 g). A total of 0.060 g (61%) of products (overall α:β 
ratio: 1.6:1). 1H NMR (300 MHz; CDCl3, 4-17α) δ 7.88-7.85 (m, 2 H), 7.66 (br d, J = 8.3 
 138 
Hz, 1 H), 7.53-7.40 (m, 3 H), 4.96 (dt, J = 8.3, 3.2 Hz, 1 H), 4.90 (d, J = 3.8 Hz, 1 H), 4.34 
(dd, J = 11.5, 3.4 Hz, 1 H), 3.95 (dd, J = 11.5, 3.1 Hz, 1 H), 3.76 (s, 3 H), 3.61-3.59 (m, 1 H) 
3.59 (s, 3 H), 3.52-3.49 (m, 2 H), 3.49 (s, 3 H), 3.44 (s, 3 H), 3.38-3.29 (m, 1 H), 3.22-3.15 
(m, 2 H). 13C NMR (75 MHz; CDCl3) δ 170.6, 167.1, 133.6, 131.7, 128.5, 127.3, 98.7, 83.0, 
81.4, 79.0, 70.9, 70.7, 70.6, 60.7, 60.4, 59.0, 58.7, 53.1, 52.6; [α]22.1D (c 1.54, CHCl3): 108˚; 
ESIMS m/z (rel. intensity) 464 (MNa+, 100). A total of 0.060 g (61%) of products (overall 
α:β ratio: 1.6:1). 1H NMR (300 MHz; CDCl3, 4-17β) δ (m, 2 H), 7.55-7.41 (m, 3 H), 7.35 (br 
d, J = 8.2 Hz, 1 H), 4.96 (dt, J = 8.1, 3.1 Hz, 1H), 4.47 (dd, J = 11.0, 2.8 Hz, 1 H), 4.25 (d, J 
= 7.8 Hz, 1 H), 3.92 (dd, J = 11.1, 3.5 Hz, 1H), 3.77 (s, 3 H), 3.62-3.60 (m, 3 H), 3.56 (s, 3 
H), 3.57-4.54 (m, 2 H), 3.51 (s, 3 H), 3.37 (s, 3 H), 3.20-3.11 (m, 3 H), 3.01-2.96 (m, 1 H). 
13C NMR (75 MHz; CDCl3): δ 170.4, 167.0, 133.6, 131.8, 128.5, 127.2, 104.3, 86.5, 83.5, 
79.0, 74.6, 70.8, 70.5, 60.9, 60.7, 60.4, 59.2, 53.2, 52.6; [α]25.3D (c 0.97, CHCl3): 25.2˚; 
ESIMS m/z (rel. intensity) 442 (MH+, 100). 
 
Methyl 3,4-di-O-acetyl-2,6-dideoxy-L-arabino-hexopyranoside (4-19α  and 4-19β). Using 
thioglycoside 4-18 (0.081 g, 0.229 mmol) and methanol (0.460 mmol), the general procedure 
afforded methyl glycosides 4-19α  and 4-19β  after flash column chromatography (10:1 
hexanes:EtOAc). 4-19α  (0.009 g, 16% yield) eluted first, followed by 4-19β  (0.037 g, 66% 
yield). The 1H and 13C NMR data for 4-19α  and 4-19β  are in good agreement with the 
literature values. 34 
 
Methyl-2,3,4-tri-O-benzyl-6-O-(3,4-di-O-acetyl-2,6-dideoxy-L-arabino-hexopyranosyl)-
D-glucopyranoside (4-20α  and 4-20β).  Thioglycoside 8 (0.080 g, 0.226 mmol) was 
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coupled to acceptor 9 (0.19 mmol) by the general procedure to yield 4-20α  and 4-20β  after 
chromatoton (eluting in 4:1 hexanes:EtOAc).  0.016 g 4-20α  (11% yield) eluted first, 
followed by 0.048g 4-20β  (31% yield).  Spectral data for 4-20α  matched literature reports. 35 
A total of 0.060 g (61%) of products (overall α:β ratio: 1.6:1). 1H NMR (300 MHz; CDCl3, 
4-20β) δ 7.25-7.42 (m, 15H), 5.21-5.30 (m, 1H), 5.00 (d, J = 10.8 Hz, 1H), 4.90 (d, J = 11.1 
Hz, 1H), 4.81 (d, J = 11.4 Hz, 2H), 4.66-4.75 (m, 3H), 4.58 (d, J = 3.6 Hz, 1H), 4.54 (d, J = 
11.1 Hz, 1H), 4.00 (t, J = 9.3 Hz, 1H), 3.74-3.87 (m, 3H), 3.55 (dd, J = 3.6, 9.6 Hz, 1H), 
3.43-3.49 (m, 2H), 3.38 (s, 3H), 2.14-2.21 (m, 1H), 2.05 (s, 3H), 2.00 (s, 3H), 1.73 (m, 1H), 
1.12 (d, J = 6.3 Hz, 3H).  13C NMR (75 MHz; CDCl3): δ 170.2, 138.6, 138.1, 128.4, 128.3, 
128.1, 128.0, 127.9, 127.8, 127.6, 97.9, 97.0, 82.1, 80.1, 77.7, 77.2, 75.8, 75.0, 74.7, 73.4, 
69.9, 68.9, 66.2, 65.5, 55.1, 35.2, 21.0, 20.9, 17.4 [α]25D (c 1., CHCl3): -37; ESI-MS m/z (rel. 
intensity) 680 (MH+, 100). 
 
19F NMR Mechanistic Studies. The reaction was performed using thioglycoside 4-4 (0.030 
g, 0.045 mmol), 9.6 µL CBrCl3 (2 eq.), Ir[dF(CF3)ppy]2(dtbbpy)PF6 (5 mol%) and 51 µL 
HFIP (0.484 mmol, 10.7 eq.). Water (1.8 µL, 2 eq.) was the nucleophile employed. The 
reaction was conducted in CD3CN (0.6 mL), and after 6 h of irradiation, trifluorotoluene (119 
µL, 0.969 mmol) was added to the complete reaction. 19F NMR spectra were obtained (at 282 
MHz) and compared to a standard consisting of HFIP (51 µL, 0.484 mmol) and 
trifluorotoluene (119 µL, 0.969 mmol) in 0.6 mL of CD3CN. The ratio of signals from 
trifluorotoluene to HFIP was 1:0.85 in the standard, and 1:0.84 in the completed reaction. 
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CHAPTER V 
CONCLUSION 
 
We have developed chemoenzymatic strategies to probe for the function of enzymes 
involved in the production of the antibiotic thiocillin and the hybrid antibiotic thiomarinol, 
with specific focus on the dithiolopyrrolone antibiotic component for the latter. We have 
utilized chemical syntheses to construct natural product variants to test for substrate 
promiscuity and mechanism of action. We have further developed a mild O-glycosylation 
strategy from thioglycosides that will allow us to construct more structural variants of natural 
products. 
In the present work, we have utilized the enzyme TclM from the thiocillin 
biosynthetic pathway to show that it catalyzes a formal [4+2] cycloaddition between two 
dehydroalanines in a linear precursor peptide analogue, prepared by native chemical ligation 
of the leader peptide thioester to a N-terminal cysteine core, of its natural substrate. Further 
studies showed a seven amino acid minimal leader peptide to induce the cyclization. A solid-
phase peptide synthesis method was developed to construct thiopeptide variants. With this 
strategy, we were able to show that TclM cyclized variants where the ring core was both 
expanded and mutated, and where the C-terminus was expanded as well. We extended our 
studies to the TclM homologue TbtD from the thiomuracin GZ biosynthetic pathway. We 
found that a C-terminal dehydroalanine or thiazole at the +1 position of the 4π partner is 
 143 
essential for cyclization to occur and that ring contractions is not permitted when a tyrosine is 
removed from the macrocycle. 
We have also showed that the thiomarinol analogue pseudomonyl C holothinamide 
can be constructed with the enzymes TmlU and HolE from the thiomarinol biosynthetic 
pathway. Additional studies on the dithiolopyrrolone constituent showed promiscuity 
towards different acyl groups in the exocyclic amide while maintaining activity against N. 
gonorrhoeae. The oxidized analogue dioxoholomycin can readily oxidize thiols into 
disulfides in small molecules and in proteins, providing a putative mechanism of action for 
the dithiolopyrrolone family of antibiotics. 
Furthermore, we have developed a technique in which we utilize visible light 
catalysis and an Ir (III) catalyst to activate thioglycosides and achieve O-glycosylation. We 
showed that 1o, 2o, and 3o alcohols readily trap the activated oxocarbenium ion. We envision 
utilizing this coupling strategy in the linkage of carbohydrate moieties in alcohol-containing 
natural products to aid in solubility and in targeted drug delivery. 
The advent of next-generation DNA sequencing has yielded a broad pool of 
biosynthetic gene clusters from bacterial whole genome sequencing from which new 
antibiotics can be discovered. Natural products have evolved for many years by the 
producing organisms to be enticing to their bacterial targets; thus, strategies to harness the 
biosynthetic pathways involved in producing the molecules is of high importance. Likewise, 
finding avenues for natural product modification by organic syntheses can enhance the 
understanding of the reactivities associated with these molecules and provide a strategy by 
which variants can be constructed with better physical properties to combat antibiotic 
resistance. 
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APPENDIX B. SPECTRA FOR CHAPTER 3 
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APPENDIX C. SPECTRA FOR CHAPTER 4 
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